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Abstract
The concept of controlled drug delivery arose in the mid-sixties, quickly leading to the
first commercial devices composed of poly(ethylene-co-vinyl acetate). Since then, the
field has suffered a tremendous evolution. As the knowledge on cell biology, physiology
and materials sciences increased, better approaches were developed. Today we stand
on the nanometric level of controlled delivery devices. These approaches rely on highly-
innovative materials, with increasing biological accuracy, having has an ultimate goal the
achievement of personalised medicine.
Impaired-angiogenesis associated pathologies, such as ischemic heart disease, chronic
wounds or stroke, have a high-burden on society. Pro-angiogenic therapies aim at recov-
ering vascularised impaired tissues. Among other approaches, the use of specific growth
factors, like vascular endothelial growth factor (VEGF), is one of the most attempted
approaches found on the literature. However, the results in clinical trials, using bolus
delivery of VEGF, did not meet the desired therapeutic efficacy. Part of this failure was
attributed to suboptimal delivery strategies, allied to the short half-life and fast clear-
ance rates of the growth factor. Cardiovascular diseases and wound healing are huge
ummet medical needs which would benefit tremendously of successful delivery strategies
for VEGF.
We have previously synthesised and characterised oxidised dextran (dexOx) hydrogels
(Maia et al. Polymer 2005;46:9604-9614). We have used this system as a benchmark
and continued its characterisation in an attempt to improve it for the desired drug
delivery approaches. A deeper analysis of oxidised dextran was performed, focused on
the oxidation degree effect and its direct influence on the microscopic and macroscopic
characteristics of the material. As a result, we observed how the oxidation degree strongly
interferes with the viscosity of dexOx aqueous solutions and how the thermal degradation
profiles, of the different samples, reflect the damage that low and mild oxidations could
originate, on the polymeric backbone.
DexOx cross-linked with adipic acid dihydrazide hydrogels were further characterised
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having in mind the future incorporation of a therapeutic biomolecule and the integration
in more complex systems. Different geometries were approached, like microgels, of which
we present some early studies.
The natural reactivity of oxidised dextran toward N-nucleophiles render this vehicle ap-
propriate for an effortless and straightforward conjugation with a proteinaceous growth
factor, conferring protection and extending the protein half-life by inhibiting fast cellu-
lar consumption. VEGF is able to maintain its bioactivity, however the conjugation to
dexOx, severely hinders the interaction with VEGF receptors and antibodies, delaying
the VEGF consumption. The hydrogels release profile of VEGF was studied and observed
to be quite different from other systems described on the literature. The initial burst
release could be fine tuned from one to forty five percent of the total initial drug.
Fibrin hydrogels were shown, elsewhere, to be appropriate carriers of endothelial cells.
They improved the survival and proliferation of such cells. Therefore, a novel hybrid
construct was designed. The dexOx hydrogels were entrapped inside the fibrin hydrogels.
The combination of both platforms in a hybrid matrix supported the attachment of
vascular cells and allowed their migration, organisation and proliferation, supported by
a possible gradient created by the controlled delivery of VEGF. This novel construct
geometry opens interesting perspectives for pro-angiogenic therapies.
Finally, we have explored the delivery of small hydrophobic therapeutics. The ultimate
frontier in drug delivery is the cells cytoplasm and the different cellular organelles. The
ability to reach this target allows the manipulation and control of cell fate, highly rele-
vant on the context of stem cells. Retinoic acid (RA) is a hydrophobic molecule which
has tremendous potential in cancer prevention and is a regulator of stem cells differenti-
ation. RA acts upon nuclear receptors, therefore, the intracellular delivery is demanded
for a successful application. We addressed this issue, by recurring to polyelectrolyte-
based nanoparticles, composed by polyethylenimine and dextran sulfate. The balance
between the different components was shown to affect the RA loading capacity and the
nanoparticles size. This system allowed the delivery of a significant amount of RA to
the subventricular zone neuronal stem cells cytoplasm and differentiate this cells into the
neuronal lineage more significantly than blank nanoparticles or by RA released outside
the cells. We antecipate that such system could be delivered through the nasal cavity,
straight to the brain, opening new perspectives on the treatment of neurodegenerative
diseases.
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Resumo
O conceito de libertação controlada de fármacos nasceu nos anos sessenta, o que seria
traduzido rapidamente em produtos comerciais compostos por dispositivos com base em
poli(etileno-co-vinil acetato). Desde essa altura, o campo evoluiu substancialmente. À
medida que os conhecimentos de biologia celular, fisiologia e ciência dos materiais foram
crescendo, abordagens mais eficazes foram sendo criadas. Hoje em dia, os dispositivos
de libertação controlada de entidades terapêuticas ou mesmo células, atingiram a escala
nanométrica. Estas abordagens apresentam elevada precisão biológica, o que nos levará,
eventualmente, a uma medicina mais personalisada.
Determinadas patologias são caracterizadas por vascularização deficiente, após o mo-
mento do insulto. Exemplos como o enfarte do miocárdio, feridas crónicas ou acidentes
vasculares cerebrais tem um elevado peso na sociedade. A angiogénese terapêutica tem
como objectivo a recuperação de tecidos lesionados com uma vascularização deficiente.
Entre outras abordagens, o uso de factores de crescimento específicos, como o factor
de crescimento do endotélio vascular (VEGF), é uma das abordagens mais frequentes
encontradas na literatura e abordada em ensaios clínicos. No entanto, os resultados em
ensaios clínicos, utilizando apenas VEGF, não atingiu a eficácia terapêutica pretendida.
Parte deste falhanço foi atribuído a uma entrega deficiente do factor bioactivo aos teci-
dos comprometidos, aliado ao tempo de semi-vida curto e à rápida filtração por parte
do organismo. A cura de feridas cutâneas e doenças cardiovasculares são necessidades
médicas que beneficiariam muito com estratégias eficientes de entrega e libertação de
VEGF.
Recentemente, o nosso grupo descreveu a síntese e caracterização de hidrogeis de dex-
trano oxidado (dexOx) (Maia et al. Synthesis and characterization of new injectable
and degradable dextran-based hydrogels Polymer 2005;46:9604-9614). Este sistema foi
usado como referência padrão e durante este estudo foi feito um esforço de realizar uma
caracterização mais exaustiva de modo a melhorá-lo. Uma análise mais profunda do
dextrano oxidado foi feita, focada na influência do grau de oxidação nas características
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microscópicas e macroscópicas do material. O grau de oxidação também foi estudado
no contexto de um transporte eficiente de factores bioactivos, bem como na síntese de
microgeis e hidrogeis após reticulação com ácido adípico dihidrazida.
A questão de libertação de VEGF foi abordada, usando o dextrano oxidado como trans-
portador. A reactividade natural do dextrano oxidado para N-nucleófilos torna este
vector bastante apropriado para uma conjugação simples e directa, conferindo protecção
e aumentando o tempo de semi-vida, por inibição do rápido consumo celular. O perfil
de libertação do VEGF observado é bastante diferente de outros sistemas descritos na
literatura. A libertação inicial pode ser moldada para ocorrer entre um a quarenta e
cinco por cento da totalidade da proteína inicial. O VEGF é capaz de preservar a sua
bioactividade, no entanto a conjugação ao dextrano oxidado, limita severamente a in-
teracção com os receptores celulares e anticorpos específicos, retardando o seu consumo
a nível celular.
Hidrogéis de fibrina foram identificados, num outro trabalho, como sendo transporta-
dores eficazes de células endoteliais. Foi mostrado que melhoravam a sobrevivência e
proliferação dessas mesmas células. Nesse contexto, os hidrogéis de dexOx foram incor-
porados dentro dos hidrogéis de fibrina. A combinação de ambas as plataformas, numa
matriz hibrída, suportou a adesão das células endoteliais e permitiu a sua migração, or-
ganização e proliferação, apoiada num possível gradiente criado pela libertação de VEGF
do hidrogel de dexOx. Esta nova geometria abre perspectivas interessantes para novas
terapias pro-angiogénicas.
Por último, foi explorada a libertação controlada de agentes terapêuticos de baixo peso
molecular e hidrofóbicos. A última fronteira em libertação de drogas é o ambiente
citoplasmático e os diferentes organelos celulares. A capacidade de atingir este espaço
permite a manipulação e controlo do destino celular, altamente relevante no contexto
de células estaminais. O ácido retinóico é uma molécula hidrofóbica com um potencial
tremendo na prevenção do cancro e como regulador da diferenciação de células estami-
nais. O ácido retinóico actua sobre receptores localizados no núcleo celular, nascendo a
necessidade de entrega citoplasmática para uma aplicação bem sucedida. Este problema
foi abordado, recorrendo a nanoparticulas baseadas em polielectrólitos (polietilenimina
e dextrano sulfato). O balanço entre os diferentes componentes afecta a capacidade de
transportar ácido retinóico bem como o tamanho final das nanopartículas. Este sistema
permitiu a entrega de uma quantidade significativa de ácido retinóico no citoplasma
de células estaminais neuronais da região subventricular promovendo a diferenciação em
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células da linhagem neuronal, ao contrário de nanopartículas vazias ou de ácido retinóico
libertado fora das células. Antevemos que este sistema possa ser entregue ao cérebro
através da cavidade nasal, surgindo como uma nova oportunidade no tratamento de
diversas doenças neuro-degenerativas.
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Thesis Outline
The research project “Polysaccharide hydrogels for vascular tissue engineering applica-
tions”, which was presented and accepted by “Instituto de Investigação Interdisciplinar”,
had as main goal, the development of “(...) a new hydrogel formulation to be studied
as a scaffold for vascular tissue growth, and that could also improve implantable-devices
acceptance by the organism”. This project was designed on the shoulders of an earlier
work, which characterised the synthesis of oxidised dextran (dexOx) hydrogels cross-
linked with a dihydrazide (Maia et al. Polymer 2005;46:9604-9614). This work was set
as our benchmark.
Throughout the period of research, the main goals were slightly shifted in other direc-
tions. The polymeric-based materials were still on the main core of the technologies
approached, however, the focus of research was oriented, towards drug delivery. To
achieve this goal, a material transfer agreement for vascular endothelial growth factor,
was arranged. Later on, the possibility of developing and characterising nanoparticles,
opened the door for the intracellular delivery of retinoic acid, to neuronal stem cells.
Several months were applied in developing different polysaccharide-based formulations.
After several failed strategies, the research focused on further characterising that pre-
viously studied system. The adipic acid dihydrazide (AAD) cross-linked dexOx system
presented many of the characteristics which we were trying to achieve. An injectable
and initiator-free hydrogel, of aqueous base and which could carry therapeutic molecules.
Therefore, it was decided to continue the characterisation of said system and advance
to the aimed goal of vascular therapies.
The general hypothesis was that an injectable hydrogel system, able to carry specific
therapeutic entities, would improve the therapeutic efficacy and benefit the recovery of
the injured tissue. Such carrier could be applied in a high number of clinical settings. The
development of such work represents a collaboration between traditional disciplines as
diverse as polymer chemistry and polymer physics to drug delivery and cellular/molecular
biology. It is impossible to address tissue engineering and drug delivery from only one
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prism, without having to face the challenges arising on other research fields.
From the biomaterials perspective, a thorough structural characterisation of dexOx was
performed. On chapter 1 we review the background of oxidised dextran on the biomedical
field, in order to contextualise the experimental issues approached. The oxidation degree,
which deeply affects the macroscopic and microscopic properties of the oxidised dextrans,
was thoroughly analysed by several techniques (chapter 4 and chapter 5), but especially,
bidimensional NMR, which unveiled interesting reactivity trends of the different aldehydes
on oxidised dextran (chapter 4). The consequences of the oxidation degree on the
design of hydrogels and microgels is presented on chapter 5 and chapter 6, respectively.
The chapter 5 results were oriented towards an injectable ocular application, due to
the context of the collaboration that was established during that period. Though, the
ocular delivery is out of the specific context of this thesis, the technical needs of such
application, regarding the hydrogels properties, are quite similar. This work work will be
presented without modifications from the published version.
Pro-angiogenic therapies are reviewed on chapter 2. The relevance of VEGF as a thera-
peutic molecule is addressed and the challenges faced on the controlled delivery are also
overviewed. A glimpse over the use of vascular progenitor cells or stem cells on pro-
angiogenic therapies is also addressed on this chapter. We have explored the delivery of
VEGF, on the context of this dexOx-based hydrogel system but also as simple drug con-
jugate to dexOx and the implications that it could have on the VEGF denaturation and
bioactivity (chapter 7). The conjugation to dexOx protects VEGF, without denaturat-
ing, extending its half-life by inhibiting fast cellular consumption. This system presented
an interesting release profile, which could be advantageous on a wound healing clinical
context. However, a new hybrid hydrogel construct is proposed, where the controlled
delivery of VEGF apparently guides the migration and proliferation of endothelial cells
inside a fibrin hydrogel.
New opportunities in drug delivery by nanoparticles arose due to our last collaboration.
The impact of nanoparticulate delivery systems is addressed on chapter 3 and some
insights on the challenges of nanoparticles design is addressed as well as the most in-
novative approaches. The intracellular delivery of retinoic acid was approached with a
polyelectrolyte nanoparticle system and the potential in differentiating neural stem cells
was assessed and described on chapter 8. We show that our NP formulation is very
effective in loading RA, a small molecule with low aqueous solubility, and to release RA
at concentrations higher than its solubility limit. Importantly, our results show that the
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intracellular internalisation of RA positive nanoparticles contribute for neurogenesis and
therefore highlighting the importance of drug spatial positioning and concentration in
terms of stem cell differentiation.
The experimental section chapters were all prepared in the form of independent publish-
able manuscripts. The author apologizes for the redundancy of some sections.
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Part I.
Introduction

1. Oxidised Dextran
Dextran is not the sexiest of the biomedical polymers out there. It is linear, neutral
and cheap. Nevertheless, it is an interesting substracte for chemical modifications and
throughout the last decades, has been a reliable resource with broad applications in the
biomedical industry.
1.1. Dextran in Biomedical Industry
Since the late nineteen forties, when dextran from Leuconostoc mesenteroids (strain
B-512; US clinical standard [1]) was accepted as a plasma volume expander (i.e. plasma
substitute) that the biomedical industry is using this polysaccharide [1, 2, 3]. From the
economical perspective, concerning the biomedical industry, when comparing dextran
to other polysaccharides of biomedical interest, such as hyaluronic acid, chitosan or
alginate, dextran is competitively priced (Tab. 1.1).
The dextran from this strain was chosen based on the high percentage (>95%) of α-1,6
linkages, more relevant to the initial application, due to the slower hydrolysis by body
enzymes, compared to the α-1,4 linkage (e.g. glycogen). The high density of hydroxyl
groups present in dextran, allows different kinds of chemical modifications [4]. Such
approaches aim at using dextran from drug conjugation [5] to particles or hydrogels
synthesis [6], easily adding value to the starting material and broadening the potential
applications. Among the chemical modifications described in the literature, one finds
different degrees of complexity. They can involve organic solvents, hazardous monomers
and troublesome procedures which may counter-balance the added value of such ap-
proaches. The dextran periodate oxidation is a simple, straightforward chemical modifi-
cation, which yields a highly versatile biomaterial with reproducible qualities. Oxidized
dextran has mild cytotoxicity, which can be mitigated [7], but still has brought value
to most therapeutic applications studied so far. Most importantly, it has entered the
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clinical trials stage before, demonstrating oxidised dextran (dexOx) as a valid low-cost
biomaterial option [8].
Table 1.1.: Price comparison for different clinical grade polysaccharides. Whenever
possible the bulk price was presented, which obviously lowers the €/gram. There is
no conflict of interests between the authors and the mentioned companies.
Material Price range€/gram Grade
Companies
scanned
Dextran 0.5 – 0.85 Ultrapure; clinical Pharmacosmos
1;
Polydex1
Chitosan ~ 45 Ph. Eur.3 Novamatrix2
Hyaluronan ~ 45 Ph. Eur.3 Novamatrix2
Hyaluronan ~100 Medical grade Lifecore1
Alginates ~ 45 Ph. Eur.3 Novamatrix2
1 - Through cotation; 2 - Through company’s website; 3 - European Pharmacopoeia
1.2. Dextran Oxidation
The dextran oxidation by periodate ion is a catalysis-free aqueous reaction which yields a
purified product with a simple dialysis step, followed by freeze-drying. Initially described
by Malaprade in 1928 [9], this method was used for the characterisation and elucidation
of the polysaccharide structure, through the complete oxidation and consequent analysis
of the degradation products [10, 11, 12, 13]. Dextran’s glucose residue, has vicinal diols
(on α-1,6 residues), presenting two different oxidisable bonds, within the same residue.
The oxidation of any of those bonds yields an aldehyde on C3, which is also susceptible
to periodate oxidation due to the neighbouring hydroxyl on C2 or C4, eventually leading
to a double oxidation of that same residue (Fig. 1.1A). This process can be observed by
the pH decrease, due to the release of the C3 as formic acid [14]. As clearly explained by
Tiziani [15], in the first oxidation step, one of the I-O bonds of the periodate ion, attacks
one of the two hydroxyl groups of the vicinal diol; the second step is the formation of the
planar cyclic ester as part of an octahedral intermediate, the rate of which, must depend
on the acidity of the oxygen of the OH groups and their relative positions. Regarding
the first oxidation step, this oxidative attack, on aqueous environment, is sensitive to
the carbon bond. The cleavage of the C3-C4 bond was described to be favoured 7.5-fold
compared to the C2-C3 bond. However, the second oxidation step was reported to have
similar kinetics [16].
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Figure 1.1.: (A) Single and double oxidation of dextran by the metaperiodate ion; (B)
hemiacetal structure proposed by Ishak and Painter [16]; (C) aldo-enol tautomerism
proposed by Drobchenko [17, 18].
When the oxidation is held in dimethyl sulfoxide (DMSO), a non-selective, single ox-
idation was described to occur. The second oxidation inhibition was explained by a
protective intra-residual hemiacetal formation [19], which does not allow further oxida-
tion on the same residue. This phenomenon, was also considered to occur in aqueous
environment, but was suggested that it is not stable enough to prevent complete dex-
tran oxidation [16]. The hemiacetals, as well as hemialdals, should be responsible for
the spectroscopic disappearance [14] of the aldehyde moiety. These structures exist in
equilibrium, allowing the aldehydes to be reactive towards their natural counterparts
(proposed hemiacetal structure for the doubly oxidised residue depicted on Fig. 1.1 B
[16]). Another set of studies focused on the spectral characteristics of the mildly oxi-
dised dextrans at different pH conditions, suggested alternative structures to hemiacetals.
The UV analysis, disclosed the presence of bands, indicating that the hemiacetals might
exist in a restricted pH window, between 4.0 and 5.2. Below pH 4, the bands were
attributed to aldehydes and above pH 5.2, to enols and enolate ions. The authors pro-
pose a pH-dependent aldo-enol tautomerism (Fig. 1.1 C) [17]. The 1H-NMR analysis of
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dexOx at different pH’s revealed the appearance of new peaks (7.5 – 9.5 ppm), which
disappeared after treatment with a borohydride salt, therefore being attributed to the
aldo-enol transition populations and hemiacetals [18, 20, 21]. However, when the dexOx
oxidation reaction is followed by 1H-NMR a putative aldehyde at ~9.7 ppm is observed.
At that moment, the pH is close to 2.5, but the following spectra failed to capture the
aldehydes again [14].
1.2.1. Oxidation Degree
The control over the modification extension is of utmost importance on the final macro-
scopic and microscopic properties of mildly oxidised dextran. The aldehyde groups gen-
erated can be easily titrated and quantified either by colorimetry or by potentiometry.
The most common methods described in the literature, involve the titration with car-
bazates [14, 22] and its indirect quantification of the excess with trinitrobenzenosulfonic
acid (TNBS). The dinitrosalycilic acid method, developed for estimating sugars in urine
[23], can also be approached to oxidised dextran and assess the reducing strength, hence,
the oxidation degree (OD) [24]. Another common method uses potentiometric titration
to quantify the released equivalents of HCl, after hydroxylamine hydrochloride reaction
with the aldehydes [25]. Interestingly, the less used colorimetric method with oxidised
dextran is the method developed by Hugo Schiff [26]. The complex between aldehydes
and fuchsin can be quantified by its absorption at 556 nm, and to the best of our knowl-
edge it was used once involving oxidised dextran [27]. As the dextran structure is very
homogenous, the 1H-NMR spectrum is well resolved, when compared to other polysac-
charides. The carbazone formed, after titration with slight excess of tert-butyl carbazate
(tBC) (taking into account two aldehydes per residue), yields a new non-exchangeable
proton, visible on D2O, around 7.3 ppm [14]. The ratio between this peak integral
and the anomeric peak, correlated well with the data from the TNBS assay, validat-
ing this 1H-NMR approach. Intuitively, the reaction stoichiometry is expected to have
two aldehydes per oxidised residue, hence, yielding two carbazones per oxidised residue.
However, the visualisation of a single correlation on the HMQC [14] suggests otherwise,
because only one population of aldehydes appears of being attacked [14]. Therefore, the
oxidation degree determination could be masked by this phenomenon, which we will try
to clarify on chapter 4.
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1.2.2. DexOx Reactivity
The attractiveness of aldehyde-activated dextran is inherently connected with the propen-
sity of this chemical group to react promptly with N-nucleophiles, forming a stable co-
valent link, yet, reversible. Amines are ubiquitous throughout a broad variety of small
therapeutic molecules and a regular presence in proteins, especially through the amino-
acid lysine. Hydrazides can be incorporated easily on several compounds [28], empower-
ing the target molecule with dexOx reactivity. The outcome from the reaction between
dexOx and amines results in an imine (widely known has Schiff base; Fig. 1.2 A) whereas
the reaction with hydrazides results in a hydrazone (Fig. 1.2C). Hydrazones are more
stable and resistant to hydrolysis than imines, which results from the delocalisation of
the π-electrons [29]. Theoretically, imines on single oxidised residues, formed on C3, can
undergo an Amadori rearrangement (Fig. 1.2B) forming stable ketoamines [30, 31].
The imine bond is susceptible of reduction, leading to a non-hydrolizable bond. The
preferred approach is performed by reductive amination, through sodium borohydride
or sodium cyanoborohydride. The reaction yields an irreversible amine covalent bond.
Cyanoborohydride is more selective, because it does not reduce aldehyde bonds as boro-
hydride does [32] and can limit the number of reduced bonds between dexOx and the
target molecule [33]. Another option is pyridine borane which has slightly greater reduc-
ing strength than sodium cyanoborohydride [34].
Figure 1.2.: (A) DexOx conjugation to amines with consequent formation of imines and
(B) the possibility of an Amadori rearrangement on C3; (C) reaction with hydrazides
and consequent hydrazone formation.
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1.2.3. Oxidation Consequences
1.2.3.1. Physico-Chemical
The periodate oxidation, promotes dextran degradation and consequent Mw decrease.
This effect can be observed by size exclusion chromatography [14, 35]. The dexOx
presents longer retention times and increased polydispersity. Usually, the polymers Mw
trend, directly influences the resistance to flow, due to the hydrodynamic radio. There-
fore, the oxidation related decrease of the Mw, should yield less viscous solutions. How-
ever, as we will demonstrate on chapter 5, the concentration increase, results in a reverse
effect, attributed to the interchain cross-linking, artificially, increasing the Mw and con-
sequently the viscosity .
1.2.3.2. Biological
From the biomedical device perspective, the excessive oxidation could bring poor qualities
concerning the macro-monomer handling. However, a high reactive molecule could
be useful for high loading efficiency hence, high payload. The biological impact of
the dextran oxidation degree has been reported across several aspects. Concerning
the release of therapeutic agents on target tissues, where the release is dextranase-
dependent, the oxidation degree was reported to confer resistance to enzymatic hydrolysis
and consequent drug release [36].
Some works have described dexOx to be toxic and inhibit cell growth of different cell
lines. It has been suggested to be directly associated with the concentration of aldehyde
groups. The mouse leukaemic monocyte macrophage cell line was shown to be sensitive
to the aldehyde concentration (IC50 3 ￿mol/mL of aldehydes), though mitigated after
reaction with ethanolamine [7]. The evaluation of cytotoxicity by specific assays also
gave indications of possible dexOx toxicity towards keratinocytes, endothelial cell and
fibroblasts, though it could be related to interference of dexOx with the mentioned
techniques [37]. Nevertheless, the cross-linked dexOx, in the form of hydrogels, has
been reported several times as cytocompatible [37, 38, 39] as well as in this work, with
endothelial cells from rabbit cornea (chapter 5).
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1.3. DexOx Applications
The rise of pharmaceutical and biotech industries brought to the market an impressive
portfolio of new drugs of different natures for all sorts of unmet medical needs. The field
of drug delivery aims at delivering any drug at the right time in a safe and reproducible
manner to a specific target in a given concentration level. However, issues such as low
stability in vivo, short half-life and immunogenicity limitations are common. Among
several approaches to overcome these issues, the polymer conjugation has been one of
the preferred methods and has seen some products entering the market [5]. Polymeric
conjugation allows the increase of the hydrodynamic volume, decreasing the excretion
rate, hence, prolonging the plasma half-life and increasing the bioavailability. This effect
is remarkable when dealing with hydrophobic drugs, due to the deliverance of a higher
payload. It can also confer protection against the host immune system by shielding the
therapeutic protein [5]. The industry gold standard is a process known as PEGylation,
characterised by the grafting of polyethylene glycol (PEG) [40]. Most of the available
polymer-drug conjugates on the market, present this FDA approved polymer. Currently,
on clinical trials, one can also find N-(2-hydroxypropyl)methacrylamide (HPMA) copoly-
mer and polyglutamate to serve such purpose [5].
1.3.1. DexOx-Drug Conjugation
The characteristics of dexOx have been explored under the perspective of drug conju-
gation. Several studies, regarding the use of dexOx as the polymeric conjugate, will be
presented, focusing on the nature of the therapeutic entity and complexity of the system.
1.3.1.1. Small Molecules
Many antibiotics and anticancer agents suffer from hydrophobicity, which can be over-
come through conjugation to water-soluble polymers. The most straightforward strategy
is by direct conjugation to the ubiquitous chemical group, the amine group. Doxorubicin
will be used as an example of small drug delivery conjugated to dexOx, due to the high
number of studies found on the literature. Doxorubicin (a member of the anthracycline
ring antibiotics) has been used in the treatment of solid tumours and leukemias. How-
ever, due to the clinical limitation of potentially developing dose-related cardiotoxicity,
it has been coupled to dexOx through its amine group (Fig. 1.3A), which can decrease
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the sub-acute toxicity compared to the free drug [41]. The retention profile on different
tissues of the dexOx - Doxorubicin amine conjugate, was demonstrated to increase the
systemic circulation and decrease the total body clearance of the drug. Higher liver ac-
cumulation of the conjugate but decreased cardiac accumulation, was described, which
improved the issue of doxorubicin associated cardiactoxicity [42].
This and other set of studies (Tab. 1.2) demonstrate dexOx to be able to overcome some
of the most chronic issues in small pharmaceuticals delivery. The lack of a N-nucleophile
is not impairment for dexOx conjugation, though it makes the process straightforward
and highly efficient. It enables the delivery of hydrophobic drug in higher percentages
and generally, increases the plasma circulation half-life, reducing systemic toxicity and
increasing therapeutic efficacy.
1.3.1.2. Proteins
Proteins, when compared to the small drugs, have higher degrees of complexity. The pro-
tein’s native conformation defines its identity and the protein’s preservation is of utmost
importance for the activity maintenance. Generally, proteins are sensitive to temperature,
organic solvents and mechanical stress, which can promote protein denaturation and lead
to stability/activity lost. The exposed lysines (Fig. 1.3B) will determine the extension
of the interaction with dexOx [33]. This interaction will depend not only on the ratio
between aldehydes and amines but also on the molecular weight difference between the
polysaccharide and the protein. Three different enzymes were conjugated with dexOx’s
with variable Mw and were successful in preserving enzymes activities and stabilities, on
the presence of organic and air interfaces [43]. On the case of multimeric enzymes, the
stability and activity, the quaternary structure of bovine catalase [44] or L-asparaginase
[45], was also preserved by dexOx conjugation. The last examples demonstrate the
protein stabilising potential of dexOx. However, most examples were performed under
reductive amination conditions, which irreversibly bind the protein-dexOx conjugate. The
protein’s bioactivity can be partially/totally impaired by steric hindrance of the active
site.
DexOx has reached a phase III clinical trial1 as a conjugate to somatostatin (sms).
Somatostatin-receptors positive tumours can be targeted by sms which triggers cyto-
static and cytotoxic effects. However, natural sms has a short in vivo half-life due to
1Personal communication from Anders Holmerg “During 2010 sms-D70 will enter a registration phase
(in Mexico) and will hopefully be given "orphan drug status"”.
10
1.3 DexOx Applications
enzymatic degradation. The conjugation to a mildly oxidised dextran, recurring to re-
ductive amination, was able to achieve ~27 hours of plasma residency in mice [46] and
was still able to maintain the same degree of affinity with every receptor [47]. The phase
I clinical trial assessment of plasma concentrations and tolerability, showed the conjugate
to be well tolerated but the limiting dose was not established. However, no responses
were found [8]. Though, the concept of increasing the plasma half-life of a small protein
was demonstrated, a few issues related with the conjugate nature, were not addressed.
The authors estimated a ratio of four sms per dexOx chain. This high ratio might have
helped retaining the conjugate activity, because the sms active site has a lysine, likely
reacting with the aldehydes.
Figure 1.3.: Schematic example of oxidised dextran conjugated to (A) small molecules
(doxorubicin); (B) proteins; (C) antibodies, used in immunoconjugation. Aldehyde
highlighted with red circle
A more detailed study, involving the human growth hormone (hGH) - dexOx conjugate,
successfully yielded a pro-drug formulation with sustained release. The release was
dependent on the imine bond, while the reduced imine failed to release any hGH. The
conjugate was shown to be stable at 4 °C for up to 10 days and that could be stored
frozen (-70 °C) without activity loss. This evidence broadens the thermo-stability window
conferred by dexOx. The release kinetics of hGH from dexOx is correlated with the
dextran oxidation degree and directly affects the half-life of the conjugate. The in
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vivo studies confirmed the increased circulation period, at higher dose, for two days,
when compared to the bolus injection [48]. The authors established a strong correlation
between the oxidation degree and the extent of complex formation, which they believe
is favoured by the higher percentage of doubly oxidised residues, compared to the singly
oxidised residues, which are suggested to be under hemiacetals.
DexOx appears to be an interesting alternative to PEG, the industry gold standard
for protein pharmacokinetics modulation. The simple mix reaction yields a reversible
conjugate, which can be reduced to a stable and irreversible amine in one simple step.
The half-life of such conjugates is dependent on the nature of that bond, but most
important is the stability and environmental protection conferred by dexOx, enhancing
the delivery to target sites, with reduced systemic toxicity. Other examples of protein –
dexOx conjugates can be found on Tab. 1.2.
1.3.1.3. Immunoconjugates
The linearity of dextran’s chain and the wide range of molecular weights available, asso-
ciated to the multiple functionalities brought by periodate oxidation, allows the multiple
conjugation of different chemical entities. As described earlier, small pharmaceuticals,
are devoid of tissue specificity, leading to systemic toxicity. However, the simultaneous
conjugation with an antibody (immunoconjugate), can increase the therapeutic efficacy
on the target tissue (Fig. 1.3C).
To overcome the toxicity of the chemotherapeutic agents, and to improve their tis-
sue selectivity, antibodies directed against the tumour cells can be used. Daunomycin
(similar to doxorubicin) was the chosen anticancer agent. The tumours were injected
intraperitoneally, so as the immunoconjugates. But the intravenous route was found to
yield better results for the immunoconjugates and has being important on the therapy
success. However, the immunoconjugates still failed to achieve better results than the
drug – dexOx conjugate alone, in two experimental murine tumour systems [49]. On
other study by the same authors, they achieved improved results with the immunocon-
jugate, this time with the monoclonal antibody (mab) against rat α-fetoprotein. Under
the experimental conditions used, the immunoconjugate was more efficient impairing the
growth of α-fetoprotein-producing tumour cells, than daunomycin alone or conjugated
to dexOx [50, 51]. Indeed, this system was successful in decreasing, hepatoma cells
transplanted intraperitoneally, in rats. When administered intravenous, the immunocon-
jugate achieved better results, than through the intraperitoneal route. The success was
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attributed to the lower toxicity of the daunomycin on the conjugated form and the higher
specificity of the antibodies [52].
These last set of examples, render dexOx as an interesting choice to increase the efficiency
of pro-drugs. The final setup has extended plasma residency periods, reduced systemic
toxicity, improved the target specificity and increased therapeutic activity.
1.3.1.4. Gene-Delivery
Gene therapy expectations, as the next medicine revolution, have had their downturns.
The promising viral gene therapy, still with the highest transfection efficiencies of all
the available techniques, suffered major setbacks, in a pioneering treatment for severe
combined immunodeficiency diseases [53]. Therefore, while viral gene therapy is being
improved, other less pathogenic and immunogenic non-viral approaches have been ex-
plored. A comprehensive review on this subject can be found elsewhere [54]. Within
the context of polyplexes (DNA/polymer complexes), polyethylenimine (PEI) has been
considered the gold standard in gene delivery, because of its excellent transfection ef-
ficiencies [55, 56]. The dexOx-based strategy grafted oligoamines to the dexOx chain,
capable of complexing genetic material. The influence of dextran molecular weight, the
oxidation degree extension, several oligoamines and the transfection efficiencies of the
obtained polyplexes were screened [57, 58]. Despite most of the combinations, yield
stable polyplexes, only a few were active in transfecting cells. The tetramine, spermine,
conjugated to dexOx, was identified as the best transfection vector [57, 59]. Histopatho-
logical assessment revealed mild toxicity in the muscle and no abnormal finding in liver
or lung, as well as no systemic toxicity was observed [60]. Certain conditionings may
increase the transfection yield, not only formulation-wise but as well environmentally
related. Mesenchymal stem cells, cultured on 3D scaffolds (collagen reinforced with
polyglycolic acid) were more susceptible to transfection than when cultured on normal
surfaces. The 3D environment provides higher surface area for cell attachment, spread-
ing and proliferation, strongly affecting and increasing these cell events, periods when
cell are more susceptible to transfection [61].
Interestingly, the same polycations, were identified as being effective in eliminating the
pathological conformation of the cellular prion protein, responsible for self-propagating
the refolding of the normal prion protein and developing into neurodegenerative diseases,
known as spongiform encephalopathies [62].
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Table 1.2.: DexOx-based drug delivery strategies, overviewing the conjugation method,
strategy followed and dexOx characteristics.
Active factor Conjugation Kind
Therapeutic Application
Scope
Mw1
(kDa)
OD2
(%)
Ref.
Acyclovir Imine
Anti-viral; Hepatitis B; Increase
circulation
32 - 42 (200) [63]
Procainamide
Imine / Amine
(NaBH3CN)
Antiarrhythmic agent; Prodrug 43 33 - 90 [64]
Amphotericin B
Amine
(NaBH4)
Antifungal agent; Assessment of
conjugate stability and activity
40 1.5 - 52 [7]
Amphotericin B Imine Antifungal agent; Injectable hydrogel 100 - 200 33 – 75 [65]
Nystatin
Imine / Amine
(NaBH4)
Antifungal agent; Stable water-soluble
conjugate
9 - 74 5 - 50 [66]
5-aminosalicylic
acid
Amine
(pyridine–borane)
Chron’s disease; Sustained and targeted
delivery
6 - 500 12 – 93 [36]
Asulacrine /
Ellipticine
Hydrazide spacer
Anticancer agent; Increase solubility
and targeting
40 ~18 [28]
Cationic
dextran
Amine (NaBH3CN)
Anticancer; Attack cell surface sialic
acid
70 (57) [67]
Doxorubicin
Amine
(NaBH4)
Cancer chemotherapy; Nanoparticles
with antitumor efficacy
10 n.a. [68]
Doxorubicin-
HCl
Hydrogen bonds; to
tertiary amines
(NaBH4)
Anti-tumor specific delivery; DexOx as
the core of polypropylene amine
dendrimers.
60 (100) [69]
Pingyangmycin
Physical
entrapment
Chemoembolisation; Gelatin
microparticles
40 78.8 [70]
Indomethacin
Hydrophobic
interaction with
cholic acid
Non-steroidal anti-inflammatory drug;
DexOx/Cholic acid hydrazide micelles.
Self aggregating particles
40
29.2;
46.5
[71]
Naproxen
Inclusion complexes
in ß-Cyclodextrins
Anti-inflammatory; Improve in vivo
efficacy; DexOx grafted with
ß-Cyclodextrin. (NaBH4)
70 (~76) [72]
14
1.3 DexOx Applications
Active factor Conjugation Kind
Therapeutic Application
Scope
Mw1
(kDa)
OD2
(%)
Ref.
Mitomycin C Imine
Solid tumours; oxidised sulfopropyl
dextran microspheres
Sephadex n.a. [73, 74]
Doxorubicin
Amine
(NaBH4)
Anticancer; Systemic accumulation
profile
10; 70;
500
n.a. [42]
Kanamycin,
Isonyazide
Imine and
hydrazone
Tuberculose; Sephadex drug reservoir Sephadex n.a. [75]
Oligosaccharides Hydrazone
Study carbohydrate mediated
interactions
500 50 [76]
Iron (III)
Complexation in
alkaline solution
Antianemic; Iron repository n.a. 26 - 43 [77]
Rhenium-188
Cysteine grafting
(NaBH3CN).
Gluconate as
transchelator
Contrast agent; Nuclear oncology;
Improve contrast agent availability
70 (22) [78]
99mTc
Complexation
through cysteamine
grafting (NaBH4)
Contrast agent; Nuclear oncology;
Improve contrast agent availability
60 - 90 ~ 6 [27]
Histidine Amine (NaBH4)
Controlled release system; Enhance
osmotic activity
40 ~ 100 [79]
Aminoguanidine;
Agmatine
Amine (NaBH3CN)
Anti-tumour agent; Increase therapeutic
efficacy
70 (59) [80]
Glucose oxidase Amine (NaBH4)
Interfacial protection; Activity
preservation
6; 20;
150;
1000
(100) [43, 81]
Catalase Amine (NaBH4)
Activity preservation; Stabilisation of
multimeric proteins
6 20; 100 [44]
L-asparaginase Amine (NaBH4)
Activity preservation; Stabilisation of
multimeric proteins
20 (100) [45]
Several proteins Amine (NaBH4)
Protein stabilisation. Detect
protein-protein interactions
1.5; 6; 20 (100) [82]
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Active factor Conjugation Kind
Therapeutic Application
Scope
Mw1
(kDa)
OD2
(%)
Ref.
Pullulanase,
Amylase,
Cellobiase
Amine (NaBH4;
NaBH3CN)
Thermal stabilisation; Enzyme activity
preservation
10; 40;
70; 500;
2000
(100) [83, 24]
Cellobiase
Amine (NaBH4;
NaBH3CN;
(CH3)2NBH3)
Stabilisation and rigidification of the
protein 3D structure
70 (100) [33]
Lipase B
Amine
(NaBH4;
NaBH3CN)
Improve thermal stability activity 40, 250 (>100) [84]
Somatostatin
Amine
(NaBH3CN)
Somatosatin receptor positive tumours;
Improve circulation time, maintain
activity
70 - 75 (25)
[46, 8,
47]
Growth
Hormone
Imine
Increase therapeutic efficacy; Sustained
release, reduce high-dosing
1 - 100
6, 31,
50, 64
[48]
Hemoglobin Imine
Blood substitution; Plasma
expander/oxygen delivery
200- 275 (56) [85]
Hemoglobin;
deoxyhe-
moglobin
Imine / Amine
(NaBH3CN/NaBH4)
Blood substitution; Plasma
expander/oxygen delivery
10 – 40 n.a.
[86, 87,
31, 88]
Factor IX;
Protein C
Imine
Blood clotting; Increase plasma
residency
10 n.a. [89]
mabT101 Amine (NaBH3CN)
Tumour targeting; Reduce
immunogenicity
6 (190) [90]
Fab fragments Amine (NaBH3CN)
Tumour targeting; Reduce
immunogenicity
6 (190) [91]
mabT1010;
Doxorubicin
Amine (NaBH3CN) Solid tumours; Immunoconjugate n.m. n.a. [92]
nucleotide
analogue;
anti-IgM
Amine (NaBH3CN) B leukemia cells; Immunoconjugate
10, 40,
50
n.a. [93]
Daunomycin; 2
￿= antibodies
Amine (NaBH4) Solid tumours; Immunoconjugate
10, 40,
50
n.a. [49]
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Active factor Conjugation Kind
Therapeutic Application
Scope
Mw1
(kDa)
OD2
(%)
Ref.
Daunomycin;
mab/pab
Amine (NaBH4) Solid tumours; Immunoconjugate 10 n.a.
[50, 52,
51]
Adriamycin
(Doxorubicin);
mab
Amine (NaBH4) Tumour targeting; Immunoconjugate 40 25 [94]
99mTc; EGF Amine (NaBH3CN)
Radiotherapy of EGF receptors
expressing tumours;
Immunoconjugate-like
10 (46) [95]
99mTc;
anticytokeratin
mab
99mTc-dextran
complex; Imine
Radio imaging
Immunoconjugate
10 n.a. [96]
p-Nitroaniline Amine (NaBH4)
nonlinear optical chromophores
Increase thermo and photostability
150 ~7 [97]
1 - Native dextran molecular weight; 2 - When the real OD was not determined, the theoretical OD is
mentioned in brackets; n.a. – not applicable; n.m. – not mentioned
1.3.2. Hydrogels
The hydrophilic nature and reactivity of oxidised dextran has been exploited on the
synthesis of hydrogels (Fig. 1.4A), either has the main backbone or has a cross-linker.
The existing aldehydes, offer complementary reactivity towards amines, hydrazides and
hydroxyl (on acidic media) groups, avoiding the need for chemical initiators or other
adjuvants. Other initiator-free cross-linking methods, include the pairs thiol/acrylate
[98] or hydroxyl/isocyanate [99], however, the latter has to be prepared on an aprotic
solvent, because of the prompt reaction of water towards the isocyanate group. A very
comprehensive review on cross-linking methods of hydrogels can be found elsewhere
[100, 101], as well as a more specific review on biodegradable dextran hydrogels [6].
Gelatine was one of the first materials, cross-linked by dexOx, to yield a hydrogel [30].
As a protein, it contains lysines, responsible for the cross-linking. This initial study,
identified a set of conditions, related to dexOx, responsible for the decrease in gelation
time, such as the increase of the oxidation degree and the increase of the dextran Mw.
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The OD increase presents higher concentration of reactive species, speeding up the
reaction and reducing gelation time. The onset of reaction can also be controlled by the
media pH, ionic strength and temperature [30, 102]. This formulation was evaluated
as a hydrogel film, for the controlled release of several proteins (BSA and EGF). The
protein molecular weight and the lysine content influenced their release profiles. As
this system is susceptible to interact with proteins, it retained BSA much easier (68
kDa; 60 Lys residues) than EGF (6 kDa; 2 Lys residues) [103]. This system proved to
have an acceptable biocompatibility, after direct comparison with commercially available
wound dressing materials, after in vitro cytotoxic evaluation and by in vivo subcutaneous
implantation in mice [37].
The chitosan derivative, carboxyethyl chitosan (CEC) which, contrary to the native chi-
tosan, is readily soluble in non-acidic aqueous media, yields versatile hydrogels [104]. The
hydrogels of dexOx and CEC have fast gelation rates (30 – 600 seconds), depending on
the polymers concentration, feed ratio and mixing temperature and could be modulated
to closely match the mechanical properties of the tissue of interest. The growth factors
free hydrogel, promoted adhesion and growth of encapsulated mouse fibroblasts. It also
accelerated wound healing on a mice full-thickness transcutaneous wound model [105].
Our research group has approached the dexOx cross-linking with adipic acid dihydrazide
(AAD). That formulation yields hydrogels with tuneable gelation rates, mechanical prop-
erties, porosity, swelling ratios and dissolution profiles. The feed concentration of dexOx
or AAD as well as the dexOx OD, control the hydrogels characteristics [14], further
characterised on chapter 5. Other compatible crosslinkers (such as PEI) were also ap-
proached (Fig. 1.4A), but without complete characterisation.
Figure 1.4.: (A) DexOx-based hydrogels cross-linked with nanoparticles of PEI (unpub-
lished data); (B) SEM imaging of dexOx-based microparticles, cross-linked with AAD
and prepared in an all-water emulsion as described in chapter 6.
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1.3.3. Particles
The use of dexOx on other configurations such as particles (Fig. 1.4B) can be useful on
drug delivery and could have advantages, over prodrugs or hydrogels matrices, yielding
higher therapeutic efficacy. Particles have higher surface to volume ratios, than hy-
drogels, allowing higher control over the drug release. Like the hydrogels, the dexOx
particles, can be prepared by cross-linking with N-nucleophile polymers, such as chitosan
[68] or gelatine [70, 106]. As with the several strategies described on the design of pro-
drugs, dexOx is susceptible of modification, broadening the strategies on the production
of particles. The grafting of moieties that promote self-aggregation and stabilisation of
the particles, is commonly used with polymeric biomaterials and some examples can be
found with dexOx as the core polymer. Methyl polyethylene glycol (MPEG) was grafted
to dexOx, sterically stabilising the nanoparticles, allowing the aldehydes to bind BSA
[107]. A micro emulsion method was used to prepare nanoparticles of chitosan and a
dexOx-doxorubicin reduced conjugate, which yielded monodispersed particles with ~100
nm of diameter [68]. Other interesting approach for doxorubicin, used dexOx as the
dendrimeric core [69]. The several aldehyde moieties were reacted with polypropylene
amine, which was subsequently reduced with sodium borohydride.
A more detailed review on nanoparticles will be presented on chapter 3.
1.3.4. Surfaces
Biomedical devices require surface biocompatibility as they will be in contact with physio-
logical environment. Therefore, the inertness of dextran render it appropriate for surface
coating strategies. Silicon is a widespread material in biomedical devices, which can be
further modified. The silanisation, for example, with aminopropyldimethylethoxy silane
(APDES) [108] or aminopropyltriethoxy silane (APTES) [109, 110, 111, 112], can be
used as an intermediary step for the consequent coating of the aminated surfaces. By
reductive amination, dexOx can be reverted to a dextran-like inert state, limiting cell
adhesion and spreading [109]. However, after a second periodate oxidation and grafting
of specific peptides, such as RGD [111], it is possible to redirect the dexOx coating to
any kind of specific surface bioactivity, by the proper grafting of specific biomolecules.
Indeed, the grafting of the laminin-based peptide, IKVAV, promoted substantial neu-
ral cell adhesion and reduced fibroblast and glial cell adhesion. This kind of approach
could lead to the development of guiding surfaces for the neurite outgrowth [112]. But it
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could also be used to minimise the effects of glial scar tissue on neural recordings in deep
brain electrodes. On another work, dexOx was used to bridge a polylysine surface and
laminin/TGF-ß1 (transforming growth factor). The grafted TGF-ß1 was successful in
avoiding the glial scar through decrease of the astrocytes proliferation on the electrodes
(Fig. 1.5) [113].
Figure 1.5.: Surface coating of biomedical devices by dexOx, bridging laminin/TGF-ß1.
Adapted with permission from reference [113].
A final and different example, where the coated surface was not aminated, came from the
gecko-inspired surface based on poly(glycerol sebacate acrylate), which was spin-coated
with dexOx. It increased the interfacial adhesion on biological tissues [114], through the
exposed amine groups of the target tissue, skin.
Table 1.4.: DexOx-based applications involving 3D matrices or surface coatings.
Application
Application /
Drug
Scope & Strategy
Mw1
(kDa)
OD2
(%)
Ref
Hydrogel No
Thorough characterisation; Gelatine XL;
Imine
10 - 500 5 - 70
[30,
102]
Hydrogel No
Thermal and rheological properties;
Gelatine XL; Imine
70 5 – 20 [115]
Hydrogel EGF; BSA
In vitro release study; In vitro and in vivo
biocompatibility; Gelatine XL; Imine
70 5 – 20
[37,
103]
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Application
Application /
Drug
Scope & Strategy
Mw1
(kDa)
OD2
(%)
Ref
Hydrogel Tissue adhesive
Characterisation and comparison to fibrin
glue; Ethylenediamine modified gelatine XL;
Imine
200 15 - 70 [116]
Hydrogel
3D vascular
tissue
engineering
EC growth on 2D; SMC growth on 3D;
Gelatine XL; Imine; IPN with glycidyl
methacrylate
400 –
500
14 (9) [117]
Hydrogel
Support in vitro
growth
General characterisation; Gelatine, chitosan
or BSA as XL; Amine (NaBH4)
40 n.a. [118]
Hydrogel
Enhanced
wound healing
Mechanical; physico-chemical; biological
characterisation; N-carboxyethylchitosan
XL; Imine
76
5, 15,
25
[104,
105]
Hydrogel None Gelation rate; Succinyl-chitosan XL; Imine 60 – 90 16 - 82 [119]
Hydrogel Bone glue
Chemical, biological and biomechanical
characterisation; Modified chitosan XL;
Imine
15 – 20 40 [120]
Hydrogel
Corneal
incisions and
tissue adhesive
Biological and functional characterisation;
8-arm PEG amineXL; Imine
10 50
[121,
122,
123,
124, 39]
Hydrogel
Hemorrhage
sealant
Physico-chemical, mechanical and blood
coagulation characterisation; Polyallylamine,
Chitosan or Glycol chitosan XL; Imine
100 –
200
36 - 88 [125]
Hydrogel Amphotericin B
Self-gelling hydrogel;
Carboxymethylcellulose hydrazide XL
100 –
200
5 – 75 [65]
Hydrogel
Prevent
peritoneal
adhesions
Self-gelling hydrogel;
Carboxymethylcellulose hydrazide XL
70 n.a. [38]
Hydrogel
Clinical
diagnostics
Protease detection by degradation rate;
Protease-sensitive peptides XL
2000 107 [126]
Nanoparticles Doxorubicin
Improve therapeutic efficacy (ø ≈ 100 nm);
Chitosan XL; Amine (NaBH4)
10 n.a. [68]
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Application
Application /
Drug
Scope & Strategy
Mw1
(kDa)
OD2
(%)
Ref
Microparticles Pingyangmycin
Synthesis, characterisation & in vitro
release (ø ≈ 50 - 200 µm); Gelatine XL
40 78.8 [70]
Microspheres
AIDS related
pneumonia;
TAPP-Br
Synthesis, characterisation & in vitro
release (ø ≈ 80 - 120 µm); Gelatine XL
70 81.7 [106]
Nanospheres
Proteins
delivery; HSA
Synthesis and characterisation; (ø < 200
nm); MPEG modified dexOx; Albumin XL
70 47 [107]
Micromicelles Indomethacin
Self-aggregating particles. Synthesis,
characterisation & in vitro release (ø ≈ 500
nm); DexOx-grafted cholic acid
40 46 [71]
Microparticles Mitomtcin C
High-load delivery, drug stability and
reduced toxicity (ø ≈ 100 µm); Oxidised
sulfopropyl dextran
Sephadex n.a.
[127,
73, 74]
Magnetic
nanoparticles
Delivery of
biomolecules
Synthesis and (ø ≈ 8 nm); Iron-dextran
conjugated particles, activated by oxidation
40 48 [128]
Dendrimers Doxorubicin
Synthesis, biological characterisation, drug
release and selective cell-uptake;
Polypropylene imine-grafted dexOx
(NaBH4) with encapsulated drug
60 (100) [69]
NP coating
Protein
stabilisation
Prevent GOX inactivation, immobilized on
magnetic nanoparticles; DexOx coating
(NaBH4)
20 (180) [81]
Surface
Possible
immobilisation
of proteins
Modification of aminated matrices;
Aminated matrices; Enzacryl AA/AH
10, 40
(6 –
20)
[129]
Surface
Biocompatible
non-fouling
surfaces
Prevent protein fouling; Functionalised
silicon with APDES; dexOx coating
(NaBH3CN)
10 6 – 100 [108]
Surface
Control
interactions at
tissue/material
interface
Control surface reactivity by oxidation
extension; Functionalised silicon with
APTES; dexOx coating (NaBH3CN)
110 20 - 50 [110]
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Application
Application /
Drug
Scope & Strategy
Mw1
(kDa)
OD2
(%)
Ref
Surface
Control cell
adhesion; RGD;
IKVAV)
Limit and promote specific cell adhesions
and growth; Functionalised silicon with
APTES; dexOx coating (NaBH4)
40, 70 (50)
[109,
111,
112]
Surface TGF-ß1
Decrease astrocyte adhesion and
proliferation; Functionalised silicon with
APTES, or poly-L-Lysine; dexOx coating
(NaBH4)
40 (20) [113]
Surface
Biomedical
devices coating
Gas-plasma n-heptylamine deposition;
dexOx coating of aminated surface
(NaBH3CN)
9, 74,
515,
2000
17 -
100
[130]
Surface
Immunochemical
microarrays
Increase detection sensitivity; Aminated
surface (APTES) dexOx dipped
(NaBH3CN)
20 4 [131]
Surface
Oligosaccharide
probes
Improve carbohydrate-mediated molecular
interactions; Hydrazide-linked
monosaccharides to dexOx
500 (50) [76]
Surface
Rennin &
Protein A
Improve performance as hydrophilic spacer;
Aminated Agarose support; (NaBH4)
6; 20 (50) [132]
Surface Lysozyme
Particles coated with dexOx for the
immobilisation of lysozyme; Amino-Silicate
carrier
35, 170
2000
(200) [133]
Surface
Improve ELISA
hapten immuno
detection
dexOx acts as long spacer, permitting easy
hapten recognition; DexOx bridging hapten
and BSA for immobilisation
20 20 [134]
Surface
Gecko-inspired
tissue adhesive
Topography and dexOx reactivity (tissue
amines) provide adhesiveness; poly(glycerol
sebacate acrylate) surface, coated with
dexOx, hemiacetal bonding
70 14 [114]
1 - Dextran native molecular weight; 2 - Real oxidation when estimated or theoretical oxidation in brackets; XL - cross-
linker; n.a. - not available
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1.4. Conclusion
Since the approval of dextran as a plasma expander, over 60 years ago, this polysaccharide
has seen many different uses in pharmaceutical sciences. The mild oxidation of dextran,
by the periodate ion, yields a very reactive macro-monomer towards N-nucleophiles
compounds. It does an interesting job in increasing the solubility, half-life and therapeutic
efficacy of small pharmaceuticals. Concerning proteins, dexOx preserves the stability and
activity across a wide range of temperatures, providing sustainable release in vivo, as
long as the imine bond is not reduced. In fact, dexOx has entered the clinical stage,
as a carrier of somatostatin, opening the door for other suitable formulations to be
commercialised, with the advantage of having a very competitive price compared to
other biomedical relevant polysaccharides. The properties of oxidised dextran have also
been used on series of different approaches for the design of hydrogels, particles and is
an interesting option in surface coating.
However, the consequences of mild periodate oxidation are not fully understood. The
periodate oxidation leads to dextran degradation which has strong consequences on the
macro-monomer’s characteristics affecting the solutions viscosity and affecting injectabil-
ity.
The assessment of the real OD after periodate oxidation is vital for the design of drug-
conjugate formulations, hydrogels or other approaches, therefore, the questions raised
about the amount of aldehydes reacting is extremely important.
Some of these issues will be approached on chapter 4 and chapter 5.
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2. Pro-Angiogenic Therapies
Impaired-angiogenesis associated pathologies, such as ischemic heart disease (leading
cause of death worldwide in 20041), wound healing or stroke, have a high-burden on
society. Regenerative medicine is getting closer to offer some solutions, however, the
regeneration of vascular tissues via polymeric-based strategies is yet to see successful
outcomes [135]. Different approaches can be found on the literature, which include the
delivery of one or more specific growth factors [136], the incorporation of bio-mimetic
motifs on the polymeric structure [137] or the delivery of specific cells [138, 139]. Usually,
the design strategy of polymeric matrices contemplates, not only the final application, but
as well the specific growth factors or cell type which are being delivered. In this section,
the VEGF biology, VEGF-delivery-based approaches, as well as cell-based strategies, on
pro-angiogenic therapies, will be overviewed.
2.1. VEGF in Health and Disease
Angiogenesis is the phenomenon by which de novo blood vessels are formed. It is ob-
served during embryogenesis, constituting the first organ in the embryo. In the adult
stage, when dysregulated, the newly formed blood vessels contribute to numerous ma-
lignant disorders, such as tumours and some non-tumoural pathologies, like age-related
macular degeneration [140]. The existence of angiogenic factors was initially postu-
lated on the basis of the strong neovascular response induced by transplanted tumours
[141]. Many molecules have been implicated as positive regulators of angiogenesis, in-
cluding acidic or basic fibroblast growth factor (FGF), TGF α and β , hepatocyte growth
factor (HGF), tumour necrosis factor α (TNF-α), angiogenin, interleukin 8 (IL-8) and
angiopoietins [142]. Over the past 20 years most of the research has been devoted to
the research and understanding of the biology of the vascular endothelial growth factor
(VEGF). VEGF is a heparin-binding growth factor specific for vascular endothelial cells
1World Health Organisation. The Global Burden of Disease - 2004 update
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that is able to induce angiogenesis in vivo, described for the first time in 1983 [143] and
fully characterised and sequenced in 1989 [144]. A very comprehensive historic perspec-
tive of the quest for angiogenesis and its most important players can be found elsewhere
[145].
The identification of clear targets on the development of angiogenesis, such as VEGF,
allowed the design and development of new therapies. Such anti-angiogenic therapies
address pathologies where the dysregulated blood vessel formation could be hindered,
preventing pathology development and hopefully leading to cure. The predominant role
of VEGF in angiogenesis led to the development of anti-angiogenic agents targeting
soluble VEGF (e.g. Avastin - humanised variant of an anti-VEGF antibody), arresting
angiogenesis and stoping the blood flow to nourish the growing tumour [146].
VEGF has been related to vascular permeability events in acute/chronic inflammation,
cancer and wound healing. Indeed, it was formerly called vascular permeability factor
(VPF), exactly because of its propensity in inducing vascular permeability and leakage.
The use of VEGF, in clinical settings, where a pro-angiogenic response is necessary, has
also been addressed. Unfortunately, clinical trials testing the pro-angiogenic potential
of VEGF alone, have not had the expected results [147, 148]. Part of this failure is
attributable to suboptimal delivery strategies. Stimulating the growth of durable and
functional vessels is a more formidable challenge than previously anticipated. Recent
advances in therapeutic neo-vascularisation, applied to ischemic disease states, focus
on better delivery of growth factors or combination of several angiogenic entities, ad-
dressing better mimicking of natural healing processes. These strategies can involve
multi-growth factor delivery in different spatio-temporal windows and encapsulation of
cells in bioresponsive polymeric matrices.
This review will briefly overview VEGF’s biology and role in the complex and coordinate
process of angiogenesis. The main focus will be on the most recent and relevant studies
dealing with the VEGF delivery on a therapeutic setting and new perspectives on cell-
based therapies.
2.2. VEGF Biology
Vascular endothelial growth factor is a homodimeric glycoprotein with a variable Mw. The
VEGF family includes VEGF121, VEGF165 (usually referred solely as VEGF), VEGF189,
VEGF206 (among other isoforms) and a structurally related molecule, placental growth
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factor (PlGF). This gene family has a unique role in controlling growth and differentiation
of multiple components of the vascular system. Lymphatic angiogenesis, for instances,
is regulated by VEGF189 and VEGF206 [149, 150]. The VEGF gene is split among eight
exons and the different isoforms arise from alternative exon splicing events [151, 152].
The shortest isoform, with 121 amino-acids is an acidic protein with no affinity towards
heparin (low extracellular matrix affinity) and is freely diffusible. The 165-amino-acids
isoform (38 kDa) has some heparin affinity and is the most similar to the native VEGF (45
kDa). The other isoforms (189 and 206) are highly basic and are completely arrested by
the extracellular matrix (ECM) [153]. The ECM bound isoforms have plasmin cleavable
sites which allow to reestablish the soluble VEGF pool upon ECM remodelation and
degradation by growing vascular vessels (Fig. 2.1) [154]. This plasmin-cleavable VEGF
Figure 2.1.: Schematic organisation of the VEGF gene and most common VEGF iso-
forms, result of alternative splicing events. Adapted from [155].
fragment, has no affinity towards heparin, compared to VEGF165 [153]. This isoform is
not so strongly bound to the ECM as the heavier isoforms, existing on an equilibrium with
a soluble form, showing optimal characteristics of bioavailability and biological potency.
The different isoforms with differential affinity towards the ECM allow the creation of
a VEGF gradient able to guide new vessel growth, having impact on development and
patterning of the vascular system [155].
There are several cell receptors which are responsible for mediating VEGF activity [142]
(Fig. 2.2). The VEGF receptor 1 (VEGFR1 or Flt1) binds preferentially to VEGF165 and
VEGF121 but also to PlGF. The signalling properties seem to evolve throughout the de-
velopment stage, but it was also proposed that it could lure VEGF from any mitogenic
activity by preventing from binding to other receptors [156]. This down-regulation is
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Figure 2.2.: The role of the different VEGF receptors. Based on reference [142]
accompanied by a soluble spliced variant of VEGFR1 (sVEGFR1). The major media-
tor of the angiogenic enhancing effects is VEGF receptor 2 (VEGFR2, Flk1 or KDR).
Upon VEGF binding, VEGFR2 dimerises and propagates its signalling through several
phosphorylation cascades, resulting in mitogenic, chemotactic and prosurvival responses
(Fig. 2.3) [157, 158, 159]. Other interesting receptors are Neuropilins (NRP 1 and 2)
which are also implicated in neuronal guidance. Neuropilin dimerises with VEGFR2 upon
VEGF165 binding, mediating chemotaxis. The interesting similarities between the vascu-
lar and neuronal networks throughout the body and the shared processes are reviewed
elsewhere [160].
VEGF is known to activate most of the signalling pathways in endothelial cells and
guiding cell fate (Fig. 2.3). It plays an important role in non-pathological conditions, as
autocrine VEGF is necessary for in vivo cell survival and consequently, for the homeostasis
of blood vessels in the adult [161]. After subjecting endothelial cells to serum starvation,
it was observed that VEGF acts as an important survival factor. Promotes survival
activity through, phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway,
preventing apoptosis induced by serum starvation [157]. It was also shown to have
neuroprotective activity, by increasing the VEGFR2 expression, stimulating the activation
of the PI3K/Akt and ERK-1/2 pathway [162].
The VEGF binding to VEGFR2 leads to receptor dimerisation, internalisation through
28
2.3 Therapeutic Angiogenesis
Figure 2.3.: VEGF pathways taken from http://david.abcc.ncifcrf.gov/.
endocytosis and consequent signal transduction. The VEGF matrix immobilisation, im-
pairs this event, but leads to prolonged activation kinetics of VEGFR2 which recurs to β1-
integrin dimerisation for signal transduction. This phenomena leads to different VEGFR2
phosphorylation patterns and enhancement of the p38/MAPK (Mitogen-activated pro-
tein kinase) cascade [163], leading to actin reorganisation and inducing cell migration
(Fig. 2.4).
The thorough knowledge of VEGF’s biology is of utmost importance on the design of
delivery strategies. VEGF is a very potent mitogen, with half-lifes below 30 minutes
[164] and the fast consumption leads to low therapeutic efficacy, claiming for better
delivery efficiency [147, 148].
2.3. Therapeutic Angiogenesis
Several unmet medical needs strive for normal vascular perfusion. Pro-vascularisation
therapies are expected to bring benefit on the healing response, by the organism. Patholo-
gies like peripheral vascular disease, ischemic heart disease, wound healing, as well as
cell and tissue transplants, could be addressed by such therapies [135].
In the complexity of the angiogenic process, VEGF is one of the most important players.
It induces activation, promotes the migration and guides the proliferation of endothelial
cells on the sprouting of new vessels. However, the sprout and proliferation of endothelial
cells is not enough to yield mature vessels. Smooth muscle cells (SMCs), are also
essential on the development of mature vessels. These cells will accommodate and
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Figure 2.4.: β1-integrin is required for clustering and continued internalisation of VEGF-
R2. Adapted from [163].
stabilise the new vessels, forming new extracellular matrix and inhibiting the new sprouts
regression [165]. Approaches, such as the dual delivery of VEGF and SMC specific growth
factors, with distinct release profiles, can lead to the formation of mature vasculature as
compared to either of the growth factors delivered alone or simultaneously [166, 136].
Parallel to this research, the last decade has seen the rise of improved pro-angiogenic cell-
based therapies, due to the identification of new cell populations from different sources,
with high therapeutic potential. The identification of endothelial progenitor cells (EPC),
among peripheral blood mononuclear cells, which migrate/proliferate to neovascularisa-
tion sites and differentiate into endothelial cells in situ, oppened new lines of research
[167]. This event has been observed to be induced by angiogenic factors, including
VEGF [168]. The therapeutic potential of EPCs was first assessed in a mice hindlimb
ischemia model, where exogenously administered EPCs improved neovascularisation and
enhanced functional recovery [169].
It is highly relevant to be aware of the pathological settings and the disease’s biol-
ogy, upon delineating strategies for regenerative medicine approaches in order to mimic
physiological signalling and achieve biologic functionality. Some of the most relevant ap-
proaches involving VEGF polymeric delivery systems will be addressed, as well as recent
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achievements in cell-based approaches, in the context of therapeutic angiogenesis.
2.3.1. Polymeric Matrices-Based Strategies
The tissue regeneration/engineering strategies usually fall into three categories, con-
duction, induction and transplantation of cells. Conductive strategies design implantable
biomaterials that can provide structural support for ingrowth of the desired healthy host
cells. Inductive strategies, include growth factors within the polymeric matrices, to
enhance cellular ingrowth events, promoting better tissue regeneration. The transplan-
tation of cells, together with the constructs, expects their participation on the tissue
regeneration process [170]. Most of the strategies to be reviewed shortly, fall within the
latter two categories.
A key challenge in engineering functional tissues is the limited capacity of oxygen and
nutrients transport into the tissue, which is confined to the maximum diffusion distance
of oxygen and nutrients ≈ 100 ￿m [171, 172]. The use of VEGF within the scaffolds has
been seen as a key factor in promoting angiogenesis and initiate the vascularisation pro-
cess. The rationale is to mimic key aspects by which the ECM controls the bioavailability
and signalling activity of VEGF in the body.
2.3.1.1. Diffusion Controlled
The incorporation of VEGF in polymeric matrices leads to a diffusion-dependent release,
controlled by the hydrogel’s micro-viscosity, unless the matrix has some kind of affinity
with the growth factor. Several cellulose derivatives, with or without ionic charge, have
been assessed for the topical delivery of VEGF. More than viscosity or micro-viscosity
of the hydrogels, the release can be controlled by the interactions of VEGF with the
polymeric chain. Possible structural similarities between carboxymethyl cellulose (CMC)
and heparin have been observed to retard the release of VEGF, when compared to
hydrypropyl cellulose (HPMC) or methyl cellulose (MC) [173].
More complex hydrogels, prepared by UV-cross-linking in the presence of polyethylene
glycol diacrylate (PEGDA) and allyl isocyanate-grafted dextran, having VEGF mixed
with the feeding solutions, were studied. Dextran was further modified with amine,
carboxilic and methacrylate moieties to increase the hydrogel potential. The different
functionalities were able to modulate the VEGF release. The aminated matrices showed
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a 20% burst release, compared to all the other ones, where VEGF remained mostly
entrapped within the scaffold [174].
However, none of this strategies relies on a strong interaction of VEGF with the matrix
and the release mechanism is mainly diffusional.
2.3.1.2. Covalent Immobilisation
Providing a sustained release by simple diffusion usually leads to non-controlled burst
releases and high VEGF concentrations on the implantation loci which could promote
vessels malformation. The rationale, behind VEGF immobilisation is related with the
induction of cell growth, mimicking the ECM-immobilised VEGF isoforms. The immo-
bilisation can be based on reversible or irreversible covalent bonds, regulating VEGF
release or not.
An uncommon approach immobilised VEGF by recurring to glycosilated species of VEGF.
The carbohydrate moiety was periodate-oxidised and further covalently linked to a hy-
drazide modified PLGA surface by the reversible hydrazone. VEGF was also bound
by carbodiimide chemistry to the PLGA surface. The immobilisation was mediated by
dihydrazide spacers of different lengths, which modulated the amount of immobilised
protein as well as its accessibility to soluble specific antibodies and receptors, stressing
the importance of the non-random immobilisation of VEGF [175].
A more traditional approach, used carbodiimide chemistry to immobilize VEGF. Collagen
is a widely used material in tissue engineering-based applications due to their growth
support of several cell types. Immobilised VEGF on porous collagen scaffolds, maintained
biological activity and promoted the infiltration and proliferation of endothelial cells in
the 3D scaffold. The system was able to promote human umbilical vein endothelial cells
(HUVEC) penetration and proliferation at deeper distances within the hydrogel compared
to when only soluble VEGF was present [176].
2.3.1.3. Composite Constructs
The assembly of scaffolds with materials of different nature, composites, is a common
approach. In nature, the bone tissue, is an example of a composite material, where a
complex mix of inorganic versus organic materials is found, deeply irrigated by blood
vessels. Commercially available bone grafts, usually do not contemplate a strategy for
the graft vascularisation throughout the regeneration process.
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To overcome this issue, VEGF was entrapped in alginate microspheres, easily prepared
by dropping an alginate solution on a Ca2+ solution. To control the initial burst release,
the microspheres were later encapsulated in several combinations of alginate, chitosan
or chitosan/polylactic acid (PLA) scaffolds. The former construct presented the most
interesting release results, with low burst release and sustained release of VEGF (≈ 50%)
during 4 weeks, leaving good indications for bone grafting [177].
The use of calcium phosphate bone cements is commonly used for replacement of autol-
ogous bone grafts. The physical adsorption of VEGF to an unmodified bone cement or
to the same material modified with collagen or O-phospho-L-serine was performed. The
composites achieved a good binding capacity to VEGF, though with moderate initial
burst releases. However, the VEGF biological efficacy was higher for the O-phospho-L-
serine modified cements, compared to the blank samples [178]. The further modification
of the same cements with heparin, was able to improve and reduce the initial burst re-
lease of VEGF. Furthermore, the presence of heparin, not only had a higher impact on
VEGF’s biological activity, as even favoured good endothelial cells adhesion and prolif-
eration [179].
2.3.1.4. Multiple Release
The angiogenesis process, relies on several timely events, from the sprouting moment up
to the maturation stage. The breakthrough study, mentioned earlier [166] was performed
with PLGA scaffolds. VEGF was mixed with the polymer and platelet-derived growth
factor (PDGF) was entrapped within PLGA microspheres. This approach temporally
controls the release of both growth factors. On an initial stage, occurs a rapid release of
VEGF, followed by the slower release of PDGF, triggering different events and promoting
a better maturation of the induced angiogenesis.
Hyaluronic acid (HA) was thiolated and further cross-linked by PEGDA, as a matrix for
the dual release of VEGF and keratinocyte growth factor (KGF) [180]. Animals receiving
hydrogel implants with both GFs developed more mature micro-vessels networks than
in any of the other study conditions, even in the absence of HA, demonstrating the
relevance of the polymeric matrix. A similar approach used HA-thiolated, but also
thiolated gelatine and heparin, cross-linked with PEGDA. Heparin was included to delay
the GF release, based on their natural interaction. Indeed, the concentration of heparin,
modulated the VEGF/bFGF release, extending the angiogenic response over a period of
weeks and providing better micro-vessel formation [181]. The same approach, involving
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HA, gelatine and heparin, studied the loading of VEGF in combination with a second
GF, like angiopoetin 1 (Ang-1), KGF or PDGF to promote neo-vessel maturation. The
inclusion of heparin, showed a growth factor specific effect, promoting higher micro-
vessel maturity for the VEGF/PDGF combination, followed by KGF, but inhibiting for
the pair VEGF/Ang-1 [182].
The multiple delivery commonly addresses several growth factors for different cell lin-
eages. However, certain cellular pathways, if down-regulated, could enhance neoan-
giogenesis. In that sense, injectable alginate matrices were used to release DATP (γ-
secretase inhibitor; inhibition of the Notch signalling pathway may enhance regional
neovascularisation [183]) and VEGF promoted increased cell migration and sprout for-
mation and induced faster recovery of blood flow on an ischemic hindlimb model [184].
Figure 2.5.: Schematic example of different VEGF immobilisation approaches and im-
pact on release profile. Coloured arrows on the timeline indicate the triggering release
stimulus on the respective system.
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2.3.1.5. Stimuli-Sensing
A research trend in the last few years has been based on taking advantage of the host
tissue feed-back, for releasing growth factors on-demand. Some ambitious approaches,
involve the production of VEGF variants, with bioactive amino-acid sequences. Hubbell’s
group has been developing several strategies, involving fibrin as the biomaterial and
modulating material responses to the wound environment. A modified version of VEGF
(VEGF-TG), which cross-links to fibrinogen by the transglutaminating activity of factor
XIII during fibrin polymerisation, but also has a proteolytic sensitive sequence, is released
by the fibrinolytic activity of the wound environment. This form of VEGF active release
showed to have superior results compared to passively released VEGF [185, 186, 187].
Simpler approaches, took advantage of the dimeric nature of VEGF to cross-link a low-
molecular-weigh-heparin-modified star PEG. The formed hydrogel is sensitive to immo-
bilised VEGF-receptors, promoting the erosion of the matrix and releasing VEGF [188].
However, VEGF can be chemically bound to plain PEG diacrylate hydrogels, engineered
with protease sensitive peptides and adhesion peptides (RGD) to induce new vasculature
growth inside the implant. The success of this approach was due to a cell-demanded
vascularisation [137].
The necessity of overcoming the bolus delivery of VEGF, providing an effective and
controlled spatio-temporal presentation to the target tissues, has seen many different
strategies arise. We have mentioned approaches that simply confine VEGF in polymeric
microspheres or matrices to the promotion of VEGF binding through chemical or physical
means to the scaffold. The sketch on Fig. 2.5 resumes the most common ways of VEGF
incorporation. Classical release profiles for the different situation are pictured, for better
visualisation of the impact of each of those strategies.
Table 2.1.: VEGF delivery from polymeric matrices.VEGF delivery from polymeric ma-
trices. Other significant literature on the past years (≥2006).
Delivery strategy VEGF integration;
Concentration
Remarks Ref.
Bioactive PEGDA hydrogel with
RGD and collagenase sensitive
peptides
PEGylated and matrix
immobilised
Promoted HUVEC motility and
matrix remodeling
[189]
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Delivery strategy VEGF integration;
Concentration
Remarks Ref.
Chitosan hydrogels coated with
collagen IV
EDC-immobilised on collagen
0.22 ng/mm2
Flk1+ progenitor cells adhere
and differentiate into EC;
without VEGF occurs
differentiation into SMC
[190]
Collagen hydrogels EDC-immobilised on collagen Scaffolds with immobilised
VEGF and Ang1 promoted
better EC infiltration
[191]
Collagen matrices immobilised through PEG
crosslinker; 10 ng/gel
Enhanced angiogenic potential [192]
Collagen matrices; heparinized Mixed; 10 ng/gel Differential release [193]
PLA scaffolds created by
supercritical technology
Supercritical encapsulation
1.7µg/0.13g PLA
Promoted significant bone
regeneration
[194]
Oxidised alginate crosslinked
with Ca2+
Mixed; 250 ng/mL Long term in vivo therapeutic
benefit
[195]
Oxidised alginate crosslinked
with Ca2+
Mixed; 3 - 10 ￿g/gel Significance of temporal
gradients
[196]
Alginate sulphate/alginate
scaffolds
Binding affinity to alginate
sulphate;
Also loaded with PDGF-BB and
TGF-β1;
Release controlled by
differential binding affinity;
improved maturation of
vasculature in implanted rats
[197]
Alginate/HPMC microparticles Entrapped upon microparticles
preparation
Zn2+/Ca2+ balance controls
diffusional release
[198]
Fibrin/collagen hydrogels Dual delivery of VEGF and
MCP1
Improved survival of
encapsulated ECs and SMCs
recruitment
[136]
Scaffolds from particulate PLG
and PLA microspheres
Mixed; 3µg / pellet 125I-VEGF [199]
PLGA microspheres loaded into
ionic crosslinked alginate gels
Entrapped in microspheres Injectable system with
sustained delivery of VEGF
[200]
Fibrin matrix + heparin coated
PLGA nanoparticles
Simply dissolved in the fibrin
matrix or conjugated to the
NPs
Release dependent on diffusion
or heparin affinity
[201]
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Delivery strategy VEGF integration;
Concentration
Remarks Ref.
HEMA-MMA hydrogels VEGF-secreting encapsulated
fibroblasts
Promoted higher local
angiogenesis in vivo
[202]
Polyelectrolyte nanoparticles
from dextran sulphate and
chitosan/PEI/poly-L-lysine
Affinity to dextran sulphate High encapsulation efficiency;
extended release and bioactivity
preservation
[203]
PGA matrices with PLGA
microspheres
Entrapped in PLGA
microspheres
Sustained VEGF release and
improved EC proliferation and
cappilary density
[204]
2.3.2. Cell-Based Therapies
The potential of cell-based therapies in the treatment of ischemic diseases, is reflected
by the 322 studies retrieved at ClinicalTrials.gov2. Most cells in adult organisms are
composed of differentiated cells. However, each tissue has its own set of quiescent stem
cells or progenitor cells, which can be activated under certain environmental stimuli,
participating on the tissue regeneration if an insult is identified. One of the first studies,
used endothelial progenitor cells, derived from the bone marrow, which can be isolated
from the peripheral blood and expanded ex-vivo. This cell population was administered
systemically to enhance neovascularisation and was observed to increase the chance of
a healing response [169]. As these type of cells are not abundant, umbilical cord blood
(UCB) has become a popular source of EPCs and other cell types (Fig. 2.6), to be used
on therapeutic vascularisation [205]. Indeed, several studies have demonstrated that
the transplantation of EPCs or vascular cells, increases significantly the vascularisation
of ischemic tissues in animal models of hindlimb ischemia [206, 139, 207], myocardial
ischemia [208, 209, 210] and diabetic chronic wounds [138].
Material-based approaches for the delivery of cells have also been proposed. An in vivo
vascular progenitor cells depot was used to promote repopulation of the damaged tissue
and participate in neovascularisation [139]. Polymeric hydrogels can be manipulated to
offer an ECM-like microenvironment by the incorporation of biological cues, in other
words, biomimicking the scaffold, for the best spatio-temporal presentation of informa-
tion and improved therapeutic outcome. In this study, Silva et al [139] designed alginate
2Search terms “cell therapy ischemia“ on the November 28th of 2010. http://clinicaltrials.gov
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Figure 2.6.: Postnatal stem and progenitor cells from the variou tissues. EPCs high-
lighted in gray. Adapted from [167].
macroporous scaffolds doped with RGD cues, to present cell adhesion ligands, and VEGF
to maintain cell viability and induce cell migration out of the scaffold. Endothelial pro-
genitors isolated from human cord blood to treat ischemic muscle tissue were used on
this approach and this system was demonstrated to dramatically improve vascularisation
and perfusion of ischemic murine hindlimb musculature, and prevented toe and foot
necrosis. These results suggest that an effective endothelial progenitor cell utilisation,
highly depends on the mode of delivery and control over cell fate after transplantation.
The bioactive scaffolds can also be used for enhancement of vascular differentiation of
progenitor vascular cells or stem cells. Vascular progenitor cells, isolated from human
embryonic stem cell aggregates (embryoid bodies), can be directed to endothelial-like
cells after exposure to VEGF [211]. Embryoid bodies (EBs) are aggregates of human
embryonic stem cells (hESC), frequently used to simulate embryonic stages in vitro.
However, the heterogenous size and spontaneous differentiation into the several germ
38
2.4 Conclusion
layers of the embryo, turns it difficult to control their differentiation [212]. An ingenious
way of controlling such differentiation was achieved by mixing growth-factor-releasing
microparticles with the EBs [213]. This system uses biodegradable and biocompatible
components and allows for the control of several variables in cell differentiation, such as,
concentration, spatial localisation and combinatorial release of growth factors. Hydrogel
platforms have also been studied, for the controlled differentiation of hESC. Hyaluronic
acid hydrogels were able to maintain the self-renewal state of the hESC, for a long term
period, in the presence of conditioned medium from mouse embryonic fibroblasts. Dif-
ferentiation could be induced by supplying the appropriate soluble growth factors [214].
The immobilisation of EBs in agarose hydrogels with covalently linked VEGF was able
to guide the aggregates into blood progenitor cells. The induction by immobilised VEGF
was more efficient in guiding hESCs differentiation than soluble VEGF [215]. The authors
believe that this system would be suitable for an up-scale and consequent collection of
large numbers of differentiated cells. However, other strategies have demonstrated that
the use of EBs may not be the most efficient. The enhancement of vascular differentia-
tion of hEBSs was also achieved by encapsulating them in bioactive RGD-functionalised
dextran-based hydrogels. The growth factor, VEGF, was microencapsulated in PLGA
microparticles, further entrapped inside the hydrogels. The 3D scaffold promotes the
stem cell differentiation into vascular lineages, more than the 2D systems. After remov-
ing the cells from these networks and promoting further vascular differentiation, they
contained higher fraction of vascular cells than the spontaneously differentiating EBs.
This approach increased the vascular differentiation of human embryonic stem cells when
compared to embryoid bodies [216].
2.4. Conclusion
The vascular endothelial growth factor is a major regulator of physiological and patholog-
ical angiogenesis, acting upon most of the metabolic pathways in endothelial cells. The
use of VEGF in therapeutic approaches relied mostly on the bolus injection, but failed
to restore compromised tissue functions. The implementation of new delivery strategies,
such as polymeric systems, to overcome the limitations of the bolus delivery and supply
VEGF in a localised and sustained way to the target site, is giving new expectations for
the utilisation of this growth factor. The use of such systems allow for different sorts of
controlled release, which could mimic the complex and sophisticated endogenous VEGF
delivery, which uses different isoforms with variable affinity towards the ECM and specific
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proteases cleavable sites. Several reviewed strategies successfully mimicked this VEGF
interplay with the endogenous environment, enabling control over spatial and temporal
release. The release in the context of other growth factors and their spatio-temporal pre-
sentation will need better fine tuning. The upgrade of these systems with the integration
of cells is also a challenge which could bring highly effective therapeutic benefits. Recent
studies suggest a different approach for endothelial progenitor cell-based therapies that
may be applicable in the treatment of ischemic diseases and more broadly in regenerative
medicine. Strategies involving bioactive materials for the delivery of vascular progenitor
cell populations, which could provide a microenvironment to enhance cell survival, and
the sustained release and repopulation of the surrounding tissue by outbound migrating
cells.
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Nanotechnology usually refers to any man-made structure with dimensions below the
100 nanometers, in at least one dimension, however, this range is usually broader, reach-
ing the 500 nanometers. Among the myriad of possible applications, drug delivery, in
a biomedical setting, is growing substantially. This chapter will briefly contextualise
the challenges of designing and preparing nanoparticles for accurate and efficient drug
delivery.
3.1. NanoBiotechnology
Nanobiotechnology, is a field located at an intersection between chemical, physical, en-
gineering and biological sciences. The research of nanotechnologies integrated with the
biomedical sciences has seen a rapid growth in the new millennium (Fig. 3.1) and is ap-
proaching the 20-years gestation period (generic interval for transition of science discov-
ery into commercial applications) after which innovative technologies will be translated
into biomedical applications [217].
Nanotechnologies, such has nanoparticles (NP) have been around for some time [218].
However, new technologies are achieving great expression, such as quantum dots [219,
220], nanotubes [221] or nanowires [222]. This new area of nanobiotechnology is gen-
erating new applications from molecular imaging to anticancer therapies with new tools
that are reaching new frontiers within cells and opening new biomedical perspectives
[223].
Drug delivery issues, such as poor drug efficacy, low drug bioavailability or systemic
toxicity are the main barriers to overcome. In the last decade, the integration with new
and alternative nanotechnologies for the improvement of drug delivery, has seen a huge
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rise in research. Some of the technologies reviewed earlier, involving polymeric-based
materials can be adapted with new processing techniques, bringing the approach to the
nano level. The advantages of nanoparticulate drug delivery systems are their small size,
which allows them to pass through many biological barriers and the high density of ther-
apeutic drug that can be encapsulated, dispersed or dissolved, within the carrier [224].
Nanoparticulate systems can improve the physicochemical properties by optimising sol-
ubility, diffusivity, biodistribution, release characteristics and immunogenicity, targeting
specific tissues without major systemic toxicity [225]. Depending on the composing ma-
terials and the preparation strategy, surface functionalities can be incorporated at the
nanoparticle surface, facilitating the protection of the nanoparticles in the organism, but
also the targeting to specific cells or tissues.
An overview on the design of polymeric-based nanoparticles will be made, focusing on
the assembly strategies regarding synthesis, response to external stimulus and surface
reactivity. It will be followed by a brief overview about nanodelivery of VEGF and retinoic
acid, as bioactive representatives of proteins and small drugs, respectively, and the last
delivery frontier, the cellular organelles. For last, a brief overlook about the use of
nanostructures as building blocks in tissue engineering applications will be given.
Figure 3.1.: Publication counts from Thompson ISI Web of Knowledge
(www.isiknowledge.com; Search performed on the 29th November 2010). Searches
under topic for “nano*” (black; left axis), “nano*+bio*” (red; right axis).
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3.2. Nanoparticle Design
Nanoparticles can be defined as solid colloidal particles containing or not an active sub-
stance. Traditional techniques, such as emulsification evaporation, solvent displacement,
salting-out and emulsification diffusion are somewhat outdated. These approaches in-
volve high volumes of organic solvents or oils and often, toxic chemical cross-linking
agents, impairing the use of many pharmaceutical drugs [226], potential downstream
toxicity, but also the possibility of reaching smaller sizes. Newer techniques rely on less
severe approaches through usage of carefully chosen starting materials more appropriate
for less aggressive synthesis strategies.
Polymers, either of synthetic or natural origin, provide great flexibility on the design
of nanoparticles. Not only due to their native physicochemical properties but as well
through the variety of possible modifications yielding new functionalities. The polymers
chemistry drive the processing reaction and the final outcome can yield nanocapsules
[227], nanogels [228], dendrimers [69], nanocoacervates [203] or other structures as
depicted on Fig. 3.2.
Nanoparticles design should also take in account that they will necessarily interact with
the physiological environment by binding to serum proteins, which can be dictated by
the surface chemistry necessarily influenced by the polymeric constituents [229]. This
phenomena will interfere with the bioavailability and biodistribution of the NP being
reflected on the therapeutic efficacy [230]. Indeed, what the “cells see” is a mix of
physiological proteins adsorbed to the NP surface. Likely, this protein layer confers the
NP its identity, rather than the NP surface itself [231].
3.2.1. Synthesis
Most of the approaches used on the nano-assembly of such structures can be divided
into two main categories of chemical and physical nature.
• Chemical nature
Chemicalwise, one of the most popular functionalisation of polymers, recurs to vinyl
monomers for posterior radical or photo-polimerization [232]. Other approaches involve
the mixture of polymers with cross-reactive chemical moieties, which promptly react
selectively establishing a covalent bond. Common examples are Michael-type additions,
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where the previously mentioned vinyl functionalisation can be used to react with thiol-
modified substrates [233] or the previously mentioned reversible Schiff bases by the
combination of aldehydes and amines [104, 234]. These sort of reactions can be termed
“click chemistry”, referring to the facile, efficient, selective and versatile chemical reac-
tion which leads to a single reaction product [235], however, it is the copper (I) catalysed
azide-alkyne cycloaddition that has almost exclusively adopted this terminology [236].
• Physical nature
The spontaneous formation of physical nanostructures relies on weak secondary forces
such as Van der Waals mediated stereo-complexes formation [237], hydrophobic [71],
ionic interactions [238], or hydrogen bonding between water soluble polymer chains [239].
The most interesting approaches involve self-assembly of nanoparticles, characterised
as the spontaneous formation of higher order structures from simpler building blocks,
driven thermodynamically [240]. The self-aggregation of the nanoparticles constituents
can simply rely on the physical properties of the polymers or appropriate moieties can
be grafted to promote the self-assembly of the system.
A simple example are nanoparticles formed via coacervation by recurring to oppositely
charged polyelectrolytes. In nature, the class of polysaccharides exhibits differently
charged molecules which can be used for this purpose. Chitosan has been preferred as
the polycation in several applications and complexed with polyanions such as carrageenan
[241], dextran sulphate [203] and heparin or hyaluronan [242]. The variation of the mass
ratios of the polyelectrolytes regulates the charge density of the final nanoparticles, which
can be used to achieve higher uploads of drug. On one series of works, polyethylenimine
(PEI) was complexed to dextran sulphate in different mass ratios, customised according
to the cargo properties. The system was custom designed to accommodate DNA [238],
insulin [243] or amphotericin B [244].
Neutral and water-soluble polymers, like dextran or pullulan, can be modified with
hydrophobic moieties, leading to nanoparticles formation by self-aggregation of the
hydrophobic moieties, like in cholesterol-grafted pullulan [245], cholic acid-grafted to
oxidised dextran [71] or by chemical conjugation of hydrophobic 5β-cholanic acid to
hyaluronic acid [246].
A second level on the design strategy of NP, deals with conferring specific characteristics,
which will improve the NP performance for the desired application. Examples of such
strategies are resumed on Fig. 3.3.
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Figure 3.2.: Different designs in nanoparticles assembly.
3.2.2. Stimulus Sensitivity
Assembling nanoparticles that are sensitive to one or more external stimulus and that
could trigger a reaction, like swelling or degradation, has many applications in biomedical
sciences. Such characteristics allow the carrier to deliver or not the cargo after reaching
the target site. The sensitivity to pH is one of the most studied. Nanoparticles of dextran
grafted with polyacrylic acid were designed to swell upon pH elevation [247] which
could possibly release an entrapped cargo by diffusion. Degradation can be achieved
by incorporation of acid-sensitive monomers in the NPs [248]. NPs that could support
external stimulus, other than the environmental stimulus, offer the possibility of external
guidance or actuation by the operator. Magnetic nanoparticles could be guided through
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Figure 3.3.: Different aspects of nanoparticles composition, commonly addressed for
improved performances and increased versatility.
the body up to the desired target place. Different polymers, like dextran, chitosan
or polyacrylic acid, can be activated with Fe3+ for the preparation of magnetic NPs,
and present low cytotoxicity and good biocompatibility [249]. The cross-linking of N-
isopropyl acrylamide monomer with PEG-diacrylates originates NP which are temperature
sensitive [250].
3.2.3. Targeting
The tissue targeting specificity of the nanoparticles can be increased by introducing
specific ligands, able to recognise particular cell surface entities (Fig. 3.3). An obvi-
ous choice, are antibodies due to their high specificity. The chemical conjugation to
nanoparticles is straightforward and drastically increases the tissue specificity [251]. Non-
chemical coatings of NP with ligands, employing electrostatic interactions, for example,
can avoid the change of the biophysical properties of the nanoparticles [252], produced
by chemical grafting of ligands. The use of specific ligands on NP surfaces, has found
applications other than target questing. Some tissues, like cartilage, lack vasculature,
limiting the bioavailability of drugs. By controlling the nanoparticles size (< 40 nm),
it is possible to achieve high yields of nanoparticles penetration within the cartilage,
furthermore, the incorporation of a targeting peptide, prevents the nanoparticles from
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leaving the tissue providing an intra-tissue releasing system [253].
3.3. Nano Delivery
An interesting review on drug delivery devices was written recently by Alan Hoffman [254]
contextualising the evolution from the “macro era” of drug delivery devices (DDD), with
zero-order release, to the “nano era” of targeted and site-controlled drug delivery sys-
tems, which will eventually lead to personalised medicine. The ideas described earlier
(sec. 1.3), concerning polymer-drug conjugates, can also be considered nano-delivery.
However, next we will present some studies using nanoparticles, for the delivery of pro-
teins and small pharmaceuticals and the implications and potential that such strategies
enclose.
3.3.1. Proteins
Proteins with therapeutic interest, like antibodies or growth factors, display a short
half-life in circulation, usually of several minutes [164, 255, 256]. They undergo rapid
degradation in vivo and the systemic or local delivery will result in low availability.
The high doses usually applied, may lead to systemic toxicity due to the non-specific
distribution. The use of nanoparticulate systems can help improve the therapeutic action,
since they can help penetrate deeper into tissues, through the epithelial lining. The
nanoparticles will be responsible for the physicochemical properties of the system.
Among the described studies in the literature, nanoparticulate systems for growth factor
delivery include lipossomes, polymers, micelles, dendrimers among other material com-
binations [225]. Focusing on VEGF, it has been formulated in PLGA [257, 199, 204],
PLGA/PEG [258] or alginate [259, 198] particles to control its release on a localised
area, however, such formulations yield particles in the micrometer range. Therefore,
PLGA nanoparticles with sizes below 200 nm, negative zeta-potentials and heparin-
functionalisation [260], appear to be interesting carriers for VEGF. Indeed, the incor-
poration in commercial fibrin hydrogels, enhanced the therapeutic efficacy in a rabbit
ischemic hind-limb model, when compared to soluble VEGF [201]. A polyelectrolyte
complex, where dextran sulphate is the polyanion and the polycation role was performed
by chitosan, PEI or poly-L-lysine was adapted for the loading of VEGF [203]. The dex-
tran sulphate structural similarities to heparin were used to promote a higher loading
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efficiency, through electrostatic complexation. In the presence of the polications, self-
assembly occurs through coacervation of oppositely charged polyelectrolytes. Negatively
charged nanoparticles, with sizes below the 300 nm were obtained. The formulation was
successful in protecting VEGF’s bioactivity, sustaining its release and showed improved
efficacy in inducing endothelial cells proliferation [203]. A less traditional approach used
lecithin (from soy bean) to create anionic nanolipids, with a lipid core and an outer
surface that binds electrostatically to the positive VEGF. Pluronics F127 was used to
confer a shell to the complex. The manipulation of the components mass ratios allows
control over size, zeta-potential and the VEGF release profile [261].
3.3.2. Small Drugs
As stressed earlier (sec. 1.3.1.1), the systemic delivery of small drugs leads to issues such
as lack of activity towards the target tissue and toxicity on other tissues were the drugs
can accumulate during the process of clearance from the organism. As with pro-drugs,
nanoparticles can increase the concentration of small pharmaceuticals and improve the
delivery efficacy. Retinoic acid, is a small lipophilic derivative of Vitamin A [262], which
has a tremendous therapeutic potential in cancer prevention [263] and could be used
to control the differentiation of stem cells. All-trans retinoic acid is a water-insoluble
molecule (0.21 ￿M [264]) which can see its water solubility increased by the simple
complexation with certain polymers like polyaminoacids [265] or PEI [266], which in
the presence of the dispersing agent poloxamer 188, forms nanoparticles. Poly(ethylene
oxide)-b-poly(L-lysine) also complexes with RA forming core-shell type micelles where
retinoic acid forms the hydrophobic core [267]. The natural polycation chitosan is also
suitable for RA delivery. Low molecular weight water soluble chitosan was able to form
complexes with RA, achieving loading efficiencies above 90% and nanoparticles sizes
below 200 nm [268]. The grafting of methoxy poly(ethylene glycol) to chitosan allows
the delivery of RA in the form of nanoparticles [269] or micelles [270] with diameters of
100 and 100 - 500 nm, respectively.
These systems are able to increase substantially the concentration of RA presented to
the cells, however, the RA actions are transmitted through the RA receptors, which are
located on the cell nucleus [263]. When delivering molecules with intracellular targets,
it is rather important, that the nanoparticles overcome the tissues and cellular barriers
and deliver the payload on the cells cytoplasm. The release outside the cell, might not
bring any action.
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3.3.3. Intracellular Targeting
Many therapeutic agents have specific intracellular molecular targets, which are located
in the cytoplasm, nucleus, mitochondria or other cell organelles. The targeting of any
of these intracellular destination, implicates a higher degree of complexity on the de-
sign of the nanomaterials. Several barriers must be taken into account, in order to
reach the site of action, where the payload has to be delivered. The efficiency of drug-
carriers for cytosolic delivery is limited mainly by their interaction with cell membranes
and the endosomal release of therapeutics [271]. The ability of nanoscale materials to
Figure 3.4.: Cellular internalisation pathways of NP. (A) Diffusion, usually on
endocytosis-inhibiting conditions; (B) Phagocytosis; (C) Macropinocytosis; (D)
Clatrin-dependent endocytosis; (E) Receptor-mediated endocytosis. Adapted from
[272].
autonomously escape from endosomal compartments can be used to deliver cargo that
can alter cell metabolism and function and regulate signalling pathways. Hydrophobic-
functionalised silica NPs were able to carry specific protein, which were shown to interfere
with cellular pathways [273]. The cellular internalization can follow several pathways,
such as receptor-mediated endocytosis, non-specific endocytosis and internalization un-
der endocytosis-inhibiting conditions (Fig. 3.4) [272, 274]. The receptor-mediated endo-
cytosis is probably the most attractive and efficient method for the specific uptake of
nanocarriers, which can be designed to incorporate a given complementary cell-surface
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receptor, enabling an increase of up to 1000-fold [274]. The nanoparticles uptake in
endosomes (mild pH’s; 5 - 6.5) goes through a maturation process up to late endosomes
that could later fuse with other endosomes and lysosomes (even more acidic pH’s), ex-
periencing degradation conditions [274]. Escaping this barrier, avoids degradation or
exocytosis, releasing the therapeutic agent within the cytosol and enabling its actuation
[272].
The awareness of the endosomal pathway as lead research towards pH-sensitive carriers,
which could rapidly release their payload, facilitating its delivery into the cytoplasm.
Polymeric cations, are efficient transfection agents without recurring to cell-targeting
or membrane-disrupting agents, being PEI a gold-standard of polyplexes [56, 55]. The
high concentration of primary and secondary amines turns PEI into a proton-sponge at
virtually any pH. On the endosomal context, it possibly buffers that small compartment,
protecting the carrier from degradation, eventually promoting swelling and rupture [56].
3.4. Nano Tissue Engineering
Biological tissues are often observed as small repeating units assembled over several
scales. Therefore, the ability to synthesise and control materials on the nano scale opens
new frontiers in tissue engineering. Designing nanomaterials as building blocks may lead
to suprastructures that can be obtained by several processing techniques or just by self-
assembly of the building blocks. These structures can be used to host and/or deliver
cells in several contexts, just as some of the 3D structures described earlier, though,
offering new control variables as well as improved macroscopic qualities.
As reviewed recently by Wan et al. 2010 [275], nanomaterials can be divided in several
classes, with chemical and physical properties which enable them to be processed or func-
tion in different contexts of tissue engineering. Commonly used nanomaterials found in
the literature enclose peptide amphiphiles, self-assembled peptides, nanoparticles, carbon
nanotubes, electrospun fibres or layer-by-layer structures. Our focus will fall on strategies
describing the preparation of nanoparticles which are able to yield suprastructures.
As illustrated on Fig. 3.2 and Fig. 3.3, the limit for nanoparticles decoration is imagina-
tion. If properly designed, ingenious suprastructures can be originated, taking advantage
of the different properties of the several components, which can be prepared either by
self-assembly or by external stimuli. Materials with several hierarchical structures may
present improved networks. Polymeric gels, for example, can be made in several sizes.
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Figure 3.5.: Nanoparticles suprastructures. (A) Polymer gel nanoparticle network; (B)
Nanoparticle-cross-linked hydrogels; (C) Self-assembly by external stimuli.
Bulk hydrogels are easy to handle, but have a slow response to external stimuli, while
nanogels act much quicker, due to the higher ratio of the surface area versus volume.
However, co-nanoparticle networks can retain the properties of each polymer nanopar-
ticle, resulting that such network could perform several tasks on a given application
(Fig. 3.5A) [276]. Other example is the polystyrene nanoparticles which were used as
cross-linkers of polyacrylamide to synthesise hydrogels. The hydrophobic character of the
nanoparticles deeply influenced the swelling behaviour, conferring excellent elasticity and
predictable swelling properties, appropriate for several human tissues (Fig. 3.5B) [277].
The rationale is that the physical properties of the nanoparticles core are transmitted to
the upper hierarchical level, while the surface is grafted with reactive pendant groups,
enabling the cross-reactivity. Gold-cross-linked pNIPAAm hydrogels display remarkably
different bulk properties of equilibrium swelling and thermo-responsive phase transition
when compared to the gold-free hydrogels [278]. Other example is the nanostructured
hyaluronic acid hydrogel, prepared by cross-linking thiol-grafted hyaluronan with acry-
lated nanogels, via Michael addition. The nanogels are sensitive to hydrolysis, propa-
gating such property to the bulk hydrogel. Gelation occurs at physiological conditions
and can be used as a cell delivery scaffold or other biological agents (Fig. 3.5B) [279].
Physical interactions are more appropriate for the self-assembly of the suprastructures.
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Usually, an external stimuli sets the trigger for the sol-gel transition. The amphiphilic
macromer constituted by PEG-PPG-PEG, self-assembles into micelles subsequently poly-
merised into nanogels. These nanogels, when concentrated, form macroscopic physical
gels upon heating (Fig. 3.5C) [280]. Fancier approaches used NPs covered with only a
few photoactive ligands, which formed metastable crystals that can be assembled and
disassembled ‘‘on demand’’ by using light of different wavelengths. For higher sur-
face concentrations, self-assembly is irreversible, and the NPs organise into permanently
cross-linked structures including robust supracrystals and plastic spherical aggregates
[281].
3.5. Conclusions.
Improving the half-life of growth factors has been achieved by several nanoparticulate
strategies. It is however beneficial to understand exactly the release mechanism and
degradation involved in each strategy. The winning strategy will find a balance between
the resiliency of nanoparticles to reach the target site, target specificity and the sustained
release of the growth factors. This will inevitably lead to more complex systems with
targeting cues and environmental/external degradation-sensitive mechanisms.
As the knowledge in disease biology increases, the more demanding the nano-scale design
of DDD will be. Allan Hoffman suggested that the evolution of DDD will become more
biological and less materials-oriented in character [254]. In fact, the trend in literature
is oriented to the seeding of biomaterials with biological cues able of mimicking and
permeating those drug delivery vectors in biological systems. This biological accuracy
will eventually lead the field into personalised medicine, where tailor-made DDD will be
the ultimate goal.
Nanoparticles will likely have a relevant role in bottom-up tissue engineering, providing
improved scaffolds that can be highly biomimetic and possibly overcome most of the
challenges faced in this field.
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Part II.
Results and Conclusions

4. Insight on the periodate oxidation
of dextran and its structural
vicissitudes
4.1. Abstract
Periodate oxidised dextran has been widely studied in a broad range of biotechnological
applications, regardless of this, usually little attention is paid to the oxidation extension
consequences on the properties of the final modified dextran. Based on a bidimensional
NMR analysis, we suggest that the two aldehydes groups, resulting from the periodate
oxidation, are not fully reactive with N-nucleophiles, under certain pH conditions. The
aldehyde group bonded to C3 appeared to be the only prone to react. The other alde-
hyde might be arrested in more stable hemiacetal structures. The hemiacetals are also
responsible for oxidised dextran cross-linking, interfering in simple processing steps, such
as dissolution and solubility, as well as increasing the viscosity of the solutions. The
molecular weight variation on the oxidised samples can be followed by dynamic mechan-
ical thermal analysis in consequence of the variation of glass transition temperature with
the molecular weight, which was corroborated by the onset temperature of the thermal
degradation.
4.2. Introduction
Dextran is a polysaccharide synthesised by a large number of bacteria, when grown
on sucrose-containing media [3]. Nowadays, Leuconostoc mesenteroids (strain B-512)
[1] is responsible for the majority of the commercially available dextrans. They are
characterised by having over 95% of α-1,6 linkages and some low degree of branching.
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From the late nineteen forties, dextrans have attracted attention from the biotechnology
world. They were accepted as a plasma volume expander, due to its linear structure,
high water solubility, and especially owing to its α-1,6 linkage, more relevant to biological
applications, in virtue of the slower hydrolysis by body enzymes, compared to the α-1,4
linkage (e.g. glycogen) [1, 2].
The dextran oxidation by the periodate ion is a catalysis-free aqueous reaction which
yields a purified product with a simple dialysis step. The periodate ion attacks vicinal
diols promoting bond breaking. Typically, the α-1,6 residues in dextran are attacked
between carbons C3- C4 or C3- C2, breaking the C-C bond and yielding aldehyde groups,
being able to be further reduced on a second and independent oxidation reaction (Scheme
1) (Fig. 4.1)[282]. Initially, this method was used in the characterisation and elucidation
of the polysaccharide structure, through the complete oxidation and consequent analysis
of the degradation products [10]. Nowadays, low and mild periodate oxidations are used
to confer the dextran chain with aldehyde functionalities, which have as main charac-
teristic the highly reactive nature towards N-nucleophiles, such as amines, hydrazines or
carbazates [29].
Figure 4.1.: Dextran’s α-1,6 glucose residue possible periodate oxidations. Periodate
attack at C3-C4 (A); C3-C2 (B) and double oxidation (C).
Concerning the dexOx application on a biomedical perspective, the accurate assessment
of the periodate oxidation consequences in mild oxidation conditions is of utmost impor-
tance in predicting the extent of drug loading [65] or the final physicochemical properties
of hydrogels [35]. Due to the highly reactive nature of the formed aldehydes, they are
easily attacked by neighbouring hydroxyl groups, leading to the formation of hemiacetals
[16]. These hemiacetals are the most consensual resulting structures, even taking into
account that some studies restrict these structures to a narrow pH window (4.0 – 5.2)
[17]. Other consequences of the dextran oxidation are the decreased average molecular
weight and polydispersity increase [14].
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Herein we address the consequences of low and mild dextran oxidation and try to further
elucidate the structural nature of dexOx through bidimensional NMR, upon reaction
with tert-butyl carbazate. Our data suggest that only one aldehyde per residue might
be involved on this reaction, while the second aldehyde could be arrested to a stable
hemiacetal structure. We will explore the oxidation influence on simple manipulation
steps, such as aqueous dissolution and the solutions viscosity outcome. Dynamic me-
chanical thermal analysis (DMTA) data on dexOx are discussed and correlated with the
molecular weight trend. The relative thermal stability of dexOx samples was evaluated
by thermogravimetric (TG) measurements.
4.3. Material and Methods
4.3.1. Materials
Dextran (from Leuconostoc mesenteroides ; Mw 60 kDa, according to Fluka’s specifica-
tion), sodium periodate, AAD, tBC, ethyl carbazate (EtC), phosphate buffered saline
(PBS; pH 7.4), dialysis membranes (MWCO 12 kDa) and NaOD were purchased from
Sigma (Sintra, Portugal) and used as received.
4.3.2. Dextran Oxidation
An aqueous solution of dextran (1 g; 12.5% (w/v) ~ pH 5.5) was oxidised with 2 mL
of sodium periodate solution with different concentrations (33 – 264 mg/mL) to yield
theoretical oxidations from 5 to 40%, at room temperature (The oxidation degree (OD)
of dexOx is defined as the number of oxidised residues per 100 glucose residues). The
reaction was stopped after 4 hours. The resulting solution was dialysed for 3 days against
water and lyophilised (Snidjers Scientific type 2040, Tillburg, Holland). The scale-up
of the reaction was done using the same procedure albeit using 30 g of dextran and a
calculated amount of periodate to yield a theoretical oxidation of 5, 10, 25 and 40%,
referred hereafter as D5, D10, D25 and D40, respectively.
4.3.3. Nuclear Magnetic Resonance
1H spectra were acquired on a Varian 600 NMR spectrometer (Palo Alto, CA) using a
3 mm indirect detection NMR probe. 1H NMR spectra were recorded in D2O (20-25
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mg in 0.2 mL; pD of c.a. 4.5 or 10.2 after addition of NaOD) using a 90° pulse and a
relaxation delay of 30 s. The water signal, used as reference line, was set at δ 4.75 ppm
and was partially suppressed by irradiation during the relaxation delay. A total of 32
scans were acquired for each 1H NMR spectra. Bidimensional spectra were recorded on
the same magnet. 1H-1H correlation spectroscopy (COSY) spectra were collected as a
2048 × 1024 matrix covering a 5 kHz sweep width using (32) scans/increment. Before
Fourier transformation, the matrix was zero filled to 4096 × 4096 and standard sine-
bell weighting functions were applied in both dimensions. 1H-13C heteronuclear multiple
quantum coherence (HMQC) spectra were collected as a 2048 × 1024 matrix covering
sweep widths of 5 and 25 kHz in the first and second dimensions, respectively. Before
Fourier transformation, the matrix was zero-filled to 4096 × 4096 and standard Gaussian
weighting functions were applied in both dimensions. The spectra were analysed with
iNMR software, version 2.6.4 (www.inmr.net). The oxidation degree (OD) refers to the
theoretical value unless otherwise stated.
4.3.4. DexOx’s Solubility and Solutions Viscosity
The different dexOx and dextran samples were dissolved in PBS (20% w/w). Aliquots of
1 mL were distributed in small glass vials, frozen at -20 °C and freeze-dried, in order to
obtain a similar freeze-drying cake across every sample. The original dextran processed
this way will be referred as D0. To each sample, 0.85 mL of miliQ water was added
and the dissolution time was recorded at different temperatures (n=3). The reason was
to mimic the reconstitution of a pharmaceutical freeze-dried product. The vials were
preserved under reduced pressure on a glass desiccator supplied with silica gel. Dextran
and dexOx solutions, with concentrations ranging from 10 to 30% w/w, were prepared
and tested in a Brookfield Programmable D-II+ Viscometer with a S18 spindle, assisted
by DVLoader v1.0 software. The chamber temperature was controlled by an external
bath to 25 °C. Low viscosity solutions were measured by a Labolan V1-R viscometer
with a LCP spindle (low viscosity adapter) and controlled temperature to 25 °C.
4.3.5. Size Exclusion Chromatography
Performed in a HPLC system composed by a degasser and a WellChrom Maxi-Star k-
1000 pump (Knauer), coupled to a LS detector (evaporative light scattering PL-EMD
960) and one column (Polymer Laboratories, aquagel-OH Mixed 8 µm). The whole
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system was kept at room temperature and the eluent used was KNO3 (0.001 M; pH 3.9)
at a flow rate of 0.4 mL/min. Samples and standards were dissolved in the eluent at 4-6
mg/mL (Fluka Chemie AG, dextran standards from 12 – 80 kDa).
4.3.6. Dynamic Mechanical Thermal Analysis
The freeze-drying samples obtained above were subjected to dynamical mechanical ther-
mal analysis (DMTA) on a Triton Tritec 2000 analyser. About 50 mg of sample were
loaded into metal pockets fabricated from a sheet of stainless steel. The pocket was
clamped directly into de DMA using a single cantilever configuration. Temperature
scans, from -200 °C to +300 °C, with a standard heating rate of 2 °Cmin−1 were per-
formed in a multifrequency mode (1 and 10 Hz) in order to identify the temperature
transition peaks.
4.3.7. Thermogravimetric Analysis
The thermal stability of dextran and dexOx samples was studied in a TA Instruments
Q500 thermogravimetric analyser (thermobalance sensitivity 0.1 ￿g). The temperature
calibration was performed in the range 25-1000 °C by measuring the Curie point of nickel
standard, using open platinum crucibles, a dry nitrogen purge flow of 100 mLmin−1, and
a heating rate of 10 °C min−1, the later being the conditions applied throughout the
thermoanalytical measurements. At least two runs were performed for each sample
(sample weights of ca. 8 mg) in order to check the repeatability of measurements.
4.4. Results and Discussion
4.4.1. DexOx Characterisation
Dextran with a molecular weight of 60 kDa, was oxidised with variable amounts of
sodium periodate in order to obtain different OD. Usually, the aldehyde group is not
observed by FTIR spectroscopy, unless in highly oxidised samples (1730 cm−1), nor in
the NMR spectrum, except during the first minutes of reaction (~9.7 ppm) [14]. It is
widely accepted that the aldehyde groups react with nearby hydroxyl groups, forming
hemiacetals or hemialdals [16, 282]. These transitory events could be either intra or
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inter-residue (Fig. 4.2) and, in certain situations, interfere with the oxidation evolution.
The most important aspect arising from this modification is the final oxidation degree.
It defines the dexOx’s reactivity on drug conjugation [65] or gelation rate on hydrogel
formulations [14, 35]. Concerning the estimation of the oxidation degree, several ways
have been used to approach the problem. On extensive oxidations, acid-base titration
is useful in assessing the released formic acid and the percentage of doubly oxidised
residues [10]. On mild oxidations, colorimetric titrations, such as the hydroxyalamine
hydrochloride [25] or the TNBS assay [22], have been used. However, the calculations
are usually performed assuming that both aldehydes react with the carbazates. On an
earlier study [14], our two-dimensional NMR results led us to suggest that just one
of the aldehydes per residue reacts with the carbazates, in agreement with the single
correlation observed on the 1H-13C HMQC spectrum. Our new results suggest that,
under the studied conditions, only one aldehyde per residue is reacting.
4.4.2. Bidimensional Nuclear Magnetic Resonance
The NMR data was collected in D2O with a measured pD of ~ 4.5, which falls inside
the consensual pH window for hemiacetals formation. Therefore, our bidimensional
NMR analysis will take into account the most likely hemiacetal populations, based on
previously proposed structures found in the literature. These structures will serve as
Figure 4.2.: (A) Single periodate oxidation outcome after periodate ion attack at C3-
C4 and (B) C3-C2 cleavage, followed by possible intra-hemiacetals formation and
tBC reaction. (C) Periodate doubly oxidised residue, possible hemiacetals and tBC
reactions.
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Figure 4.3.: (A) COSY (B) HMQC spectra of D25. The peaks assigned with plain
numbers refer to correlations arising from the intact residue. The correlations arising
from the different oxidised residues are represented by: a: C3-C4 oxidation; b: C3-C2
oxidation; c: C4-C2 double oxidation; and d: α-1,3 branched oxidised residue.
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a starting ground for the carbazone peak assignment. The C3-C4 cleavage (Fig. 4.2A)
was described to be 7.5-fold faster than the C3-C2 cleavage (Fig. 4.2B) [16]. On a
mild oxidation, the double oxidised structure (Fig. 4.2C) is likely less representative, as
most periodate would be rapidly consumed on single oxidations and such scenario is
favored by the starting pH (~ 5) [283]. Furthermore, it is thought that the hemiacetal
formation could hinder further oxidation, even of neighboring residues [16]. Therefore,
the structures arising from the C3-C4 oxidation will be treated as more representative,
followed by the C3-C2 oxidation and the double oxidation. The titration of dexOx with
carbazates yields a carbazone moiety, evidencing the former aldehydic proton, which
helps clarifying the bidimensional spectra. The region around 7.3 ppm (proton axis) and
145 ppm (carbon axis) on the 1H-13C-HMQC (Fig. 4.3A inset) unveiled two main peak
populations of carbazone protons. A third carbazone peak exists (7.16 ppm), only seen on
the COSY (correlation spectroscopy) spectrum (Fig. 4.3B) and is apparently correlated
with the α-1,3 anomeric proton (see left axis dextran’s proton spectrum overlay for
the native peaks). Therefore, it seems to exist two main carbazone peaks, out of four
possible different carbazones (C2, C4 and two different C3’s), though each of them could
have different environments influencing the chemical shifts. Analysing the C3-C4 cleavage
(Fig. 4.2A), an intra-hemiacetal structure is likely to occur, after a hydroxyl (C2) attack to
the C4 aldehyde, forming a stable six sides ring [284], despite several different possibilities
due to the rotativity of the oxidised residue. The aldehyde on C3 could suffer an attack
from any hydroxyl (HO-C4 from the downstream residue suggested in the structure).
We propose this aldehyde to be the more susceptible of attack by tBC, represented by
the most shielded of the protons (Fig. 4.3A 3a; ~ 7.28 ppm) in the 7.3 ppm region.
Analysing this peak correlation on the COSY, one can see a correlation with a proton at
~ 4.25 ppm (2a), correlating itself with a carbon (Fig. 4.2A) on the same chemical shift
as glucose C2 (~ 71.6 ppm). The same proton (2a) further correlates downfield, with
a possible anomeric proton/carbon (1a). Supposing this structure as the most likely
and stable after C3-C4 cleavage, the C4 proton has an anomeric-like environment and
possibly could be associated with a correlation with C5 like those proposed aacording to
the bidimensional spectra (4a and 5a, respectively).
The C3-C2 cleavage yields an aldehyde on C2, which has been proposed to form a stable
and conformationally plausible 1,4-dioxepane ring after reaction with the OH on C4 from
the downstream residue (Fig. 4.2B) [16]. Again, the aldehyde on C3 (3b) would be more
prone to react with tBC. Following the other carbazone proton at ~ 7.35 ppm (Fig. 4.3B;
3b), it correlates with a proton at ~ 4.55 ppm (4b), which further correlates with a single
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proton upfield, falling near the glucose residue proton/carbon 5 (5b). There is a strong
correlation between an anomeric proton and a proton at ~ 3.65 ppm, which could be an
unshielded proton on C2 and also correlates with a carbon in the same chemical shift
as glucose C2. This correlation could likely arise from 1b and 2b, but also 1c and 2c,
from the doubly oxidised residue, as the environments are very similar. Regarding the
doubly oxidised residue, the hemiacetal structure depicted in Fig. 4.2 was also suggested
by Ishak and Painter (1978) [16] to be plausible.
Figure 4.4.: NMR spectra acquired at alkaline pH (10.2). (A) 1H-NMR of D25 with
close up (7.8 - 9.2 ppm); (B) D25 mixed with EtC, close up of the region of interest;
(C) COSY overlay of D25 (red contour) with D25 mixed with EtC (black contour).
The new correlations arising from the carbazone protons are identified.
Therefore, C4 would be more sensitive to a carbazate attack. However, the third major
visible correlation in the COSY spectrum, at 7.16 ppm, apparently correlates with the
anomeric proton (α-1,3), which would be an unlikely chemical shift for a proton on
C5. It would be more reasonable if this correlation arose from the carbazate attack
at C2 of the doubly oxidised, but a second correlation would have to be present in the
HMQC spectrum (Fig. 4.3B). It is possible that the correlations from the doubly oxidised
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residue, as well as other minor populations, are masked within the major peaks. The
transient nature of the hemiacetals and the similar environments turn the peak assigning
task a hard mission, which could have several interpretations. Anyhow, the two main
correlations on the COSY spectrum suggest that not every aldehyde is reacting with a
carbazate under these pH conditions.
At alkaline pH (10.2), some new peaks can be seen in the range of 7.5 to 9.5 ppm for the
D25 sample (Fig. 4.4A). These peaks were previously attributed to isomeric enol forms.
Such structures are under an aldo-enol equilibrium [18]. Many other peak populations
are observed between 4 and 6 ppm, due to the higher resolution (Fig. 4.41A). Though,
the addition of EtC, at this pH, did not revert most of the identified new peaks, it
presented more correlations on the zone of interest for the carbazone protons (~7.3
ppm; Fig. 4.4 B & C). We have observed before, that dexOx crosslinked with AAD
hydrogels dissolved quickly at pH 9 [14], suggesting the sensitivity of the hydrazone
bond to alkaline pH’s, thus, the likelyhood of a similar behaviour for the carbazone bond
also exists. These new correlations, suggest that, every aldehydic carbon is sensitive to
a carbazate attack. Under this pH, the aldo-enolic structures are likely more exposed
to attack than under the hemiacetal form, establishing a higher number of equilibriums,
concomitantly expressed on the COSY spectrum (Fig. 4.4D). The overlay of both COSY
spectra shows the appearance of a high number of new correlations after the addition
of EtC (Supplementary Figure 1D, black contour), partially reverting the correlations of
D25 (red contour). These results identify pH as a strong modulator of dexOx reactivity,
which might be interesting to contemplate under certain pH sensitive applications.
4.4.3. Macroscopic Consequences of the Oxidation
The extensive and complete dextran oxidation leads to the destruction of the molecule
into characteristic degradation by-products [10]. Low and mild oxidations also degrade
dextran, leading to slight molecular weight decrease. The destruction of the glucose
residue, yielding aldehydes, could also contribute in altering the dexOx behaviour in
solution. The periodate oxidation in non-buffered solutions leads to pH decrease, after
formic acid release [14], possibly contributing for acid-hydrolysis [285]. This phenomenon
can be observed in several ways. The reference technique in the characterisation of
polymers is the size exclusion chromatography (SEC), which separates the different
populations in accordance with the hydrodynamic volume, which can be translated to
molecular weight and the polydispersity index (Tab. 4.1). The molecular weight is a
64
4.4 Results and Discussion
Table 4.1.: Macroscopic characteristics of native dextran and the several oxidised sam-
ples. OD estimated by 1H-NMR analysis, Mw and PDI calculated by SEC, viscosities
at different concentrations and time necessary until complete dissolution.
Sample Oxidation
degree
Mwc PDId ηe
20%
ηf
5%
t37ºCg
IO4a EtCb kDa (mPa.s) (mPa.s)
Dextran - - 60.1 1.47 30.7 2.7 1.0±0.04h
D5 5 3.6 ± 0.1 61.2 1.59 35.9 2.9 1.3±0.08
D10 10 8.6 ± 0.2 60.8 1.61 35.1 3.0 1.5±0.05
D25 25 22.2 ± 0.7 60.3 2.03 26.8 2.7 3.9±0.65
D40 40 33.0 ± 0.8 25.4 3.05 102.8 2.7 26.6±0.44
a Theoretical OD, calculated as the molar ratio of sodium periodate per initial glucose unit in dextran.
b Calculated by 1H-NMR after titration with tert-butyl carbazate/ethyl carbazate, taking into account
the ratio between the integral of the peak at δ 7.3 ppm and the integral of the anomeric proton at δ
4.9 ppm. Average and standard deviation of 5 independent integrations.
c Weight-average molecular weight estimated by SEC.
d Polydispersity index corresponding to Mw/Mn.
e Viscosities of dextran and oxidised dextrans at 20% w/w. Taken from the slope of the curves Shear
Stress = f(Shear Rate) plot. The linear regression was forced to cross the origin as every sample showed
a Newtonian behaviour.
f Viscosities of dextran and oxidised dextrans at 5 % w/w, at 200 rpm.
g Dissolution time taken, at 37 °C, in PBS, without agitation.
key property of polymers, defining certain macroscopic characteristics, such as solubility,
viscosity and clearance rates in biological systems [2]. Besides 1H-NMR and SEC, we have
gathered results of techniques and empirical evidences, which clearly reflect the molecular
weight differences between the several dexOx samples. One direct consequence of the
dextran oxidation is the longer dissolution times in aqueous media. This phenomenon is of
utmost importance on an off-the-shelf freeze-dried product. The dissolution time periods
of the several samples under exactly the same conditions (Fig. 4.5A) but at different
temperatures, show that D5 and D10 have very close dissolution profiles to dextran
(D0). However, the D25 and D40 dissolution profiles clearly reflect the OD increase. The
viscosity of a dextran solution is directly related to its concentration and Mw [286, 287].
The molecular weight decreasing due to periodate oxidation should theoretically yield a
less viscous solution than the original dextran, for the same concentration conditions.
At lower concentrations (5%) the viscosity variation is negligible (Tab. 4.1). However,
the reactivity of the oxidised dextran, through inter-hemiacetals formation, has great
influence on the behaviour of the solutions. We observed that the oxidation degree could
invert the viscosity trend, depending on the dexOx concentration. Concentrated solutions
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Figure 4.5.: Dissolution time profiles, at different temperatures (A) and the shear stress
vs. shear rate profile at 20% (w/w) concentration and 25 ºC (B) for dextran (￿), D5
( ), D10 ( ), D25 ( ) and D40 ( )
favour the inter-chain hemiacetals formation, resembling a molecular weight increasing,
hence the higher resistance to flow. Within the same concentration range (20% w/w),
only D25 viscosity falls below the dextran viscosity. On the other hand, D40 has an
extremely high resistance to flow, reflecting the cross-reactivity (Tab. 4.1 and Fig. 4.5B).
We suggest that this effect is due to the interchain hemiacetals formed, inverting what
would be the natural viscosity trend and demonstrating how both parameters (OD and
Mw) can interfere with the viscosity of a given dexOx solution.
4.4.4. Thermal Analysis
We have extended the study on the influence of the oxidation extension by analysing
the thermoanalytical curves of the different oxidised species. The DMTA method is
frequently used to evaluate the effects of excipients on polymer’s glass transition tem-
perature (T g). In amorphous polymers, a primary relaxation transition may be observed
at a characteristic temperature Tg. In this point, the glass-like state (restricted mo-
tion of the polymeric chains) changes to a rubber-like state indicating loss in rigidity
(i.e. increased relaxation) associated with enhanced polymeric chain mobility. Typically,
the glass transition is defined as the temperature(s) at which either a maximum in the
mechanical damping parameter (tan δ) or loss modulus (G’’) occurs [288]. The pres-
ence of moisture can also be assessed by DMTA, visible in the thermoanalytical curves
as characteristic transitions at certain temperatures [289]. In terms of damping, it is
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possible to identify four main transitions for the pristine dextran, approximately at -80
ºC, 105 ºC, 235 ºC and 305 ºC (Fig. 4.6A */**). The peak at -80ºC is a secondary
relaxation due to absorbed water, which contributes to the formation of a more diffuse
and stronger H-bond network than observed in a dry sample [289]. The peak at 105
°C refers to the water evaporation from dextran. These thermal events show that even
after the freeze-drying process some residual water is present. These events have differ-
ent profiles on the oxidised samples (not shown), which will not be addressed since this
issue is out of the scope of this work. The next peak at ca. 235 °C corresponds toT g.
At this temperature, the storage modulus decreases rapidly and is frequency dependent
on the Tan δ (Fig. 4.6A inset). This peak reflectes an α - relaxation from non-frequency
dependent events, such as crystalization, melting, curing or thermal degradation [290].
The peak at 305 °C reflects an overall degradation stage and will be discussed further
ahead.
It has been reported that the molecular weight of dextrans influences the Tg due to
the decrease of the free volume with the Mw increase [291]. To confirm such influence,
the thermoanalytical data of several dextrans (Mw: 580, 60 and 19.5 kDa; tested as
supplied) were analysed. In fact, the T g of the tested dextrans samples decrease directly
with the Mw, being the correspondent peak values observed at 237.8, 235.4 and 231.1
°C, respectively (Fig. 4.6B). These T g are in agreement with the trend described by
Icoz et al [291] for a comparable Mw, despite determined by a different technique. The
different oxidised samples were processed in a similar way to avoid any artifacts that
could arise from freezing and freeze-drying and there was an effort to minimize samples
moisture. Interestingly, D0 presented a broader peak and shifted to lower temperature
(223.6 °C) when compared with the original dextran (Fig. 4.6B). The presence of the
phosphate salts could interfere with the freezing process of dextran, leading to different
dextran chain conformation, which is reflected by the broader T g peak and the shift
to lower temperatures [292]. By freeze-drying a phosphate buffered aqueous dextran
solution, it can impair the crystallization process of the salts [293] as well as the dextran
derivative itself. Nevertheless, the Mw difference, within the dexOx’s samples, is clearly
visible on the DMTA curves (Fig. 4.6C and Tab. 4.2) corroborating the SEC and NMR
data. It is known that cross-linking agents can also increase the T g [288]. However,
the hemiacetals cross-linking effect, observed on the viscosity studies, apparently is not
reflected on the T g, suggesting that the real molecular weight is dominant on the T g
onset.
A first look to the TG curve profiles (Fig. 4.7A) allows to identify a quite dramatic change
67
Chapter 4 Insight on the Periodate Oxidation of Dextran
Figure 4.6.: (A) Full thermogram of native dextran marked with the non-frequency de-
pendent transitions (*) and T g identification (inset; **) through frequency dependent
transition; (B) T g of the different molecular weight dextrans; (C) T g of the different
oxidised samples. All samples presented with a frequency of 1 Hz, except for dotted
line at a frequency of 10 Hz.
in going from native dextran to its processed (freeze-dried PBS solution) counterpart,
D0. Apart from a shift in the onset temperature of the main mass loss stage towards
lower temperatures (by 41 °C), a remarkable difference is observed in the residual mass
(at 600 °C), which should be ascribed to the salts coming from PBS. The original dextran
exhibits a quite familiar behaviour [294, 247, 289, 295], with a first mass loss stage below
ca. 120 °C due to the elimination of water, as observed in the DMTA, followed by the
overall degradation stage (depolymerization) along the approximate temperature range
from 298 to 328 °C, in good correspondence with the fourth transition, identified by
the DMTA results (Fig. 4.6A). However, the thermal decomposition of oxidised dextran
samples should be analysed with reference to thermal decomposition of the sample
that reflects the influence of PBS in dextran, D0. In this case, the differences in the
thermoanalytical curves appear to be more subtle.
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Figure 4.7.: (A) TG and (B) DTG curves of dextran and dexOx samples. (Φ=10
°Cmin−1; dry nitrogen at 100 mLmin−1).
Both D0 and oxidised dextran samples exhibit a first mass loss stage, from the ambient
temperature to 150 °C. The correspondent mass loss rate is somewhat variable among
the samples, but the residual mass at 150 °C is quite comparable (see Tab. 4.2). This
first weight change is caused by the loss of adsorbed water, and, probably, of some water
of crystallization related with the PBS components (phosphates). Above 150 °C, the
differences in the response of samples under comparison become more apparent. The
complexity of the global thermal decomposition, probably involving several kinetically
independent processes as suggested by the TG data and, mainly, by the differential
thermogravimetric (DTG) curves profiles (Fig. 4.7B), increases with the degree of the
oxidation of the samples. A first change in the mass loss rate within the approximate
temperature range 180-220 °C can be observed (Fig. 4.7B inset), being only incipient in
the case of the D5 sample, moderate in the D10 one, and rather evident in the remaining
oxidised dextran samples (see also Tab. 4.2 for the onset temperatures). This stage is
followed by the main decomposition process, whose pattern is also clearly influenced by
the oxidation degree, as revealed by the DTG curve profiles. In terms of characteristic
quantities, while the onset temperature of the main decomposition stage obeys to a well
defined pattern, monotonically decreasing with the increase of the oxidation degree from
247.5 °C (D5) to 233.0 °C (D40), the undefined trend of the peak temperature at the
maximum decomposition rate (Tab. 4.2) reflects differences in decomposition pathways.
The residual mass at 600 °C for the most oxidised sample (D40) suggests a pronounced
different decomposition course when compared to the remaining oxidised samples.
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Table 4.2.: Glass transition temperatures obtained from the DMTA curves (see Fig. 4.6)
and characteristic quantities (mean and standard deviation) obtained from the
TG/DTG curves (see Fig. Fig. 4.7).
Sample Tg
(C°)
Tona
(C°)
Tpb
(C°)
∆mc
(%)
Dextran 235.5 298.6±0.4 315.0±0.2 92.8±0.2 8.3±0.4
D0 223.6 257.6±1.4 269.9±1.7 96.3±1.1 29.7±0.2
D5 211.5 195.2±1.4 247.5±0.8 267.1±1.6 94.7±0.2 29.7±0.2
D10 207.9 198.6±0.6 241.5±0.4 279.2±0.2 93.2±0.3 28.8±0.0
D25 200.5 190.8±0.4 234.1±0.3 266.2±0.2 93.1±0.4 30.9±0.3
D40 190.7 179.7±0.2 233.0±0.7 274.4±1.8 94.3±0.3 35.4±0.0
a Ton: extrapolated onset temperatures (TG curve).
b Tp: peak temperature, corresponding to the maximum decomposition rate (DTG curve).
c ∆m: residual mass at the temperatures 150 °C and 600 °C.
4.5. Conclusion
Our bidimensional NMR data suggests that only one aldehyde per residue is responding
to the carbazate under mildly acidic conditions. We propose that the two main peak
populations (~ 7.3 ppm) arise from carbazates on C3 from single oxidised residues. There
are more downfield shifted peaks, but not more than 5.5 ppm, which indicate the non-
existence of more carbazate proton populations. These peaks should arise from protons
involved in hemiacetals. The enol forms appear to be more reactive towards carbazates,
though more labile and less stable.
The periodate oxidation of dextran is a harsh reaction which promotes chain degrada-
tion, confers high chemical reactivity to a natively neutral molecule and deeply alters its
physicochemical properties. The increasing OD, impairs water solubility, taking longer
periods of time to solubilise, and interferes with the resulting viscosity, especially at high
polymer concentrations. The solutions viscosity could impair injectability and mixibility
of certain formulations. The degree of oxidation is also reflected on the glass transition
temperature according to DMTA data. Interestingly, the hemiacetals do not seem to
affect the thermal properties of the freeze-dried samples. The glass transition tempera-
tures shift is in direct accordance with the molecular weight decrease, but do not give
much insight on the structural consequences of the oxidation. On the other hand, the
DTG profiles, for the diverse samples, are quite interesting. An increase in the ther-
mal decomposition complexity with the increase in the oxidation degree was identified,
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evidencing the deleterious effect of periodate oxidation on dextran’s structure. Low ox-
idative conditions, up to 10%, do not damage extensively dextran’s structure, however
milder oxidation conditions, result in extensive disruption of the dextran structure. These
set of results may rise awareness for the consequences of periodate oxidation on the final
structural properties of the modified dextran, helping researchers to better guide the
design of dexOx-based formulations.
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5. Ocular Injectable Formulation
Assessment for Oxidised
Dextran-based Hydrogels
5.1. Abstract
Initiator-free injectable hydrogels are very interesting for drug and/or cell delivery appli-
cations, since they can be administered in a minimally invasive way, without recurring to
chemical initiators that could be harmful. In the current work, oxidised dextran cross-
linked (dexOx) with adipic acid dihydrazide (AAD) hydrogels were further characterised
and tuned to produce formulations, having in sight an injectable ocular formulation for
the possible treatment of posterior eye diseases. The gelation rate and the hydrogels
dissolution profile were shown to be dependent on the balance between the dextran
oxidation degree, and both components concentration. On the in vitro studies, rabbit
corneal endothelial cells were seeded on the hydrogels, to assess cytotoxicity. Hydrogels
prepared with low oxidised dextrans were able to promote cell adhesion and proliferation
to confluence in just 24 hours, while higher oxidised samples promoted cell adhesion and
proliferation, but without achieving confluence. Cell viability studies were performed
using MTS assays to verify the non-cytotoxicity of hydrogels and their degradation by-
products, rendering these formulations attractive for further in vivo studies.
5.2. Introduction
Ocular diseases of the posterior eye segment are the most common cause of visual dis-
orders in industrialised countries [296]. These illnesses include, for example, cataracts,
diabetic retinopathy, macular degeneration associated with ageing and retinitis pigmen-
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tosa [296, 297]. The visual disorders cause discomfort, anxiety and fear of losing the
vision in patients.
Until now, ocular drug market is dominated by drugs, which were conceived to treat
illnesses that affect the anterior eye segment, such medicines include: antibiotics, anti-
inflammatory agents or anti-glaucoma drugs, usually as eye drop formulations [296, 298].
These topical applications, in the form of eye drops, are ineffective in many cases, due
mainly to the drainage system of the eye, which leads to poor ocular bioavailability
[299]. New drugs have been developed to reach the posterior eye segment, although,
most of them are administered through repeated intravitreal injections. This method
is associated with complications such as pain, increased intraocular pressure, retinal
detachment and endophtalmitis (which may lead to blindness). New methods of drug
delivery, more secure, efficient, comfortable and with prolonged activity are needed,
to minimise the number of injections. Currently, there are systems of controlled drug
delivery on the market or being tested, such as implants, hydrogels and colloids [296].
Hydrogels are hydrophilic polymer networks, which may absorb up to thousands of times
their dry weight in water. Hydrogels may be chemically stable or they may degrade and
eventually disintegrate and dissolve. They are called “reversible” or “physical” gels when
the networks are held together by molecular entanglements, and/or secondary forces
including ionic, H-bonding or hydrophobic forces. Hydrogels are called “permanent” or
“chemical” gels when they are covalently cross-linked networks [300]. Recently, Van
Tomme and collaborators compiled the different strategies used in producing dextran-
based hydrogels, demonstrating dextran as a very versatile starting polymer for hydrogel
synthesis [6]. Furthermore, pharmaceuticals and various potential therapeutic agents
can easily be incorporated and its release profile controlled. Recently, human embryonic
stem-cell encapsulation was also successfully achieved in bioactive hydrogels of dextran-
acrylate [216].
Dextran is biocompatible and can be degraded through the action of dextranases in
various organs in the human body, including liver, spleen, kidney and colon [2].
Dextran oxidation by sodium periodate is an easy and well-known way to functionalise
dextran with aldehyde moieties [10]. This chemical functionality has been widely tested
to conjugate N-nucleophiles, due to their fast and almost complete reaction [29]. This
approach has been tested on the synthesis of pro-drugs [66], as a spacer in enzyme
immobilisation [132] or for growth factor controlled release [103]. On the preparation of
hydrogels, different aminated cross-linkers, like chitosan [104, 105], gelatine [102], 8-arm
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PEG amine [39] or polyhydrazides [28] have been used to yield chemical initiator-free
formulations.
Recently, we described an injectable formulation composed of oxidised dextran (dexOx)
cross-linked with adipic acid dihydrazide (AAD) [14]. The dexOx with 15% oxidation
degree (OD) was cross-linked with AAD, forming a gel within 2–4 minutes, depending
on the AAD concentration used. The obtained hydrogels were characterised by their
mechanical properties (7 – 32 kPa), swelling and degradation (9 to 23 days) behaviour
under physiologic conditions.
In this work, oxidised dextran, with various OD, was studied in order to improve the
control of the system properties. The influence of dextran OD and concentration in the
solution viscosity was monitored. We observed that the hydrogel swelling and dissolution
could also be controlled by the dextran oxidation degree and that the dissolution profile
could be extended for more than 2 months, improving the previous studied formulation.
Cell toxicity assays were carried out in 96-well plates with different dexOx’s hydrogels.
Cell viability studies were performed using rabbit corneal endothelial cells, which were
seeded on top of the dexOx’s hydrogels. The cell adhesion and growth was visualised
by optical microscopy and dehydrogenase activity of cells was evaluated by reduction of
the MTS reagent.
5.3. Materials and Methods
5.3.1. Materials
Dextran (from Leuconostoc mesenteroides; Mw 60 kDa, according to Fluka’s specifica-
tion), sodium periodate, AAD, tBC, EtC, PBS, dialysis tubes (MWCO ~12 kDa), am-
photericin B, L-glutamine, Minimum Essential Medium Eagle, penicillin G, streptomycin,
and trypsin were purchased from Sigma (Sintra, Portugal). Foetal bovine serum was
purchased from Biochrom AG (Berlin, Germany). The 3-[4,5-dimethylthiazol-2-yl]-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) and electron
coupling reagent (phenazine methosulphate; PMS) were purchased from Promega. T-
flasks and 96 well plates were purchased from Nunc (Denmark).
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5.3.2. Dextran Oxidation
An aqueous solution of dextran (1 g; 12.5%, w/v) was oxidised with 2 mL of sodium
periodate solution with different concentrations (33 – 264 mg/mL) to yield theoretical
oxidations from 5 to 40%, at room temperature. The reaction was stopped after 4
hours. The resulting solution was dialysed for 3 days against water, using a dialysis tube
with a MWCO 12-14 kDa, and then lyophilised (Snidjers Scientific type 2040, Tillburg,
Holland). The scale-up of the reaction was done using the same procedure albeit using
30 g of dextran and a calculated amount of periodate to yield a theoretical oxidation of
5, 10, 25 and 40%.
5.3.3. Nuclear Magnetic Resonance and Size Exclusion
Chromatography
The OD of dexOx is defined as the number of oxidised residues per 100 glucose residues
(OD refers to the theoretical value unless otherwise stated) and quantified by using tBC
[22, 301]and EtC. The carbazates react with aldehyde groups to form carbazones in the
same way hydrazones are formed in the presence of hydrazides.
1H spectra were acquired on a Varian 600 NMR spectrometer (Palo Alto, CA) using a
3 mm broadband NMR probe. 1H NMR spectra were recorded in D2O (20-25 mg in
0.2 mL; pD of ca. 5.0) using a 90° pulse and a relaxation delay of 30 s. The water
signal, used as reference line, was set at δ 4.75 ppm and was partially suppressed by
irradiation during the relaxation delay. A total of 32 scans were acquired for each 1H NMR
spectra. The spectra were analysed with iNMR software, version 2.6.4 (www.inmr.net).
Size exclusion chromatography (SEC) was performed in a HPLC system composed of a
degasser and a WellChrom Maxi-Star k-1000 pump (Knauer), coupled to a LS detector
(evaporative light scattering PL-EMD 960) and one column (PL aquagel-OH Mixed 8
µm) from Polymer Laboratories. The whole system was kept at room temperature and
the eluent used was KNO3 (0.001 M; pH 3.9) at a flow rate of 0.4 mL/min. Samples
and standards were dissolved in the eluent at 4-6 mg/mL (Fluka Chemie AG, dextran
standards from 12 – 80 kDa).
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5.3.4. DexOx’s Solutions Viscosity
Dextran and dexOx’s solutions, with concentrations ranging from 10 to 30% (w/w)
in PBS, were prepared and analysed in a Brookfield Programmable D-II+ Viscometer
with a S18 spindle, assisted by DVLoader v1.0 software. The chamber temperature was
controlled by an external bath to 25 °C, and the chamber was loaded with 8 mL of
solution.
5.3.5. Hydrogel Preparation and Characterisation
The several oxidised dextrans were dissolved in different concentrations; dexOx 5% (D5)
and 10% (D10) solutions were used at 30% (w/w) and dexOx 25% (D25) at 20% (w/w),
in aqueous solvent (PBS) at 37 °C until a liquid solution was obtained and then kept at
5 to 8 °C, until further use. Then, 250 µL of a given dexOx solution was mixed with 250
µL of a given AAD solution on home-made Teflon® moulds and let to cross-link never
less than 2 hours (except for the D5 hydrogels, which were let to cure over night). The
AAD concentrations used are calculated based on a given molar percentage of dextran
residues. The hydrogels nomenclature is as follows: dexOx 5% + AAD 5% - D5A5; and
so forth.
5.3.6. Dynamic Swelling Experiments
DexOx hydrogels, after being prepared and weighted (Wi), were immersed in PBS (ca. 5
mL) in 6-wells cell culture plates, at 37 °C. At regular time intervals, they were removed
from the aqueous solution, blotted in filter paper, weighted (Wt) and returned to the
original well while PBS was replaced. The swelling index (SI) is defined as:
SI = Wt/Wi (5.1)
where W t is the weight on a given time point and W i represents the initial hydrogel
weight.
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5.3.7. Rheological Analysis
Rheological experiments were carried out using the parallel plate geometry (20 mm
diameter, steel) of a Haake Rheostress RS 1. On the calculation of gelation period,
both solutions (190 µL each) were mixed on the bottom plate, and the upper plate was
positioned at a gap of 1 mm (after gap optimisation). This procedure took around 20
seconds after which the experiment was started at low frequency (0.5 Hz) and stress (0.1
Pa), to avoid interference with the network formation. The gelation rate was followed
and the gelation period was considered to be the crossover point between G’ and G’’
(G’=G’’).
5.3.8. Cell Source and Growth
Corneal endothelial cells from rabbit were obtained as previously described [302]. Sub-
sequently, cells were platted in T-flasks of 25 cm3 with Minimum Essential Medium
Eagle (MEM) with heat-inactivated foetal bovine serum (FBS, 10% v/v) and growth
factors to do primary culture in agreement with the procedures previously described in
the literature [303]. T-flasks with cells were incubated in a 5% carbon dioxide humidified
atmosphere at 37 °C. On day 3, the medium was changed and here after every three
days. Six days after cells attained confluence. After confluence was obtained, cells were
sub-cultivated using 5 min incubation in 0.18% trypsin (1:250) and 5 mM EDTA. The
free cells were added to an equal volume of culture medium. Following centrifugation,
cells were re-suspended in sufficient culture medium and seed in 96 well plates containing
the biomaterials.
5.3.9. Cell Culture and In Vitro Cytotoxicity Studies
Two cross-linking degrees of AAD for each dexOx were selected and used on cytocom-
patibility tests. The oxidised dextran samples and AAD were either dissolved in PBS or
in the appropriate cell culture medium, MEM.
Each formulation in the form of hydrogel was introduced (n=6), on wells of 96-wells cell
culture plates, never exceeding 60 µL. The plates were irradiated for 30 minutes with
UV, before being seeded with cells.
Forth passage endothelial corneal cells were seeded, at a density of 90’000 cells per
well, into a 96-well plate containing the hydrogels. The plate was incubated at 37 °C,
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under a CO2 (5%) humidified atmosphere. After 1, 3 and 7 days, cell viability was
assessed through MTS assays. A CellTiter 96® AQueous Assay composed of 3-[4,5-
dimethylthiazol-2-yl]-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, in-
ner salt (MTS) and an electron coupling reagent (phenazine methosulphate; PMS) from
Promega were used. 20 µl of MTS/PMS were added to each sample and incubated
for 4 h at 37 °C, under a CO2 (5%) atmosphere. The absorbance of the samples was
determined at 492 nm using a Biorad Microplate Reader Benchmark.
Wells containing cells in culture medium without biomaterials were used as negative
control (K-). Ethanol 96% was added to wells containing both types of cells to have
a positive control (K+). The samples were analysed using an Olympus CX41 optical
microscope equipped with an Olympus SP-500 UZ digital camera.
5.4. Results and Discussion
5.4.1. DexOx Characterisation
Following previous work [14], we characterised hydrogels made from dexOx with a wider
range of oxidation degrees, cross-linked with different amounts of AAD. Dextran was
oxidised by using sodium periodate at different percentages and characterised by 1H-
NMR. The oxidation degree was not estimated by the TNBS assay, due to the good
correlation of the NMR titration with the colorimetric assay, as shown in previous work
[14]. The tert-butyl carbazate titration, however, causes sample precipitation when
reacted with high oxidation degree samples, not allowing NMR spectra acquisition (D40,
Tab. 5.1). We suggest that this effect is caused by the large tert-butyl moiety and we
hypothesised that a less bulky molecule, such as ethyl carbazate, would not cause sample
precipitation. In fact, both spectra are similar except for the ethyl protons peak which
is sharper and slightly shifted up-field in comparison to the tert-butyl peak (spectra
not shown). The real oxidation degree was calculated by taking into account the ratio
between the integral of the peak at δ 7.3 ppm (arising from the carbazone group formed
either with tBC or EtC) and the integral of the anomeric proton at δ 4.9 ppm. The
oxidation degrees obtained with EtC were slightly higher (Tab. 5.1) than that obtained
with tBC titration, which may suggest some difficulty of tBC to react further due to its
bulkier moiety.
The dexOx number-average molecular weight (Mn), estimated by a SEC analysis, showed
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Table 5.1.: Oxidation Degree of several oxidised dextrans calculated by 1H-NMR anal-
ysis after titration with different carbazates and molecular weight evolution.
Sample Oxidation degree Mnc PDId
NaIO4a tBCb EtCb
Dextran - - - 40.9 1.47
D5 5 2.5 ± 0.3 3.6 ± 0.1 40.8 1.59
D10 10 7.4 ± 0.9 8.6 ± 0.2 37.9 1.61
D25 25 18.9 ± 0.4 22.2 ± 0.7 29.7 2.03
D40 40 -e 33.0 ± 0.8 8.3 3.05
a - Theoretical OD, calculated as the molar ratio of sodium periodate per initial glucose
unit in dextran.
b - Calculated by 1H-NMR after titration with tert-butyl carbazate/ethyl carbazate,
taking into account the ratio between the integral of the peak at δ 7.3 ppm and the
integral of the anomeric proton at δ 4.9 ppm. Average and standard deviation of 5
independent integrations.
c - Number-average molecular weight estimated by SEC
d - Polydispersity index corresponding to Mw/Mn
e - Precipitation occurred
a clear decrease with increasing oxidation degree, but also an increasing polidispersity
index (PDI), reflecting the higher range of dexOx molecular weights (Tab. 5.1).
5.4.2. DexOx Solutions Viscosity
On the design of injectable hydrogel formulations, details, like viscosity characterisation,
become increasingly important, in order to choose the best syringe geometries and/or
needle gauges. Generally, the hydrogel characteristics can be tailored by the feed con-
centration [104], degree of polymer modification and in other cases, chemical initiators
concentration [304]. This particular system involves the mixing of two equal-volume
solutions, each of which, with its own reactive species, oxidised dextran residues and the
dihydrazide. Thus, the formulations design has to take into account the feed concentra-
tion halving, of both solutions, after mixing.
Every dexOx sample, at any of the concentrations tested, showed a linear shear stress
increase regarding the different shear rates, hence, a Newtonian behaviour. For every
concentration tested, across the different OD’s, the obtained viscosities for each dexOx
series show a natural trend directly related with the concentration, as can be observed
on Fig. 5.2A for dextran and D40. The OD influence on viscosity seems to have a
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Figure 5.1.: The reactive aldehyde groups formed upon periodate oxidation are prone
to establish inter (A) or intra (B) hemiacetals, when reacting with hydroxyl groups
from nearby residues. The addition of AAD (C) promotes the reversible cross-linking
with the formation of hydrazones.
higher effect, when the polymer concentration is high, but as the polymer solution is less
concentrated, the viscosity tends to decrease and eventually be lower than the reference
solution (original dextran).
Within the same concentration range, only the D25 viscosity falls below the dextran
viscosity, but on the other hand, D40 has an extremely high viscosity reflecting the
influence of the high reactivity, due to the high OD (Fig. 5.2B).
We suggest that this effect is due to the molecular weight decrease with oxidation,
which, below a certain concentration, counter-balances the cross-linking via hemiacetals
(Fig. 5.1A), decreasing the solution viscosity (Fig. 5.2A), which could possibly be fur-
ther enhanced by a dexOx chain coil due to the intra hemiacetal formation (Fig. 5.1B),
demonstrating how both parameters (OD and Mw) can interfere on the viscosity of a
given dexOx solution.
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Figure 5.2.: Shear stress versus Shear rate. (A) – Dextran with concentrations (w/w)
of: - 30%, ￿ - 20%, - 15% and - 10%; and D40 with concentrations (w/w)
of: ￿ - 20%, - 15% and - 10%. (B) All solutions at 20% (w/w) ￿ - dextran,
- D5, - D10, - D25 and - D40
5.4.3. Hydrogels Characterisation
The hydrogels preparation took into consideration three factors: the dexOx concentra-
tion/oxidation degree and the AAD concentration. The first two are closely related due
to the viscosity issues that were discussed above. Therefore, the concentration used was
as high as the viscosity would allow it. Solutions of D5 and D10 with 30% concentration
allow a good homogenisation, despite the high viscosity, but for D25, we had to use a
20% concentration. The D40 macro-monomer was not studied in deep detail as the oth-
ers, due to its high reactivity for the concentration range wanted. The D40 with a 20%
concentration yields a very viscous solution that reacts promptly with AAD, impairing a
good homogenisation. Lower concentrations produce nicer hydrogels, however with less
attractive and more unpredictable swelling profiles. Yet, the D40 gelation rate data is
presented (15% feed concentration), to strengthen the issue on the balance between OD
and AAD feed concentration effect on the gelation rate, discussed below.
The balance between the available cross-linking points (oxidation degree) and the amount
of cross-linker used (AAD feed concentration) clearly affects the gelation rate, as shown
on Tab. 5.2, however, not always on the same direction. The gelation periods of D25
and D40 hydrogels decrease with the AAD increase, while for the D5 and D10 hydrogels,
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the gelation periods increase directly with the AAD concentration. When low OD’s are
present, the excess AAD increases the number of non-valid cross-links, caused by the
reaction of a single hydrazide, leaving a dangling end [305], and retarding the hydrogel
formation. The polymer feed concentration also affects the gelation periods, as can be
observed with the D40 hydrogels, which should be faster than the D25, for the same
AAD feed concentrations.
Table 5.2.: Gelation periods estimated for each dexOx with different AAD
concentrations.
dexOx Feed Conc. Gelation period (min)a
% (w/w) 5% AAD 10% AAD 20% AAD
D5 30 66.7±1.4 77.8 ± 5.2 -b
D10 30 14.9 ± 1.7 16.8 ± 0.5 18.8 ± 1.3
D25 20 2.8 ± 0.3 1.6 ± 0.9 1.3 ± 0.2
D40 15 3.7 ± 0.4 2.6 ± 0.1 2.3 ± 0.1
a The gelation period was considered when G￿ = G￿￿ ; values are means ± SD (n=4).
b Hydrogel not formed.
The dexOx/AAD hydrogels were prepared in Teflon moulds and let to cure for at least
two hours, except for the D5 hydrogels, which were left overnight, due to the slow curing
rate. Equal volumes of dexOx and AAD solutions were added and mixed vigourously
with the pipette tip, to achieve a good homogenisation of both solutions.
The hydrazide groups in AAD react with the aldehyde groups in oxidised dextrans
forming hydrazone bonds, which are hydrolysable, retrieving the same chemical groups
(Fig. 5.1C), therefore, making these hydrogels soluble in different time frames. The
swelling index (Equation 5.1) of the different sets of hydrogels showed how the disso-
lution profiles could be controlled, not only by the AAD amount but as well by the
dextran OD. By increasing the OD, we can significantly increase the dissolution time of
the hydrogels. This oxidation increase, allows that more AAD can be used as a cross-
linking agent, reflecting on more lasting hydrogels. By balancing these two variables it
is possible to control the dissolution profile of the hydrogels.
As shown, low oxidation degrees do not allow long dissolution times. However, it is
perfectly possible to control the dissolution profile with the AAD concentration, within
a range of 5 days (Inset in Fig. 5.3). Rising up the oxidation, hydrogels more resistant
to dissolution are obtained. The D25 hydrogels have very interesting profiles (Fig. 5.3).
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The dissolution time could be extended up to 70 days. Furthermore, one can observe
an interesting plateau, with 20% AAD, resembling a saddle, approximately from the 2nd
until the 50th day of immersion on phosphate buffer. Within this period the hydrogels
maintained their size and shape without abrupt swelling variations. This profile seems to
be interesting for the proposed application, as it will not swell above the injected volume
and takes few weeks to dissolve. Just before the hydrogel collapses and dissolve, a maxi-
mum swelling peak is observed. We hypothesise this peak to be a fracture point, reached
when the osmotic force equals the polymeric matrix force, which weakens through time,
due to the AAD diffusion out of the hydrogel.
Figure 5.3.: Swelling index profile of dexOx+AAD hydrogels. D25 with feed concentra-
tion of 20% and D10 and D5 with feed concentration of 30%. Main plot: ￿- D25A5;
￿- D25A10; - D25A20; Inset: ￿ - D10A5; ￿ -D10A10; - D10A20; - D5A5;￿- D5A10.
The water content of the vitreous humour is around 98%, mainly composed of collagen,
hyaluronic acid [306] and hyalocytes of Balazs, which take care of removing cellular debris
and reprocessing the hyaluronic acid [307]. Since the dexOx hydrogels are soluble in water
and electrolyte solutions we think that the vitreous humour will naturally contribute to
the dissolution of the hydrogel and help the hydrogel elimination. The by products
of the designed hydrogel are its same initial components. oxidised dextran and AAD.
Both by-products should be excreted, to the aqueous humour, by the anterior route.
This elimination is probably faster than through the blood-retina barrier to the systemic
circulation [296], despite that dextrans, up to 150 kDa, are diffusible through the sclera
[308].
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5.4.4. Assessment of Cytotoxic Potential
The characteristics of these formulations render them suitable as a drug carrier to the
posterior part of the eye, due to its injectable character, the controlled gelation rate or the
dissolution profile shown. Formulations composed partially by dexOx have been tested
for their biocompatibility. Recently, Bhatia and co-workers [39], seeded 3T3 fibroblast
cells on top of oxidised dextran (20% – 50% OD) cross-linked with 8-arm PEG amine
and showed that their formulation, was non-toxic and could lead to cell confluence after
24 hours of growth. This suggests, that the cross-linked oxidised dextran can promote
better cell adhesion than dextran itself [109], despite showing some toxicity when present,
alone, in cell culture with mesothelial cells [38].
In the present work, endothelial cells from rabbit cornea were chosen based on the need
to assess the oxidised dextran AAD cross-linked hydrogels cytotoxicity for the proposed
application.
To assess the cytotoxicity of these materials, several combinations of hydrogels involving
the different dexOx’s and AAD concentrations, were prepared. The 96-well cell culture
plates were covered with 60 µL of hydrogels or just controls and the cells were seeded
on top, after an over-night curing period. The materials used were not only dissolved in
PBS but also on the appropriate cell culture media. Occasionally, the initial dexOx feed
concentration had to be slightly decreased, due to the high viscosity, probably due to
medium proteins, that cross-link with the oxidised dextran through the existing amine
groups.
After cell seeding on top of the hydrogels, each well was visualised in optical microscope,
to observe whether there was any cell adhesion and/or proliferation. Cells grew in the
presence of all hydrogels tested, although cell growth, in the presence of D25 hydrogels,
did not achieve confluence during the period of study (Fig. 5.4).
Dextran is neutrally charged and we expect dexOx to keep the neutrality, as the periodate
oxidation reaction does not yield any charged chemical groups. However, the cross-
linking of dexOx with AAD (pKa 2.5) yields hydrazone bonds which were reported to
have a pKa in the order of 3 to [309]. Hence, due to the nature of the cross-linking
bond, we suggest that the hydrogels zeta potential shifts negatively, allowing cell growth
and proliferation.
It is well known that the surface chemistry of hydrogels can affect cell adhesion, prolif-
eration and other phenomena. Chen et al [310] work showed how the polymer nature
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Figure 5.4.: Endothelial cells isolated from rabbit cornea seeded in dexOx + AAD
hydrogels, dissolved in MEM or PBS, after 72 h. (A) D5A5, PBS; (B) D5A5, MEM;
(C) D10A10, PBS; (D) D10A10, MEM; (E) D25A10, PBS; (F) D25A10, MEM; (G)
negative control; (H) positive control. Original magnification 100X.
and cross-linker concentration can dictate the surface charge density of the gels and
strongly influence the cell behaviour. They have identified a threshold on the surface
zeta potential (- 20 mV), below which cell adhere and proliferate.
Schneider and collaborators also reported that charge density of the hydrogel can regulate
cell attachment either directly in the absence of extra-cellular matrix components, or
indirectly through the association of extra-cellular matrix proteins found within the serum
associated with charges of the hydrogel surface [311].
The MTS assay is a quick effective method for testing mitochondrial impairment and
correlates quite well with cell proliferation. In recent years, it has been frequently used as
a preliminary screen for the evaluation of in vitro cytotoxicity of polymeric components.
The MTS assays were performed at 1, 3 and 7 days after cells being seeded on top of the
hydrogels. Cellular activity did not seem to be affected by the medium used to prepare
the hydrogels (MEM or PBS). The results (Fig. 5.5) emphasise that every formulation
promoted dehydrogenase activity. In the first 24 hours, all hydrogels promoted higher
enzyme activity than the negative control. By the 3rd day, the activity doubled for most
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Figure 5.5.: Cellular activities measured by the MTS assay after 1 day (open bars), 3
days (grey bars) and 7 days (black bars). Endothelial cells from rabbit cornea, seeded
onto dexOx+AAD hydrogels. The materials were either dissolved in PBS or MEM.
K+: Positive control; K-: Negative control. All error bars represent one standard
deviation from six experiments.
hydrogels, with a few exceptions, and by the 7th day, the activity maintained the same
levels. These results demonstrate the tested formulations as non-cytotoxic.
5.5. Conclusions
On the estimation of the dextran oxidation degree, we have identified ethyl carbazate as
a better and more accurate titrant, than tert-butyl carbazate, especially for the higher
oxidised samples. The bulkier tBC moiety causes sample precipitation and it also seems
to impair good access to the oxidised residues lowering the measured oxidation degree.
The viscosity studies revealed how the dextran oxidation degree can limit the concentra-
tion used. However, for diluted dexOx solutions, the lower molecular weight, counter-
balances the oxidation effect, decreasing the viscosity.
The characterised hydrogels have a dual cross-linking control method, which lies on
the dextran OD and the amount of AAD used. The OD allows a given percentage of
residues to serve as reactive points to molecules such as AAD. The amount of AAD used
is crucial in defining the gelation period, mechanical properties and dissolution profile of
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the hydrogels. It should be within the same range of the amount of oxidised residues
present in dextran, to avoid forming dangling ends, and not valid mechanical cross-links.
On the cytotoxicity assay, the different dextran oxidation degrees tested were successful
in promoting cell adhesion and growth. However, with the increasing oxidation, the cells
took longer to proliferate in the hydrogels. Oddly, the metabolic activity, measured by
the MTS assay, showed very high levels of activity for the higher oxidised hydrogels, not
corresponding to the cellular proliferation observed.
The proposed and studied system aims at providing a sustainable drug delivery device
to the posterior part of the eye, which requires a single injection, but does not require
further surgery on the removal of the device. The designed formulation is expected to
dissolve and be eliminated naturally by the organism.
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6. Dextran-Based Microgels
6.1. Abstract
The use of micro or nano drug carriers in biomedical applications is an extremely at-
tractive approach, in order to circumvent the commonly associated issues with drug
delivery. This chapter reports the use of an all-aqueous methodology to prepare degrad-
able dextran-based microgels of variable sizes by the cross-linking of oxidised dextran
with adipic acid dihydrazide. The size and polydispersity of microgels is deeply affected
by the concentration of adipic acid dihydrazide as assessed by scanning electron mi-
croscopy. The light scattering analysis revealed monodispersed populations with sizes
above 100 ￿m and slightly dependent of the dextran’s oxidation degree. The continuous
phase has a strong influence on the polydispersity of the microgels.
6.2. Introduction
Microgels, in the same way as hydrogels, are networks prepared from hydrophilic poly-
meric materials, which are cross-linked in several different ways, to avoid dissolution of
the polymeric chains into solution [100]. Microgels offer an interesting platform as the
basis of a drug delivery system due to their high water content and good biocompatibility.
These systems nature allow polymer-based drug conjugation or simply drug entrapment
into the network, which couples perfectly with the tuneable microsphere size, surface
area/volume ratio and release time-profile [312].
The polysaccharide nature, dictates the processing techniques that can be used in or-
der to achieve a target final application. However, these natural-origin polymers are
quite versatile, and their structure can be modified and tuned with extra functionalities
[313], broadening the range of processing techniques able to manipulate the polymers.
Oxidised-dextran (dexOx) is easily obtained after periodate oxidation and yields a shorter
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dextran chain with aldehyde functionalities [14], which are extremely reactive towards
N-nucleophiles [29]. The most common application has been in drug conjugation, which
can be called 1D processing, where small molecules [66, 7] but as well proteins [47] have
been studied for improved drug delivery. A 2D processing has also been approached, best
exemplified by the coating of aminated surfaces [109, 111, 112] and finally, the 3D pro-
cessing, in structures such as hydrogels, where a dexOx solution can be cross-linked with
several different substrates [14, 35, 30, 104]. Apart from hydrogels, dexOx has not been
involved in many different 3D micro-processing. Some of the few existing studies inte-
grate oxidised modified dextrans. Methyl polyethylene glycol (MPEG) modified dextran,
for example, that after oxidation, cross-linked with human albumin in a water/acetone
mixture to yield nanospheres, with narrow size distribution and under 200 nm diame-
ter [107]. Oxidised sulfopropyl dextran microspheres for the delivery of mitomycin C
were also successfully achieved [73, 74]. Another study, used oxidised dextran modified
with cholic acid, hydrophobic core, to promote self-aggregation in nanomicelles [71].
However, simple dexOx has only been used as a cross-linker, in the case of gelatine, to
prepare microspheres as carriers of pingyangmycin [70] and polyamidine TAPP-Br [106],
interestingly, both studies obtained mean diameter sizes shy of 100 µm.
Figure 6.1.: Oxidised dextran and adipic acid dihydrazide reversible cross-linking
reaction
The formulation of oxidised dextran cross-linked with AAD has the potential of being
injectable, and it has the capacity to form a hydrogel within a few minutes without
requiring the use of a chemical initiator (Fig. 6.1) [14]. The hydrogel eventually dissolves,
in variable periods of time, depending on the dextran oxidation degree; the AAD feed
concentration or environment conditions, such as pH. Therefore, we intended to adapt
the components of this hydrogel formulation, and broaden the range of techniques,
able to process this system. An all-water emulsion technique was preferred over other
emulsion techniques, specially the organic/aqueous emulsions, where protein aggregation
can occur at the aqueous/organic interface [314, 315]. This is an important aspect if a
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protein drug, should be carried by such system. This water/water approach has only been
used with formulations involving cross-linking by radical polymerisation [316]. We chose
the method described by Hennink’s group, where an all-aqueous system is used, taking
advantage of the polymer-polymer immiscibility due to a thermodynamic constraint. In
a ternary system consisting of two water-soluble polymers and water, liquid–liquid phase
separation can occur. From a thermodynamic point of view, phase separation in these
systems occurs when the change in Gibbs free energy is positive [317, 318, 319]. To the
best of our knowledge, we will approach this emulsion technique, with a self-gelling and
initiator-free system, for the first time.
6.3. Materials and Methods
6.3.1. Materials
Polyethylene glycol (PEG; 20 kDa) was obtained from Merck – Schuchardt. PEG (6
kDa) (Fluka), Polyvinyl Alcohol (PVA; 13 to 23 kDa), Dextran (from Leuconostoc
mesenteroids; Mw 60 kDa, according to Fluka’s specification), sodium periodate, adipic
acid dihydrazide (AAD), ethyl carbazate (EtC), phosphate buffered saline (PBS), Tween
60, dialysis tubes with a MWCO ~12 kDa were purchased from Sigma – Aldrich (Sintra,
Portugal). All the reagents were used as received.
6.3.2. Preparation of Microspheres
Dextran with several oxidation degrees were prepared and characterised as described
elsewhere [35]. The dexOx samples used, have oxidation degrees of 8.6 ± 0.2 (D10),
22.2 ± 0.7 (D25) and 33.0 ± 0.8 (D40) as calculated by 1H-NMR using EtC as titrant.
Typically, a 25% (w/v) PEG or PVA solution was used as the continuous phase (CP), with
AAD in the concentration range of 0.01 to 10 µg/mL. The dexOx solution (20% w/v)
was used as the discontinuous phase (DP), either with or without Tween 60 (2% dexOx
weight). On a first formulation screening, a capped reaction tube was filled with 10 mL
of the CP and 250 µL of the DP were added. The system was vortexed at maximum
speed allowed for 60 seconds. The system was let to rest for 10 -15 minutes and then
centrifuged at 5000 rpm for 5 minutes. The supernatant was discarded and the pellet
was washed with PBS three times before being freeze-dried. The upscale was performed
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with a 100 mL round-bottom vial with 3 entries. The stirring was provided by a home-
made inox stirrer, and a Heidolph rotor (model RZR1). The CP and DP compositions
respected the same concentrations and weight ratios as on the initial screen, described
above. The microgels were collected on the same way as described before.
6.3.3. Scanning Electron Microscopy and Particle Sizing Analysis
Freeze-dried microparticles, were mounted into an aluminium stud and gold coated by
plasma vapour deposition and were recorded by a field emission scanning electron mi-
croscope (JEOL model JSM-5310), at 15.0 – 20.0 kV. Particle size distribution was
performed with a COULTER LS 130 (Coulter Electronics) standard bench.
6.4. Results and Discussion
The mixing reaction of dexOx and AAD solutions is characterised as being fast, depend-
ing on the feed concentration of the reactive species [35]. Therefore, the production
of microgels had to take this aspect into account on the expectation that it would not
perturb significantly the phase separation. We observed that when AAD was formulated
within the discontinuous phase (DP), a better phase separation occurred. After establish-
ing the best system configuration we screened the AAD concentration, oxidised dextran
OD and the surfactant presence. Based on the work of Hennink’s group [317, 318, 319]
we prepared a continuous phase (CP) composed of 6 kDa PEG dissolved in PBS to
25% w/w. The DP was composed with dexOx dissolved in PBS (20% w/w) plus AAD.
After adding the DP, a turbid solution was formed, suggesting the phasing out of the
microgels. With AAD above this concentration range, aggregates could be seen with
the naked eye, indicating the formation of macrogels. Within the concentration range
chosen, a homogenous turbidity was always observed. The SEM visualisation (Fig. 6.2)
of the freeze-dried microgels elucidated the extreme importance of AAD on the microgels
size. Not only the microgels sizes decreased directly with the AAD concentration, but
the homogeneity in sizes also improved.
Because microgels tend to aggregate and form networks, we evaluated the effect of
the addition of Tween 60 during their preparation. Previous studies have reported that
the addition of a surfactant could avoid this phenomena [248]. According to Fig. 6.2,
Tween 60 had little effect in the stabilisation of microparticles. These results suggest
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Figure 6.2.: Freeze-dried microparticles morphology with varying concentrations of
AAD in PEG continuos phase, in the presence or not of Tween 60, as the surfac-
tant. Bar corresponds to 10 µm.
that the aggregation of the microparticles might be due to the cross-linking of individual
microparticles promoted by the adipic acid dihidrazide.
Next we evaluated the influence of oxidation degree of dextran as well as the composition
of the two-aqueous system in the size of the microgels. The oxidation degree of dextran
appeared to have a slight influence on the particles sizes. There was a slight shift to
larger average sizes with the lowest oxidised dextran (D10), which could be due to the
less cross-linking points available (Fig. 6.3A). On the other hand, the highest oxidised
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Figure 6.3.: Differential volume percentage for microgels synthesized with different ox-
idised dextrans in CP with PEG 6 kDa (a); and D40 microgels synthesized in different
CP (b). Every CP presented 0.01 µg/mL of AAD
sample (D40) originated other populations with lower diameter sizes. Analysing the
continuous phase, apart from PEG 6 kDa, we also tested a higher Mw PEG (20 kDa),
but also a different synthetic polymer, PVA with ~10 kDa. The results suggest that the
Mw increase of PEG, directly affected the microparticles polydispersity. PVA, however,
promoted a less polydispersed sample (Fig. 6.3B).
The sizes obtained by light scattering were considerably higher than the apparent sizes
observed by SEM. We need to take into consideration that a few aspects might have
influenced this difference. The SEM observed samples were in a freeze-dried state com-
pared to the ones measured by LS, which were re-suspended in water and subjected to
sonication. This phenomenon might be ascribed to the physical state of the nanoparticles
when characterised by the two techniques: dry state for SEM and hydrated state for light
scattering analyses. Similar differences have been described elsewhere for peptide-coated
self-assembled nanoparticles of poly(ß-amino ester) and DNA [252]. These microgels,
should behave similarly with the previously characterised hydrogels therefore, some ini-
tial burst swelling is expected. The higher ratio surface/volume of the microgels should
promote a faster uptake of water, which leads to the much higher particle sizes when in
solution.
6.5. Conclusion
The results obtained, in this work, suggest that it is possible to obtain microgels based on
oxidised dextran cross-linked with AAD, using this all-water emulsion system. Compared
to other systems, we were able to avoid the use of chemical initiators, which reduce the
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amount of toxic components. We observed, that the cross-linker concentration, AAD,
present on the continuous phase, is responsible for the particles size and homogeneity.
As the concentration decreases, so does the particle size. Higher AAD concentrations
should lead, not only to larger particles but also to higher microgels aggregation. The
oxidation degree, also seems to affect the polydispersity of the microgels, but to a lower
extension. The microgels, should behave similarly with the studied hydrogels, having
dissolution time profiles, dependent on the oxidation degree [35]. The type of polymer
used on the continuous phase appears to have a relevant role. Both the polymer nature
and the molecular weight were shown to affect the microgels polydispersity. Other
excipients (e.g. surfactants) should be screened, to improve the microgels stability upon
cryopreservation or freeze-drying.
Further studies to evaluate the dissolution profile of this system and the efficiency as
carrier for small molecules with amine moieties or proteins should be performed.
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7. Dual Pro-angiogenic Therapy
Based on Hybrid Hydrogel
Networks
7.1. Abstract
We present a hybrid hydrogel, where a VEGF-loaded matrix was combined with an
endothelial cells-loaded fibrin matrix. Oxidised dextran was used as the basis for the
matrix-bearing VEGF. Oxidised dextran conjugates to VEGF, through covalent imine
bonds. The oxidation degree effect on VEGF’s three-dimensional structure was evalu-
ated by circular dichroism and the bioactivity was assessed by the stimulation effect on
some VEGF receptor 2-mediated metabolic pathways. The VEGF release profile from ox-
idised dextran hydrogels was followed by radioactivity and ELISA. The dexOx hydrogels
were entrapped in fibrin matrices loaded with endothelial cells and an influence on gene
expression and 3D cell organisation was observed which is dependent on the oxidation
degree. We envision that these constructs might be beneficial for the induction of a
rapid pro-angiogenic response in ischemic tissues, as well as matrixes to drive the in situ
differentiation of vascular progenitor cells.
7.2. Introduction
Ischemic diseases such as myocardial infarction, chronic wounds and stroke, are the
cause of high morbidity and have an important social impact on the western society.
Two major angiogenic therapies are under study to treat patients suffering from these
diseases. One is based on the delivery of growth factors, such as, VEGF, placenta growth
factor (PlGF) or FGF among others [135] and the second one takes advantage of cells,
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such as EPCs [167]. In the first group, VEGF has been extensively examined in the
promotion of tissue vascularisation. Unfortunately, the bolus delivery of VEGF in phase
II human clinical trials failed to demonstrate significant benefits in the approved end
points [148]. The fast plasma clearance (19.1 ± 5.7 mL/min/kg) and short half-life
(33.7 ± 13 min) of VEGF [164] are likely in the origin of the poor therapeutic efficacy
observed [147, 320, 148, 135]. To overcome this issue, several polymeric matrices have
been developed for the efficient delivery of VEGF [170]. The strategies range from
simple VEGF diffusion out of the gel [173], to delayed release due to VEGF affinity-
based interactions with the matrix [188] or due to covalent binding [137]. Overall,
the spatio-temporal presentation of VEGF is essential for a proper therapeutic actuation
[321]. Despite these advances, alternative therapeutic solutions are needed to potentiate
the effect of VEGF in ischemic tissues and rapidly form blood vessels.
The transplantation of vascular cells could be a potential platform for the quick formation
of blood vessels after an ischemic insult. Indeed, several studies have demonstrated
that the transplantation of EPCs or vascular cells, derived from umbilical cord blood
stem cells, can increase significantly the vascularisation of ischemic tissues. This was
demonstrated in animal models of hindlimb ischemia [169, 206, 139, 207], myocardial
ischemia [208, 209, 210] and diabetic chronic wounds [138]. Unfortunately, the survival of
these cells is relatively low in the first days of post-transplantation due to a combination
of different factors, including oxidative stress or inflammation. A three-dimensional
scaffold able to support the attachment of vascular cells and simultaneously deliver
VEGF could be beneficial for the development of more potent and rapid pro-angiogenic
therapies. The combination of both platforms in a single matrix should meet several
design criteria. First, it should support the attachment of vascular cells and allow their
migration and organisation. Second, it should allow the delivery of VEGF at appropriate
rates and concentrations. Although recent studies have reported the incorporation of
pro-survival factors with vascular cells in the same matrix [322], it is difficult to decouple
the growth factor delivery component from the cell-matrix component.
Herein, we developed a new approach to integrate in the same three-dimensional hydrogel
scaffold a growth factor delivery system and a substrate able to support cell attachment
and remodelation. Both components can be tailored separately to match different needs.
VEGF was covalently conjugated to oxidised dextran and the immobilisation efficiency,
VEGF three-dimensional structure and bioactivity were characterised. We show that the
oxidation degree of dextran has a tremendous impact on the presentation of VEGF to its
natural cellular receptors, as evaluated by the effect on intracellular signaling molecules
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like Ca2+, ERK and Akt. We further show that the crosslinking of these conjugates
with adipic acid dihydrazide yield gels having variable VEGF release kinetics, depending
on the OD of dexOx. The incorporation of these VEGF-releasing systems within fibrin
hydrogels containing endothelial cells, showed a pro-survival effect dependent of the OD
of the dexOx hydrogels, as observed by contrast phase microscopy and qRT-PCR.
7.3. Materials and Methods
7.3.1. Materials
Adipic acid dihydrazide, EtC, dextran (from Leuconostoc mesenteroides; Mw 60 kDa, ac-
cording to Fluka’s specification), NaBH3CN (Fluka), dialysis tubes (MWCO of 12 kDa),
human fibrinogen, human thrombin, phosphate-buffered saline (PBS), Tris-buffered saline
(TBS), Histopaque-1077 Hybri Max, rhodamine B isothiocyanate (TRITC), serum free
medium 199 and Pluronics F127 and oligonucletides used as primers in qPCR were pur-
chased from Sigma. Endothelial growth medium (EGM-2) and human umbilical vein
endothelial cells (HUVEC) were purchased from Lonza. Slide-a-lyzer (10 kDa) was ac-
quired from Thermo Scientific. N-Succinimidyl-[2,3-3H] Propionate (3HNSP; 1 mCi/mL
with specific activity of 80 mCi/mmol) was purchased from Scopus Research. scintilla-
tion liquid Ultima Gold XR purchased from Perkin-Elmer. DuoSet ELISA kit from R&D
Systems. Fura-2AM was purchased from Molecular Probes. Phosphoprotein assay kit
was purchased from Biorad. Taqman Reverse transcription reagents and Power SYBR
Green PCR Master Mix were from Applied Biosystems. The RNeasy Mini Kit was pur-
chased from Qiagen. CaCl2 was acquired from Merck. DiI-Ac-LDLwere purchased from
Biomedical Technologies. The mini-MACS immunomagnetic separation system was pur-
chased from Miltenyi Biotec. Fetal bovine serum, Trizol reagent, Fibrinogen - Alexa
Fluor 488 conjugate and the LIVE/DEAD kit were purchased from Invitrogen.VEGF was
a kind gift of Genentech, Inc, South San Francisco, CA. All materials were used as
received.
7.3.2. Dextran Oxidation and Characterisation
An aqueous solution of dextran (1 g; 12.5%, w/v) was oxidised with 2 mL of sodium
periodate solution with different concentrations (33 – 165 mg/mL) to yield theoretical
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oxidations from 5 to 25%, at room temperature. The reaction was stopped after 4 hours.
The resulting solution was dialysed for 3 days against water, using a dialysis tube with a
MWCO 12 kDa, and then lyophilised (Snidjers Scientific type 2040, Tillburg, Holland).
The scale-up of the reaction was done using the same procedure albeit using 30 g of
dextran and a calculated amount of periodate to yield a theoretical oxidation of 5, 10
and 25%, referred as D5, D10 and D25, respectively.
The real oxidation degree (OD) was quantified by 1H NMR (Varian 600 NMR spectrom-
eter, Palo Alto, CA) using EtC as a titrant and taking into account the ratio between
the integral of the peak at δ 7.3 ppm and the integral of the anomeric proton at δ 4.9
ppm. The spectra were analysed with iNMR software, version 2.3.3 (www.inmr.net).
7.3.3. VEGF Labelling
The N-Succinimidyl-[2,3-3H] Propionate (3HNSP) solution was transferred to a glass
vial with a rubber stopper and the airspace was flushed with N2, to allow evaporation
of the ethyl acetate. A PBS-dialysed solution of VEGF with 2.54 mg/mL was moved
to the 3HNSP vial and stirred magnetically, at room temperature, for 4 hours. The
solution was transferred to a slide-a-lyzer cassette (10 kDa) and dialysed against PBS.
The resulting absorbance at 276 nm (εvegf = 0.37) revealed a 2.13 mg/mL VEGF-3H
solution. The estimated radioactivity is 1.33 ± 0.07 mCi/mmol of VEGF. The samples
were mixed with scintillation liquid and the scintillation counts were read on a Perkin-
Elmer Tri-Carb 2900T Liquid Scintillation Analyser.
7.3.4. Characterisation of VEGF Conjugates by Gel
Electrophoresis
The SDS-PAGE was performed on a 12.5% polyacrylamide gel and 0.75 mm thick.
Approximately 5 - 10 ￿g of protein was loaded into each well, after denaturing for
5 minutes at 95 °C. The samples were run at 200 V and later revealed with Comassie
Blue. The loaded samples consisted of VEGF or mixtures between VEGF and the several
dextrans at 100-fold weight excess of dextran or the different dexOx’s. In onne case D25-
VEGF sample was reduced with an VEGF equimolar amount of NaBH3CN.
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7.3.5. Characterisation of VEGF Conjugates by Circular
Dichroism
Far-UV circular dichroism (CD) spectra were collected using a Olis DSM 20 spectropo-
larimeter equipped with a Peltier temperature controller. Protein samples (~0.6 mg/mL)
were analysed at 37 °C in a quartz cuvette with a 0.2 mm path-length. Spectra were
collected at resolution of 1 nm with 4 seconds of integration time with a bandwidth of
0.6 mm. To monitor changes in the secondary structure of VEGF bound with dexOx,
CD spectra were obtained for VEGF in the presence of a 100-fold weight excess of dex-
tran or the different dexOx’s. Spectra for VEGF bound with dextrans were background
corrected with respect to the same dextran in buffer.
7.3.6. Evaluation of VEGF Conjugates Bioactivity
HUVECs (passage 7) or endothelial cells (derived from CD34+ umbilical cord blood cells
[138]) were cultured in EGM-2 medium at 37 °C and 5% CO2 until sub-confluence was
achieved. The cells were tripsinized and plated into an opaque 96-wells plate (Costar)
with an initial seeding of 30,000 cells per well. After reaching sub-confluence, they
were kept in starvation for 20h in M199. The medium was discarded and the wells
were loaded with Fura-2 calcium fluorescent indicator by incubation with 5 ￿M of the
membrane permeable acetoxymethyl (AM) derivative FURA-2/AM (1 mM in DMSO,
Molecular Probes, Invitrogen) and 0.06% (w/v) Pluronic F-127 (Sigma), using basal
medium (M199, Sigma) as a vehicle (35 ￿l/well, not supplemented with serum nor
antibiotics), for 1 hour at 37 °C in 5% CO2 and 90% humidity. Cells were washed twice
with sodium salt solution (140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM glucose,
10 mM HEPES Na+pH 7.4) and once again before testing each condition. The reading
was performed at 25 °C (Spectramax Gemini EM, Molecular Devices, with SoftMax Pro
Software), by measuring emission at 510 nm using two alternating excitation wavelengths
(340 and 380 nm). Cells were stimulated with 2 ￿L of VEGF, D25-VEGF and D25-VEGF
(cyanoborohydride reduced) solutions to yield a 100 ng/mL final concentration of VEGF
and 1000-fold more of D25, when present (n=4). Activation of Akt and extracellular
signal-regulated kinase (ERK) in HUVECs (80% confluency, in 6 well plates) was induced
by starving the cells for 20 h in serum-free M199 medium (with Earle’s Salts and L-
glutamine; Sigma-Aldrich) [157] and then treating them for 10 minutes, by replacing the
medium by fresh M199 containing VEGF or VEGF conjugates. Following treatment, the
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plates were immersed on ice and the medium discarded. Then the proteins were isolated
from the cells (total protein concentration of 220-300 ￿g/mL) using the Bio-Plex Cell
Lysis kit (Bio-Rad) and the levels of Akt and ERK phosphorylation were determined
using a Bio-Plex kit (Bio-Rad), according to manufacturer’s recommendations.
7.3.7. Release of VEGF from DexOx Hydrogels
The D25 was dissolved in aqueous solvent (PBS) to obtain a 20% (w/w) and stored at
4 °C if not used immediately. The hydrogels were produced by mixing thoroughly 100 µL
of D25 and 100 µL of AAD, with different concentrations. The AAD concentration used
was calculated based on a given molar percentage of dextran residues. The hydrogels
were let to cure for never less than 2 hours and the swelling was performed in 24-wells
cell culture plates immersed in 1 mL of PBS at 37 °C. At regular time intervals, the
hydrogels were removed from the aqueous solution, blotted in filter paper, weighted (Wt)
and returned to the original well while the buffer was replaced.
For the in vitro studies, VEGF or VEGF-3H were added to the D25 solution or the AAD
10% solution, to obtain a 0.2 mg/mL final concentration, delivering 20 µg of VEGF,
per hydrogel. The VEGF release study was performed in the same conditions as the
swelling study. At regular time intervals, the immersion media was collected and saved
and replaced by new media. The released VEGF was quantified either by ELISA or
scintillation.
7.3.8. Hybrid Hydrogels of DexOx and Fibrin
DexOx hydrogels were prepared on top of the plungers of 1 mL sterile syringes with cut
tips and were let to cure for 2 hours. They were later washed with PBS (three times)
and let in contact with fibrinogen solution for 30 minutes. The hydrogels were later
covered with mixed fibrin gel precursor solution to yield a hydrogel. The 10 ￿L dexOx
hydrogels were prepared with D5, D10 (30% w/w)chapter 5 and D25 (20% w/w) with
10% crosslinking degree of AAD. When required, VEGF was added to the feed solution of
dexOx or AAD, at 20 ￿g/mL, before the preparation of the hydrogels. Endothelial cells
(induced from CD34+ UCB isolated cells, as described elsewhere [138]) were delivered in
the fibrin hydrogels as previously described [138]. Fibrin gels were formed by crosslinking
of fibrinogen in the presence of thrombin. The 50 ￿L fibrin gels contained 10 mg/mL
fibrinogen (in TBS, pH 7.4), 2 U/mL thrombin and 2.5 mM CaCl2. CD34+-derived
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ECs (0.35 × 105) were centrifuged, ressuspended in the fibrin gel precursor solution
and transferred to the syringes containing the dexOx hydrogels. Polymerisation was
initiated at 37 ºC and allowed to proceed over 30 minutes. After polymerisation, the
cell constructs were removed from the syringes and placed in 96-well plates containing
culture medium identical to EGM-2 but without VEGF (unless otherwise stated), for up
to 6 days. After 6 days, the live cells were counted and enough hydrogels were saved
and stored at –80 °C for posterior analysis.
DexOx (D25) modified with TRITC and fibrinogen conjugated with Alexa fluor 288 were
used to prepare fluorescent hydrogels. To 100 ￿L of D25 (20% w/w) was add 1 ￿L
of 10 mg/mL of TRITC in DMSO and the final solution was diluted 100-fold in D25
(20% w/w) solution, before crosslinking with AAD (20%). The Alexa fluor conjugated
fibrinogen was resuspended to 20 mg/mL in TBS buffer (pH 7.4) and diluted 1000-fold
with a plain fibrinogen solution (20 mg/mL). The hybrid hydrogels were prepared between
glass slides for visualisation under the fluorescence microscope. A Zeiss Axiovert 200M
fluorescence inverted microscope with 1.25x and 5x objectives was used. Endothelial
cells stained with Hoechst were encapsulated in the fibrin hydrogel.
7.3.9. Viability of Encapsulated Endothelial Cells
Cell viability was determined using a LIVE/DEAD kit. The gels containing the encap-
sulated cells were washed in PBS, immersed in a working solution of 2 ￿g/mL calcein
AM and 4 ￿g/mL ethidium homodimer-1 in PBS for 30 minutes at 37 ºC and visualised
under a Zeiss Axiovert 200M fluorescence inverted microscope. The statistical signifi-
cance was determined by using one-way ANOVA followed by Dunnett’s post hoc test for
comparison with control, with P < 0.05 considered to represent statistical significance.
7.3.10. Quantitative Real time Reverse-Transcription
Polymerase Chain Reaction
Cell constructs were collected at day 6 and stored at – 80 °C until further use. Cell
constructs were disrupted in Trizol reagent in 2 mL tubes containing a 5 mm diame-
ter stainless steel bead (Qiagen), in a TissueLyser II aparatus (Qiagen) for 2 min, at
30 Hz. Total RNA was isolated by using the RNeasy Mini Kit, according to manufac-
turer’s instructions. cDNA was synthesized from 1 ￿g total RNA using Taqman Reverse
103
Chapter 7 Pro-angiogenic Hybrid Hydrogels
transcription reagents. Quantitative PCR (qRT-PCR) was performed using Power SYBR
Green PCR Master Mix and the detection was carried out in a 7500 Fast Real-Time PCR
System (Applied Biosystems). Quantification of target genes was performed relatively
to the reference gene (GAPDH): relative expression= 2[−(Ctsample−CtGADPH)] [323]. The
mean minimal cycle threshold values (Ct) were calculated from four to six independent
reactions. The primer sequences can be found on Tab. 7.1.
Table 7.1.: Primer sequences used for rtPCR.
Target Gene Primer Sequence
Human GAPDH Forward: AGCCACATCGCTCAGACACC
Reverse: GTACTCAGCGCCAGCATCG
Human VEGF Forward: AGAAGGAGGAGGGCAGAATC
Reverse: ACACAGGATGGCTTGAAGATG
Human Flk-1 Forward: CTGGCATGGTCTTCTGTGAAGCA
Reverse: AATACCAGTGGATGTGATGGCGG
Human MMP2 Forward: CCCAGAAAAGATTGACGC
Reverse: CGACAGCATCCAGGTTAT
Human MCP-1 Forward: CCCCAGTCACCTGCTGTTAT
Reverse: TGGAATCCTGAACCCACTTC
7.3.11. Statistical Analysis
For the cell viability and the qRT-PCR analysis a paired t test was used. Results were
considered significant when P ≤ 0.05. GraphPad Prism 4.0 (San Diego, CA) was used.
7.4. Results and Discussion
7.4.1. VEGF Conjugation to DexOx
The periodate ion attacks vicinal diols in dextran, between carbons C3 - C4 or C3 - C2,
breaking the C - C bond and yielding aldehyde groups. The oxidation degree of dexOx
was determined by 1H-NMR after titration with ethyl carbazate (chapter 5). The dexOx
samples, D5, D10 and D25, used in this study, have an OD of 3.6 ± 0.1, 8.6 ± 0.2 and
17.8 ± 1.2, respectively. The dexOx derivatives were then conjugated with VEGF to have
a final mass ratio of 100-fold. The conjugation of VEGF to dexOx is mediated by imine
bonds (Schiff base) [48]. The reversible imine bond can then be reduced to an amine,
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an irreversible and stable bond, by sodium cyanoborohydride. The presence of VEGF
in both dexOx-VEGF conjugates (non-reduced and reduced forms) was characterised by
SDS-PAGE (Fig. 7.1A). In this case, the presence of unconjugated VEGF contributes
for a band with an electrophoretic mobility at approximately 40 kDa (lane 1), while
conjugated VEGF contributes for bands with an electrophoretic mobility above 40 kDa
(lanes 2-4), likely depending in the degree of VEGF immobilisation into each polymer
chain. Solutions of non-oxidised dextran with VEGF (lane 5) and VEGF reduced with
NaCNBH3 (lane 6) were used as controls to demonstrate that the presence of dextran
or the reducing activity of NaCNBH3 does not affect the electrophoretic mobility of
unconjugated VEGF, respectively.
Figure 7.1.: Conjugation of oxidised dextran to VEGF followed by SDS-PAGE (A). vegf
(1); D5-vegf (2); D10-vegf (3); D25-vegf (4); dextran + vegf (5); reduced vegf (6);
reduced D25-vegf (7); D25 (8); (B) Schematic representation of dextran oxidation
and subsequent immobilization of VEGF.
According to Fig. 7.1A the conjugation of VEGF to dexOx without reduction with sodium
cyanoborohydride is directly proportional to the OD in dexOx (lanes 2 - 4). The image
analysis (ImageJ) revealed an amount of free protein of 32.6 %, 15.5 % and ~ 0 % for the
D5, D10 and D25 conjugates, respectively. The presence of free VEGF in D5 and D10
conjugates might be due to two different reasons. First, dexOx with low oxidation degree
might be unable to immobilise chemically all the VEGF added initially to the polymeric
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solution. Second, because dexOx with low oxidation degree immobilises VEGF by a low
number of attachment points, the biomolecule might be released overtime due to the
instability of imine bonds. The absence of free VEGF in D25 might be due to the slow
dissociation of VEGF from dexOx due to multi-point attachment. In line with our results,
the conjugation of VEGF into dexOx with high OD (D25) and subsequent reduction with
sodium cyanoborohydride yields a conjugate with complete immobilisation of VEGF (lane
7).
7.4.2. Structure Stabilisation of VEGF
We investigated the three-dimensional (3D) structure of VEGF chemically immobilised
into dexOx by circular dichroism (CD). Previous studies have shown that in most cases
the chemical immobilisation of proteins into dexOx does not affect its native structure
and activity [48] even at wide temperature ranges [84]. The CD spectra of either reduced
or non-reduced D25-VEGF conjugates showed comparable 3D structural organisation as
unconjugated VEGF (Fig. 7.2A). There was a decrease in the intensity of the 204 nm
peak, either for the reduced VEGF or reduced D25-VEGF conjugate. As cyanoborohy-
dride does not reduce disulphide bridges (lane 7, Fig. 7.1A) [324], a drastic secondary
structure change is not expected. This might be due to differences in protein concen-
tration. Any potential interference in the 3D VEGF structure was expected to promote
shifts in the absorption band of the spectrum. However, the denaturation of VEGF by
temperature, did not affect the overal spectrum, except after reaching 90 ºC, where a
peak shift occurred to approximately 200 nm. With the temperature increase, protein
precipitation was observed, which was reflected on a decrease in intensity (Fig. 7.2B).
Other denaturation conditions failed to be observed by CD, due to the high amount of
necessary salts, which interfere in the absorption spectrum.
Next, we estimated the secondary structure of VEGF chemically immobilised into dexOx
by fitting the CD data with CONTIN software. The secondary structure percentages
were estimated taking in account the number of residues assigned to each structure (α-
helix and β-strand) reported in previous studies. One study characterised the fragment
corresponding to the KDR-binding domain (95 residues; 2VPF from Protein Data Bank)
[325] and other characterised the heparin-binding domain (55 residues; 2VGH from Pro-
tein Data Bank) [326] fragment of VEGF). All the other residues were considered to be
random coil for a total of 165 residues (Tab. 7.2).
According to Tab. 7.2, an increase of 7% on the α-helixes and a decrease of 6% on the
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β-sheets content were observed on D25-VEGF conjugate as compared to the original
VEGF.
Figure 7.2.: (A) Circular Dichroism spectra of VEGF; D25-VEGF; reduced D2-VEGF;
reduced VEGF at 25 °C. (B) Circular Dichroism spectra of VEGF at increasing tem-
peratures. * Spectrum at 25 °C after decreasing temperature from 90 °C.
However, this result might be affected by the high absorbance observed on the infrared
window of the spectrum, likely interfering with our fit curve. Interestingly, the reduction
of D25-VEGF by cyanoborohydride reverted this shift up to normal percentual values.
This could be due to an increase in rigidity of the conjugate, possibly promoted by the
Table 7.2.: Estimation of rhVEGF secondary structure percentage from circular
dichroism.
Entry α-helix
(%)
β-sheet
(%)
Unordered
(%)
SDE Ref.
VEGF1 11-12 37-41 48-51 - PDB; [325, 326]
VEGF 14 39 47 ≤ 0.01 -
VEGF reduced 15 36 48 ≤ 0.01 -
D25 + VEGF 21 33 46 ≤ 0.01 -
D25 + VEGF reduced 14 37 49 ≤ 0.01 -
1 - Based on crystallography and NMR studies [325, 326]; 2VPF and 2VGH files from the Protein Data
Bank. Both estimations considered 165 residues
increasing number of links within the conjugate [33], maintaining the original conforma-
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tion. On the other hand, the reversible character of the imine bonds in the non-reduced
D25-VEGF conjugate might promote some changes in the 3D VEGF structure, explain-
ing the higher deviations observed for this sample. Overall, the 3D structure of VEGF
is substantially not affected by the chemical conjugation to dexOx.
7.4.3. Intracellular Ca2+ Uptake in Endothelial Cells
To assess the bioactivity of VEGF conjugated to dexOx we evaluated its ability to induce
an increase in intracellular Ca2+ [327] mediated by the activation of VEGF receptor 2
[142, 328]. Initially, we tested the ability of VEGF conjugates to induce an increase of
intracellular Ca2+ in HUVECs. Previous results have shown that free VEGF activates the
transient increase in cytosolic calcium in HUVECs through VEGFR2 [329]. This calcium
is released initially from intracellular Ca2+ stores and only after is due to extracellular
calcium influx [329].
Figure 7.3.: Intracellular Ca2+ uptake as determined by Fura-2-loaded HUVECs. (A)
VEGF dose-dependent Ca2+ uptake (blue dots; VEGF concentration in ng/mL). (B)
Changes in the concentration of intracellular Ca2+ in the presence of the different
dexOx-VEGF conjugates (green dots; VEGF at 100 ng/mL). Histamine (100 ￿M)
and BSA (1%, w/v) were used to set the limits (100% and 0%, respectively) and
normalized the experimental data of Ca2+ uptake (n = 4 – 8).
In this work, HUVECs were cultured in serum-free medium for 20 hours to reduce the
influence of VEGF present in the serum and loaded with a fluorescent dye to monitor
the intracellular concentration of Ca2+. As a first step, cells were activated by different
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concentrations of free VEGF to determine a dose response profile (Fig. 7.3A). Histamine
and BSA were used to set the range of Ca2+ uptake. The administration of VEGF
induces an increase in Ca2+ uptake (first 5 minutes), followed by a plateau phase where
Ca2+ remains constant for the remaining of the experiment. In line with previous studies
[327], the levels of cytosolic Ca2+ increased in direct correlation with an increase of
VEGF concentration. The VEGF concentration decrease also promoted a rate decrease
on Ca2+ uptake.
Figure 7.4.: Intracellular Ca2+ uptake as determined by Fura-2-loaded endothelial cells
derived from cord blood stem cells. (A) VEGF dose-dependent Ca2+ uptake (blue
dots; VEGF concentration in ng/mL). (B) Intracellular levels of Ca2+ mediated by
VEGF conjugates (D25-VEGF, D10-VEGF and D5-VEGF). (C) Intracellular levels
of Ca2+ mediated by VEGF cyanoborohydride-reduced conjugates (D25-VEGF, D10-
VEGF and D5-VEGF). The concentration of VEGF conjugate assessed in these assays
corresponds to a concentration of 100 ng/mL of VEGF (n = 4 – 8).
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Next, we evaluated the inductive effect of different dexOx-VEGF conjugates in the intra-
cellular concentration of Ca2+ (Fig. 7.3B). For that purpose, HUVECs were stimulated
with VEGF conjugates having a concentration of 100 ng/mL VEGF . Interestingly, D25-
VEGF induces an initial increase of intracellular Ca2+ corresponding to the effect of 25
ng/mL of free VEGF, reaching a plateau after 7-8 minutes with a similar intracellular
Ca2+ concentration, as observed for 100 ng/mL of free VEGF. Our results indicate that
although D25-VEGF loses approximately 75% of the initial induction effect (taking into
account that D25-VEGF has 100 ng/mL of VEGF), the later response is similar to 100
ng/mL VEGF. The D5- and D10-VEGF conjugates have similar Ca2+activation profiles.
Both conjugates induce an initial increase of intracellular Ca2+ corresponding to the
effect of free VEGF between 50 and 100 ng/mL, reaching the plateau after 7-8 minutes
with an intracellular concentration of Ca2+ that is slightly lower than the one observed
for 100 ng/mL of free VEGF. The differences found in the initial intracellular Ca2+ pro-
files between unconjugated and conjugated VEGF might due to the accessibility of VEGF
to interact with its receptors. It is likely that only part of the immobilised VEGF in all
three conjugates will activate VEGF receptor due to conformational barriers; however,
the conjugates could maintain their activation for long time without the complex ligand-
receptor being internalised and eliminated by the cell. The same effect was observed
with CD34+-derived endothelial cells. The dexOx conjugation to VEGF, reduced the
Ca2+ activation profile and this reduction was dependent on the OD (Fig. 7.4B). The
reduction on calcium uptake was not so drastic, as observed earlier for the HUVECs,
which might be due to the differences between both kinds of cells and the density of
VEGF receptors at the cell surface ([138]). Again, the higher the OD, the more imines
are formed between the dexOx and VEGF, which is more extensive in the case of D25.
The reduction of the conjugate, to non-hydrolisable amine bonds, with cyanoborohy-
dride, further reduced this calcium uptake. This effect is more expressive with D25,
strongly inhibiting the bioactivity of VEGF (Fig. 7.4B&C). The Ca2+ uptake reduction
was less pronunciated with D10 (Fig. 7.4B&C) and D5 (Fig. 7.4B&C), suggesting the
higher conjugate lability on these two last conditions.
7.4.4. Phosphorylation of Akt and ERK in Endothelial Cells
To further confirm the activation of endothelial cells by D25-VEGF, the activation of
Akt [157] and ERK [330, 331] (downstream effectors of VEGF signaling pathway), were
evaluated by protein analysis. In this case, HUVECs were starved for 20 hours in serum-
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free M199 medium and then treated for up to 20 minutes with M199 medium containing
VEGF or D25-VEGF conjugate. The levels of phosphorylated and total Akt and ERK
proteins were determined using a Bio-Plex kit. A VEGF concentration of 100 ng/mL
was used in all experimental groups. VEGF increased Akt phosphorylation as early as
5 minutes and produced a maximal effect at 15 minutes (Fig. 7.5A), declining there-
after. The same samples were evaluated for the activation of ERK1/2 signaling pathway
(Fig. 7.5B). The activation of ERK1/2, a mediator in the mitogen-activated protein ki-
nase (MAPK) cascade, may promote cell proliferation [331] or cell survival when cells
are cultured under stress conditions [330]. ERK1/2 signaling was highly activated when
HUVECs were exposed to VEGF.
Figure 7.5.: Phosphorylation pathways. (A) Akt and Erk expression (phospho/total
protein ratio) throughout 20 minutes, after stimulation by VEGF (100 ng/mL) and 20
hours of starvation. Upper dashed lines represente the positive control: EGM-2; and
lower dashed lines represent the negative controls: M199. (B) Erk phosphorylation
ratio by soluble VEGF, D25-VEGF and D25-VEGF (reduced) at 10 minutes after
stimulus, after 20 hours of starvation. All conditons presented VEGF at 100 ng/mL.
Free VEGF increased ERK1/2 phosphorylation as early as 5 minutes (first time point)
followed by a decrease on the effect up to 20 minutes. A similar profile has been reported
elsewhere for the activation of ERK by free VEGF [331]. As the ERK pathway was the
most responsive under the studied conditions, the effect of non-reduced or reduced
D25-VEGF conjugate was assessed. Importantly, cells exposed to unconjugated VEGF
for 10 min have higher activation than non-reduced or reduced D25-VEGF conjugate
(Fig. 7.5C). This is in line with the previous intracellular Ca2+ results. This is likely due
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to the fact that VEGF conjugated to DexOx has decreased access to the VEGF receptor
due to the physical restrictions exerted by the dextran polymer.
7.4.5. VEGF Controlled Release from Hydrogels
Next, we evaluated the release of VEGF from hydrogels prepared by the cross-linking of
dexOx-VEGF with AAD. Considering that the terminal half-life of VEGF, after a 4-hour
intravenous steady infusion, is around 30 minutes [164], the dexOx-VEGF-AAD hydrogels
may be a valuable sustained delivery system of VEGF. Several formulations have been
reported in the last years, for the sustained release of VEGF, based on the physical
immobilisation of VEGF such as heparin-based hydrogels [188], dextran sulphate-based
nanoparticles [203] and on the chemical immobilisation of VEGF to networks formed
by collagen, PLGA and PEG [175, 176, 137, 195]. In this work, VEGF was chemically
conjugated to dexOx (100-fold weight excess of dexOx to VEGF) and the remaining
aldehyde groups reacted with AAD to form a gel. The gel was formed within minutes
[14] depending on the feed concentration of dexOx and/or AAD. Several gel formulations
were prepared based in D25-VEGF, different concentrations of AAD (10% and 20%),
and different methodologies (addition of VEGF to the D25 or the AAD solution).
Hydrogels with or without VEGF have similar dissolution profiles. Hydrogels with low
cross-linking density (5% AAD) are dissolved completely before the fourth day and were
not further studied. Hydrogels with medium cross-linking density (10%) and containing
VEGF have similar dissolution times as hydrogels without VEGF, however presenting a
higher swelling profile (Fig. 7.6A). Hydrogels with high cross-linking density (20%) did
not dissolve up to over 30 days (Fig. 7.6A).
To determine the release of VEGF from hydrogels we used two methodologies: (i)
quantification by ELISA and (ii) quantification by tritium (3H-VEGF). We evaluated the
release of VEGF in hydrogels having D25 and different cross-linking densities (10 and
20% AAD) and hydrogels where (i) VEGF was first conjugated with dexOx and then
cross-linked with AAD or where (ii) VEGF was added first to AAD and then cross-
linked with dexOx. The formulation where VEGF is conjugated to dexOx before gel
preparation promotes higher levels of conjugation than when VEGF is conjugated during
the preparation of the gel.
ELISA results showed that only a tiny amount (< 4%) of VEGF is released from the
gels (Fig. 7.6B). This is likely due to the fact that most of the VEGF released from
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Figure 7.6.: (A) Swelling of D25 hydrogels crosslinked with 10% AAD, with (￿) and
without ( ) VEGF, and D25 hydrogels crosslinked with 20% AAD with VEGF ( ).
(B, C, D) Release of VEGF, as quantified by ELISA (B, D) or scintillation (C), from
D25 hydrogels crosslinked with 10% AAD, in which VEGF was added in the dexOx
solution (￿) or in the AAD (￿) solution, from D25 hydrogels crosslinked with 20%
AAD ( ), from D10 hydrogels crosslinked with 10% AAD (￿), and from D5 hydrogels
crosslinked with 10% AAD ( ). Results are average ± SD, n=3.
the gel is still conjugated to dexOx. The presence of dextran attached to VEGF will
prevent its interaction with the antibody that recognises VEGF. In line with all this,
when VEGF is released from gels where the biomolecule was incorporated in the network
during its formation (mixed with AAD), therefore less conjugated to the network, the
content of VEGF released is higher (up to 3.5% of the total VEGF incorporated in the
network) than in the other experimental groups. When VEGF is firstly conjugated with
dexOx and then used for gel preparation, only 0.1% of the total VEGF is released over
30 days (Fig. 7.6B). In a subsequent step, radio-labeled VEGF (3H-VEGF) was used for
the release studies (Fig. 7.6C). In contrast to the ELISA results, a significant release
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of VEGF was observed for all the experimental groups, showing that most of VEGF is
conjugated with DexOx. The release of VEGF in gels with medium cross-linking density
(10% AAD) peaks at day 5 corresponding to the total dissolution of the gel. The release
of VEGF in gels with high cross-linking density (20%) is low (< 2%) for the first 20
days and increases abruptly afterwards. Next, we evaluated VEGF release from D5 or
D10-based hydrogels. In contrast to D25-VEGF hydrogels, D10 and D5-based hydrogels
release high concentration of VEGF as assessed by ELISA (Fig. 7.6D). The D5 hydrogels
degrade in less than 2 days and release approximately 30% of the initial VEGF over that
time while D10-based hydrogels degrade in 4 days and release approximately 7% of the
initial VEGF over the same time.
The amount of VEGF identified by ELISA, may not account for the total real released
drug, but it qualifies as the active VEGF, as it was identified by anti-VEGF antibodies.
The slow release of the VEGF, plus the protecting effect of the binded dexOx, could
help establish a gradient within an optimal concentration range (0 - 10 ng/mL) [321],
which could promote endothelial sprouting and a directional growth towards the hydrogel.
The fact that dexOx remains conjugated to VEGF, after the release from the hydrogel,
means that there is an extended protection which can prolong significantly the life-time
of VEGF.
7.4.6. Endothelial Cells Encapsulation in Hybrid Hydrogels
Containing VEGF
The hybrid construct was formed by two components: (i) a hydrogel of dexOx-VEGF
crosslinked with AAD and (ii) a fibrin hydrogel embedding the dexOx-VEGF hydrogel
(Fig. 7.7A&B). The dexOx hydrogels containing VEGF (10 ￿L volume) were prepared
initially on a syringe plunger, after which a mixed aqueous solution of fibrinogen and
thrombin (50 ￿L in total) was placed on top of the dexOx hydrogel (Fig. 7.7A&B).
Umbilical cord blood-derived endothelial cells, previously characterised by Pedroso et al.
[138], were immersed in the fibrin gel precursor solution. These cells have a typical
cobblestone morphology, express high levels of EC markers, including CD31, Von Wille-
brand factor (vWF), CD34 and Flk-1/KDR over time [138]. After the curing of the
fibrin gel, the hybrid constructs were placed in EGM-2 media and incubated at 37 °C.
The constructs were monitored for six days by contrast microscopy and the cell viability
was quantified by a live-dead assay at the 6th day(Fig. 7.7C).
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Figure 7.7.: Hybrid hydrogels visualisation in a fluorescence microscope. (A) Image of
the whole hybrid hydrogel. DexOx hydrogel in red (TRITC) and fibrin hydrogel in
green (Alexa 488). Scale bar 2 mm. (B) Image of the hybrid hydrogel dexOx/fibrin
interface with cells stained with Hoechst (blue). Scale bar 200 ￿m. (C) Cellular
viability assessed by live/dead assay (P<0.05).
Figure 7.8.: Contrast phase images from endothelial cells encapsulated in the fibrin
section of the hybrid hydrogels. All scale bars are 100 ￿m.
D5 hydrogels located within fibrin gels were completely degraded before the 6th day,
while no macroscopic degradation was observed for the remaining hydrogels (D10 and
D25). The survival of the ECs was high (> 80%) for all the experimental groups
tested (Fig. 7.7). With the exception of gels containing D25, cell survival was higher
for constructs with VEGF than without VEGF (P<0.05). These results demonstrate
the cell pro-survival effect of VEGF. In addition, images obtained by light microscopy
indicate that the release of VEGF within the hybrid gel induce a cord-like organisation
115
Chapter 7 Pro-angiogenic Hybrid Hydrogels
of the endothelial cells (Fig. 7.8). This effect was observed for constructs containing D5
and D10 hydrogels, but not D25 hydrogels. In addition, no visible network formation
was observed in constructs containing D5 and D10 hydrogels without VEGF, suggesting
that the formation of cord-like structures was mediated by VEGF.
Figure 7.9.: Genetic profiling of endothelial cells after six days.
The effect of VEGF in the encapsulated endothelial cells was evaluated by qRT-PCR
analysis. We analysed the expression of VEGF and Flk-1 (VEGFR2), but also the ma-
trix metallo-proteinase 2 (involved in the remodeling of ECM and cell migration and
which has been shown to be stimulated by VEGF in vitro [332]) and MCP-1, an endoge-
nous cytokine with chemotactic properties towards SMCs [333] and up-regulated when
endothelial cells are exposed to certain conditions [334]. Gene expression in cells encap-
sulated in constructs with VEGF was normalized by the corresponding gene expression
in cells encapsulated in fibrin hydrogels without VEGF. Interestingly, the expression of
matrix metallo-proteinase 2 (MMP-2) was higher for gels that have the ability to release
faster VEGF (D5 and D10). The constructs with D25-VEGF have no statistical signif-
icant upregulation of MMP-2 gene at day 6, as compared to the control. In addition,
constructs that release faster VEGF induced a downregulation in the expression of the
VEGF gene. Constructs with D25-VEGF hydrogels, that have no significant release of
VEGF over 6 days, have cells with an upregulation of VEGF and Flk-1 gene. Under these
conditions, the cells need to secrete VEGF and to express VEGF receptor for survival.
These constructs have cells that express high levels of MCP-1, a chemotactic protein,
specific for SMCs, which would benefit the survival of the ECs, by the segregation of
EC-specific cytokines and growth factors [335].
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7.5. Conclusion
We report a novel pro-angiogenic therapy based on a construct able to release VEGF at
variable rates and support the attachment and organisation of endothelial cells derived
from umbilical cord stem cells. These constructs allow tailoring the properties of the
growth factor release system separately from the matrix encapsulating the cells. We
show that the degree of oxidation in dexOx is very important to control the release of
VEGF. DexOx with high degree of oxidation (D25) tend to form multi-point attachment
with VEGF retarding its delivery. By circular dichroism we demonstrate that the 3D
structure of VEGF is substantially not affected by the chemical conjugation to dexOx.
We also show that the VEGF conjugates induce an increase of intracellular Ca2+ in
endothelial cells and the induction profile is dependent on the degree of oxidation of
the VEGF conjugate. We confirmed these results also by evaluating the phosphorylation
of Akt and ERK proteins. Our results also indicate that dexOx-VEGF hydrogels can
release between 1 to 45% of the total initial protein. Yet, most of the protein is released
as a conjugate, accompanying hydrogel dissolution. We show that when dexOx-VEGF
hydrogels are incorporated in a fibrin gel containing endothelial cells, the released VEGF
(mainly for the low cross-linked hydrogels) can modulate gene expression and three-
dimensional cell organisation. We envision that these constructs might be beneficial for
the induction a rapid pro-angiogenic response in ischemic tissues, as well as matrixes to
drive the in situ differentiation of vascular progenitor cells.
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8. Controlling the neuronal
differentiation of stem cells by the
intracellular delivery of retinoic
acid-loaded nanoparticles
8.1. Abstract
The manipulation of endogenous stem cell populations from the subventricular zone
(SVZ), creates an opportunity to induce neurogenesis and influence brain regenera-
tive capacities in the adult brain. Herein, we demonstrate the ability of polyelectrolyte
nanoparticles to induce neurogenesis exclusively after being internalized by SVZ stem
cells. The nanoparticles are not cytotoxic for concentrations equal or below to 10
￿g/mL. The internalisation process is rapid and nanoparticles escape endosomal fate in
few hours. Retinoic acid-loaded nanoparticles increase the number of neuronal nuclear
protein (NeuN)-positive neurons and functional neurons responding to depolarisation
with KCl and expressing NMDA receptor subunit type 1 (NR1). These nanoparticles
offer an opportunity for in vivo delivery of proneurogenic factors and neurodegenerative
diseases treatment.
8.2. Introduction
Several biomolecules have the capacity to differentiate stem cells progeny towards de-
sired lineage-specific precursors [336, 337, 213]. However, the administration of some
of these bioactive factors presents a significant challenge because of their poor water
solubility, short half-life, and potentially undesired side effects. One example is retinoic
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acid (RA) which interacts with members of the hormone receptor super-family, including
the RA receptor (RAR) and the retinoid X receptor (RXR), located in the cell nuclei
[262]. These receptors heterodimerise and bind to a DNA sequence called retinoic acid-
response element (RARE), activating gene transcription involved in cell proliferation,
differentiation and apoptosis. Many factors regulate neurogenesis and several studies
have demonstrated that RA is able to induce the differentiation of progenitor cells into
neuronal cells [262, 338, 339], suggesting that this molecule is a good candidate for
enhancing postinjury neurogenesis. However, RA is rapidly metabolized by cells and has
low solubility in aqueous solutions [264]. In addition, the use of this biomolecule in an
in vivo setting for the differentiation of resident stem/progenitor cells remains elusive.
Nanoparticles can be an excellent platform to ensure intracellular transport and controlled
release of RA [266, 267, 340]. Several nanoparticle formulations have been developed
for the release of this molecule [266, 267, 340]. However, until now none of the reported
formulations was designed to deliver RA within cells, and particularly for the differ-
entiation of stem/progenitor cells. Nanoparticles can be internalised via endocytosis,
macropinocytosis or phagocytosis, but these processes confine the compounds to closed
vesicles (endosomes or phagosomes), where the pH is progressively lowered to 5.5-6.5
[271, 274]. Polycations, such as polyethylenimine, that absorb protons in response to
the acidification of endosomes (i.e. cationic polymers with a pK around or slightly below
physiological pH) can disrupt these vesicles via the “proton sponge” effect that promotes
the swelling of the endosome in situ [56, 341]. Once the polymeric nanoparticles reach
the cytosol, the bioactive molecule may be released by desorption, diffusion through the
nanoparticle or nanoparticle erosion.
Herein, we present a novel strategy to differentiate the progeny of stem cells into neu-
rons using nanoparticles able to intracellularly release RA. We demonstrate that the
internalisation of the RA-loaded nanoparticles has a minimal effect on cell viability and
proliferation but a large impact on differentiation. Importantly, nanoparticle-conditioned
medium is unable to promote the differentiation of stem/progenitor cells indicating that
neuronal differentiation is only mediated by internalisation of the nanoparticles.
8.3. Materials and Methods
Disclaimer: From sec. 8.3.9 onward, the work respecting the biological characterisation
of the developed nanoparticulate system, was performed by Tiago Santos under the
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guidance of João Malva and Liliana Bernardino with assistance by Fabienne Agasse and
Luisa Cortes.
8.3.1. Materials
All-trans retinoic acid, polyethylenimine (PEI, average Mw ~25 kDa by LS, average Mn
~10 kDa by GPC, branched), zinc sulphate heptahydrate (ZnSO4), ninhydrin reagent
solution, Azure-A, fluorescein isothiocyanate (FITC) and tungstic acid were purchased
from Sigma-Aldrich. Dextran sulphate (DS, Mw=500 kDa) was purchased from Fluka.
Dimethyl sulfoxide (DMSO) and Ethanol (EtOH) were acquired from Merck. All reagents
were used without further purification.
8.3.2. Fluorescent Labeling of PEI
PEI (10 g) was dissolved in 90 mL of borate buffer (pH 8.5) and a 10-fold molar excess
of FITC, dissolved in 2 mL of DMF, was added dropwise and stirred for 1 hour. The
solution was transferred to a dialysis membrane with 6 - 8 kDa cut-off and dialyzed
against milliQ water. The dialysed solution was freeze-dried for 2 to 3 days, protected
from light.
8.3.3. Preparation of Nanoparticles
Nanoparticles with a weight ratio of DS to PEI of 1 were prepared by adding dropwise 0.6
mL of RA (2% w/v, in DMSO)) into 12 mL of PEI (1% w/v, in pH 8.0 borate buffer).
The formation of complexes between RA-PEI occurred immediately and was allowed to
proceed for 30 min with intense magnetic stirring. Then, 12 mL of DS solution (1% w/v)
was added dropwise and stirred for another 5 min. Finally, 1.2 mL of ZnSO4 aqueous
solution (1 M) was added and stirred for 30 min. Nanoparticles were centrifuged 3 times
in 5% mannitol solution at 14,000 g for 20 minutes. Supernatants from each step were
collected to determine PEI and DS amounts in nanoparticles. Resulting nanoparticles
were frozen and lyophilised for 4 days to obtain a dry powder. Lyophilised nanoparticles
were stored at 4°C. Similar protocol was adopted for the preparation of nanoparticles
with a weight ratio of PEI to DS of 5 and 0.2, by changing the concentration of the
polymers accordingly. Blank nanoparticles were prepared using the same procedure in
the absence of RA.
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8.3.4. Characterisation of the Nanoparticles
The morphology of the nanoparticles was evaluated by transmission electron microscopy
(Hitachi SU-70, with a STEM detector at 30 kV) following negative staining with tungstic
acid solution (1%, w/v; pH 7.5). Initially, an aliquot of lyophilised NPs (5 mg) was
resuspended in PBS (1 mL), centrifuged for 5 minutes at 14,000 g, ressuspended in
PBS, centrifuged again, and finally ressuspended in PBS (0.5 mg/mL). Five microliters
of both sample and tungstic acid solution (1%, w/v; pH 7.5) were placed on a 300
mesh copper grid with a carbon-coated formvar membrane and dried overnight before
examination by TEM.
Particle size was determined using light scattering via Zeta PALS Zeta Potential Analyzer
and ZetaPlus Particle Sizing Software, v. 2.27 (Brookhaven Instruments Corporation).
Nanoparticles suspended in water and sonicated for short times (< 10 min) were used.
Typically, all sizing measurements were performed at 25 °C, and all data were recorded
at 90°, with an equilibration time of 5 min and individual run times of 60 s (5 runs
per measurement). The average diameters described in this work are number-weighted
average diameters. The zeta potential of nanoparticles was determined in a 1 mM KCl
pH 6 solution, at 25 °C. All data were recorded with at least 6 runs with a relative
residual value (measure of data fit quality) of 0.03.
8.3.5. Determination of Weight Ratio of Cationic to Anionic
Polymer in Nanoparticles
Anionic-to-cationic polymer (DS:PEI) mass ratios in nanoparticles can be determined
by subtracting the known amount of PEI and DS in the supernatant of completely
centrifuged particles from the initial amount present [244]. The amount of PEI was de-
termined using ninhydrin. Twenty microliters of supernatant from a centrifuged nanopar-
ticle suspension were mixed with 380 mL of an acetic acid solution (0.05% w/v). One
milliliter of ninhydrin reagent solution was then added. The mixture was placed into a
boiling water bath for 10 min and then cooled to room temperature. Three milliliters
of 95 % ethanol were added and mixed. The amount of PEI was then determined spec-
trophotometrically at 575 nm using a calibration curve from 10 to 30 mg/ml of PEI. The
amount of unreacted DS in the supernatant was detected spectrophotometrically at 630
nm using an azure A dye binding method in which 400 mL of supernatant from a cen-
trifuged nanoparticle suspension were mixed with 1.0 mL of azure A (10 mg/mL). Again
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a calibration curve of 1.0 to 3.5 mg/mL of DS was used to determine the concentration
of unknown samples.
8.3.6. Loading Efficiency of RA in Nanoparticles
In order to determine the amount of RA in loaded nanoparticles, a given amount of
nanoparticle powder was dissolved in 1 mL of DMSO:HCl (9:1) solution and the ab-
sorption for RA at 350 nm was measured. The RA concentration was obtained from a
calibration curve from 0.47-0.0023 mg/mL of RA in DMSO:HCl (9:1) solution. Loading
efficiency was calculated using the following equation:
Loading Efficiency = Amount of RA in the nanoparticles
Initial amount of RA
× 100
8.3.7. RA Release from Nanoparticles
Nanoparticles (2.5 mg) were placed in PBS (0.5 mL) and incubated under mild agitation,
at 37 °C. At specific intervals of time, the nanoparticle suspension was centrifuged (at
20,000 rpm for 20 min) and 0.4 mL of the release medium removed and replaced by a new
one. The reserved supernatant was stored at 5 °C until the RA content in release samples
was assessed by spectrophotometry at 350 nm. Concentrations of RA were determined
by comparison to a standard curve. All analyses were conducted in triplicate.
8.3.8. In vitro Degradation of Polymeric Nanoparticles
Nanoparticles with or without RA were suspended at ~10 mg/mL in 10 mM PBS (pH
7.4) or 0.2 M citrate buffer pH 5 or 6 and incubated at 37 °C, under mild agitation.
In one experimental set, the incubation lasted 7 days, after which, the nanoparticle
suspension was centrifuged (20,000 g for 15 min) and the pellets lyophilised for final
mass. On the second experimental set, the incubation lasted for 21 days and at daily
intervals, the nanoparticles suspension was centrifuged (20,000 g for 15 min) and 0.4
mL of the release medium removed and replaced by a new one, for RA quantification
and particles size measurements. At the final day, the resulting nanoparticle suspensions
were lyophilised for 3 days to obtain a dry powder for mass determination.
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8.3.9. SVZ Cell Cultures and Experimental Treatments.
All experiments were performed in accordance with NIH and European (86/609/EEC)
guidelines for the care and use of laboratory animals. SVZ cells were prepared from
1-3 day-old C57BL/6 donor mice as described by [342]. Briefly, mice were killed by
decapitation and the brains were removed and placed in calcium- and magnesium-free
HBSS solution (Gibco, Rockville, MD, USA), under sterile conditions. Fragments of SVZ
were dissected out of 450 ￿m-thick coronal brain sections using a McIlwain tissue chopper
and then SVZ was digested in 0.025% trypsin (Gibco) and 0.265 mM EDTA (Gibco) (10
min, 37 °C), following mechanical dissociation with a P1000 pipette. The cell suspension
was diluted in serum-free medium (SFM) composed of Dulbecco’s modified eagle medium
[(DMEM)/F12 + GlutaMAXTM-I)] supplemented with 100 U⁄ml penicillin, 100 ￿g⁄ml
streptomycin, 1% B27 supplement, 10 ng⁄ml epidermal growth factor (EGF) and 10
ng⁄ml basic fibroblast growth factor (FGF)-2 (all from Gibco). Single cells were then
plated on uncoated Petri dishes at a density of 3000 cells⁄cm2 and were allowed to
develop in an incubator with 5% CO2 and 95% atmospheric air at 37 °C. Six-day-old
neurospheres were adhered for 48 hours onto 24 well plate poly-D-lysine-coated glass
coverslips for all experiments except western blots, which were left adherent onto poly-D-
lysine-coated 6 well plates, all in SFM devoid of growth factors. Then, the neurospheres
were allowed to develop for 2 or 7 days at 37 °C in the presence a broad range of RA-
releasing NP concentrations. Cell death assays were done after 2 days of incubation.
At the end of the 7 day treatment, Single Cell Calcium Imaging (SCCI) experiments,
western blots and immunocytochemistry were performed. (Fig. 8.5).
To determine whether the proneurogenic effect of RA was due to its release in the cell
medium or the nanoparticles internalized, RA+-NPs were dissolved in SFM devoid of
grow factors and incubated for 7 days at 37 °C. Thereafter, the resulting cell medium
containing the RA+-NPs was centrifuged (14,000 rpm, 15 min), nanoparticles were
discarded and the supernatant was recovered and used for conditioned medium (CM) on
SVZ cells for 7 days, followed by NeuN immunocytochemistry.
8.3.10. Single Cell Calcium Imaging
To functionally characterise neuronal differentiation in SVZ cells, variations of intracellu-
lar calcium concentration ([Ca2+]i) following stimulation with 50mM KCl and 100µM his-
tamine (Sigma-Aldrich) were analysed. KCl depolarisation causes the increase of [Ca2+]i
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in neurons, whereas stimulation with histamine increases [Ca2+]i in stem/progenitor cells
[343]. SVZ cultures were loaded for 40 minutes at 37 °C with 5µM Fura-2 AM (Molecu-
lar Probes), 0.1% fatty acid-free bovine serum albumin (BSA), and 0.02% pluronic acid
F-127, in Krebs buffer (132 mM NaCl, 1 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2, 10
mM glucose, 10 mM HEPES, pH 7.4). After a 10 minutes post-loading period at room
temperature (RT), the coverslip was mounted on RC-20 chamber in a PH3 platform
(Warner Instruments) on the stage of an inverted Axiovert 200 fluorescence microscope
(Carl Zeiss). Cells (approximately 100 cells per field) were continuously perfused with
Krebs and stimulated by applying 100 µM histamine or high-potassium Krebs solution
(containing 50 mM KCl, isosmotic substitution with NaCl) by the mean of a fast pres-
surized (95% air, 5% CO2 atmosphere) system (AutoMate Scientific Inc.). [Ca2+]i was
evaluated by quantifying the ratio of the fluorescence emitted at 510 nm following alter-
nate excitation (750 milliseconds) at 340 and 380 nm, using a Lambda DG4 apparatus
(Sutter Instrument) and a 510 nm band-pass filter (Carl Zeiss) before fluorescence acqui-
sition with a 40x objective and a CoolSNAP digital camera (Roper Scientific). Acquired
values were processed using the MetaFluor software (Universal Imaging Corporation).
Histamine/KCl values for Fura-2 ratio were calculated to determine the extent of neu-
ronal maturation in cultures. The percentage of cells displaying a neuronal-like profile
was calculated on the basis of the histamine (Hist)/KCl ratio.
8.3.11. Internalisation Studies
In order to visualise the cellular uptake of RA+-NP by SVZ cells we performed a live
imaging experiment on a confocal microscope (LSM 510 Meta, Carl Zeiss). 50 µg/mL
RA+-NPs were administrated to SVZ neurosphere seeded on glass bottom petri dishs
(35 mm, IBIDI, Germany) and incubated at 37 °C for 60 min. For imaging, cells were
then placed into a special stage (Heating Insert P Lab-Tek and Incubator S, Pecon) at
37 °C, 5% CO2 on a confocal laser scanning microscopy (LSM 510 META, Carl Zeiss).
This system maintained normal cell culture and allowed multiple regions of interest to
be imaged regularly throughout the duration of the experiment. internalisation of NP
was followed over a 4 hours period (4 frames −1), by detection of FITC bound to the
NPs using a 488 nm argon laser (45 mW) for excitation and a 510-550 nm band-
pass emission filter, and a 63x objective (Plan-ApoChromat, N.A. 1.4). Differential
interference contrast (DIC) images were simultaneously acquired in order to visualise
alterations on cell morphology during the experiment. Finally, Hoechst 33342 (2 ￿g/ml)
125
Chapter 8 Retinoic Acid-Loaded Nanoparticles
(Invitrogen) was added in order to visualise nuclei morphology. Images were acquired
using a 405 nm Diode laser (30 mW) and a band-pass emission filter (420-450 nm).
8.3.12. Western Blots
SVZ cells, previously incubated with RA+-NPs for 7 days in differentiation conditions,
were washed with 0.15 M phosphate-buffered saline (PBS) and incubated in a lysis
buffer [0.15 M NaCl , 0.05 M Tris-Base, 5 mM EGTA, 1% Triton X-100, 0.5% DOC,
0.1% SDS, 10 mM DTT containing a cocktail of proteinase inhibitors (Roche)]. To-
tal protein concentration from the lysates was determined by BCA assay and samples
were treated with SDS-PAGE buffer [6x concentrated: 350 mM Tris, 10% (w/v) SDS,
30% (v/v) glycerol, 0.6 M DTT, 0.06% (w/v) bromophenol blue], boiled for 5 min at
95 °C, and stored at -20 °C until use for western blotting. Then, proteins (40 µg of
total protein) were resolved in 15% SDS polyacrilamide gels and then transferred to
PVDF membranes with 0.45 µm pore size in the following conditions: 300 mA, 90 min
at 4 °C in a solution containing 10 mM CAPS and 20% methanol, pH 11) (protocol
adapted from Pinheiro et al. (2005) [344]). Membranes were blocked in Tris-buffer
saline containing 5% low-fat milk and 0.1% Tween 20 (Sigma) for one hour, at RT, and
then incubated overnight at 4 °C with the primary antibody rabbit monoclonal anti-NR1
(1:100) (CHEMICON International Inc., Billerica, MA, USA) diluted in 1% TBS-Tween
and 0.5% low fat milk. After rinsing three times with TBS-T 0.5% low-fat milk, mem-
branes were incubated for 1 h, at RT, with an alkaline phosphatase-linked secondary
antibody anti-rabbit IgG 1:20,000 in 1% TBS-T and 0.5% low-fat milk (GE Healthcare,
Buckinghamshire, UK). For endogenous control immnunolabelling, primary antibody so-
lution consisted of mouse monoclonal anti-GAPDH (1:10,000) (Millipore, MA, USA).
Protein immunoreactive bands were visualised in a Versa-Doc Imaging System (Model
3000, BioRad Laboratories, CA, USA), following incubation of the membrane with ECF
reagent (GE Healthcare, Buckinghamshire, UK) for 5 min. Densitometric analysis were
performed by using the ImageQuant software.
8.3.13. Immunocytochemistry
Cells were fixed with 4% paraformaldehyde (PFA). After washing three times with PBS,
unspecific binding was prevented by incubating cells in a 3% BSA and 0.3% Triton X-
100 solution for 30 min, at RT. Cells were kept overnight at 4 °C in a primary antibody
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solution, then washed with PBS the following day, and incubated for 1 h, at RT, with
the corresponding secondary antibody. Antibodies were used as listed: mouse mono-
clonal anti-Tuj1 (Covance, Princeton, NJ, USA) (1:100), mouse monoclonal anti-NeuN
(Millipore) (1:100), rabbit polyclonal anti-GFAP (1:100) (Cell Signaling Tech., Beverly,
MA, USA) prepared in 0.1% Triton X-100, 0.3% BSA solution; Alexa Fluor 594 goat
anti-mouse; Alexa Fluor 488 goat anti-rabbit (both at 1:200 in PBS, from Invitrogen).
For nuclear labelling, cell preparations were stained with Hoechst 33342 (2 ￿g/ml) (In-
vitrogen) in PBS 5 min, at RT, and mounted in Dakocytomation fluorescent medium
(Dakocytomation Inc., Carpinteria, CA, USA). Fluorescent images were acquired using
a confocal microscope (LSM 510 Meta, Carl Zeiss).
In order to visualise the NPs internalisation, cells were incubated overnight with the
RA-releasing NPs (10 µg/mL) and then fixed in methanol-acetone 1:1 for 20 min at -20
°C. After fixation, non-specific binding sites were blocked with 6% BSA (Sigma) in PBS
for 1 h. Cells were subsequently incubated with the primary antibody mouse monoclonal
anti-FITC (1:100, Sigma) in PBS containing 0.3% BSA (Sigma). Thereafter, coverslips
were rinsed in PBS and incubated for 1 h, at RT, with the secondary goat anti-mouse
Alexa 594 (1:200, Invitrogen). After rinsing with PBS, cell preparations were incubated
with Hoechst 33342 (2 µg/ml, Invitrogen) in PBS for 5 min at RT. Finally, the prepa-
rations were mounted using Dako Fluorescent Mounting Medium (Dakocytomation).
Fluorescent images were acquired using a confocal microscope (LSM 510 Meta, Carl
Zeiss).
8.3.14. TUNEL Assay
SVZ cultures were fixed with 4% PFA for 30 min, at RT, rinsed in PBS and permeabilised
in 0.25% Triton X-100 (Sigma) for 30 min at RT. Thereafter, coverslips were incubated
for 20 min in 3% H2O2 and reacted for terminal transferase (0.25 U⁄µL) biotinylated
dUTP (6 µM) nick-end labelling of fragmented DNA in TdT buffer (pH 7.5) (all from
Roche, Basel, Switzerland) for 1 h 30 min at 37 °C in a humidified chamber. The
enzymatic reaction was stopped by 15 min incubation in 300 mM NaCl and 30 mM
sodium citrate (both from Sigma) buffer. Following an additional rinse in PBS, cultures
were incubated for 30 min at RT with the avidin-biotin-peroxidase complex (1:100;
Vector Laboratories Inc., Burlingame, CA, USA). Peroxidase activity was revealed by the
DAB chromogen (0.025%; Sigma) intensified with 0.08% NiCl2 in 30 mM Tris-HCl (pH
7.6) buffer containing 0.003% H2O2. The cell preparations were then dehydrated in an
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ethanol gradient (70%, 2 min; 80%, 2 min; 90%, 2 min; 95%, 2 min; 100%, 2 min),
cleared in xylene (3 min) and mounted using DEPEX mounting medium (Fluka Chemie
AG, Buchs, Switzerland). Photomicrographs of TUNEL labelling were recorded using a
digital camera (Axiocam HRC, Carl Zeiss) adapted to an Axioskop 2 Plus fluorescent
microscope (Carl Zeiss).
8.3.15. Propidium Iodide Incorporation
Propidium iodide (PI; 3 µg/mL, Sigma) was added 40 min before the end of the 48
h of incubation with RA+-NPs. Thereafter, cells were fixed with 4% PAF for 30 min,
rinsed in PBS and stained with Hoechst 33342 (2 ￿g/ml; Invitrogen) in PBS, for 5 min,
at RT, and mounted in Dakocytomation fluorescent medium (Dakocytomation Inc.).
Photomicrographs of PI-uptake labelling were recorded using a digital camera (Axiocam
HRC, Carl Zeiss) adapted to an Axioskop 2 Plus fluorescent microscope (Carl Zeiss).
8.3.16. Statistical Analysis
Data are expressed as means ± standard error of mean (SEM). Statistical significance
was determined by using Student’s t-test or one-way ANOVA followed by Dunnett’s
post hoc test for comparison with control or Neuman-Keuls for multiple comparison
test, with P<0.05 considered to represent statistical significance. All measurements
were performed in the monolayer of cells surrounding the seeded SVZ neurospheres. For
SCCI experiments, the percentage of neuronal responding cells (Hist/KCl ratio<0.8)
was calculated on the basis of one microscopic field per coverslip, containing about 100
cells (40× magnification). Percentages of NeuN-, TUNEL-, or PI-positive cells were
calculated from cell counts in five independent microscopic fields in each coverslip with
a 40× objective (approximately 200 cells per field). Because no significant differences
were found between experiments from different SVZ cell cultures, the corresponding data
were pooled.
8.4. Results and Discussion
Nanoparticles were prepared by complex coacervation, i.e., through the electrostatic in-
teraction of polyethylenimine (PEI, polycation) and dextran sulphate (DS, polyanion)
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(Fig. 8.1A). Initially, complexes of RA with PEI were formed by the electrostatic interac-
tions of the carboxyl groups of RA with the amine groups of PEI. According to previous
studies the maximum loading is obtained for a ratio of amino groups to carboxylic acid
groups of about 2:1 [266]. In this work we used a ratio between 4:1 (for the NP formu-
lation DS:PEI with weight ratio of 5.0) and 17:1 (for the NP formulation DS:PEI with
weight ratio of 0.2), only considering the primary amines present in PEI. The electro-
static interaction between RA and PEI is confirmed by a shift in the RA peak at 350 nm
to near 300 nm, as confirmed by spectrophotometry (Fig. 8.2).
Figure 8.1.: Physico-chemical properties of the nanoparticles. A) Chemical structures
of retinoic acid (RA), polyethylenimine (PEI) and dextran sulphate (DS). B) Typical
profile obtained by DLS for the formulation RA+-NPs (0.2). Results are expressed
as number-weight average diameter. C) Transmission electron microscopy (TEM)
images of RA+-NPs. Scale bar: 200 nm. D) Mass loss on nanoparticles suspended in
buffered solutions at pH 5.0, 6.0 and 7.4 for 7 days, at 37 °C. Nanoparticles with or
without RA were used in these degradation studies. Results are shown as mean ± SD,
n=6. ** and *** denotes statistical significance P<0.01 and P<0.001, respectively.
These complexes formed nanoparticles with 100 to 250 nm in diameter, although they
tend to dissociate relatively easy. To stabilize the nanoparticle formulation DS and zinc
sulfate were added in successive steps [244]. The electrostatic interaction of DS with PEI
previously has been confirmed by Fourier Transform Infrared (FTIR) analysis in PEI/DS
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nanoparticles [244] and this physical crosslink may contribute for the stabilization of
the NPs. Then, DS and zinc sulphate were added in successive steps to stabilise the
formulation [244]. Nanoparticles without zinc sulphate tend to aggregate and form large
particles. Mannitol was added to the NP suspension during centrifugation steps and
lyophilisation to prevent their aggregation.
8.4.1. High-Loading Capacity and Positive-Net Charge
Nanoparticles
Three different weight ratios of DS relatively to PEI were selected for our initial screening:
5.0 (large excess of DS), 1.0 (similar weight of both polymers), and 0.2 (large excess
of PEI). In each formulation we determined particle size, zeta potential and RA loading
efficiency. A Brookhaven ZetaPALS analyser was used to evaluate NP zeta potential
and size distribution (deionized water). The number-weighting profile of all formulations
tested was usually unimodal (>99%) (Fig. 8.1B). The formulation DS:PEI weight ratio of
5 yielded nanoparticles with an average diameter between 40 and 120 nm, and a negative
net charge, while the formulation DS:PEI weight ratio of 1 yielded large aggregates of
nanoparticles (diameter > 500 nm), with a positive net charge (Tab. 8.1). This is
in line with other results previously reported, indicating that an excess of one of the
NP components is needed to act as a colloidal protective agent and preventing the
coalescence of the NPs [244]. Nanoparticles prepared from the formulation DS:PEI
weight ratio of 0.2 had an average diameter between 80 and 90 nm; however, presenting
a significantly higher RA loading efficiency (48 versus 2%) and positive net charge (15
versus 2 mV) than the other formulations tested. The high loading efficiency is explained
by the high content of PEI able to interact with RA. Based on the loading capacity and
net charge results, nanoparticles obtained from the formulation 0.2 were selected for
subsequent experiments. The morphology of these nanoparticles was then characterised
by transmission electron microscopy (TEM). TEM micrographs (Fig. 8.1C) show a similar
range of sizes as observed by DLS.
The dissolution profile of nanoparticles is affected by pH. The dissolution of the nanopar-
ticles (~10 mg/mL) was evaluated at pH 7.4, 6.0 and 5.0, under agitation, at 37 °C.
This pH range is typically found at the cytoplasm and intracellular organelles [274].
After 7 days, the suspensions were centrifuged, lyophilised and finally weighed. Interest-
ingly, the disassembly of RA-containing nanoparticles (RA+-NPs) was lower than blank
nanoparticles (RA−-NPs) (Fig. 8.1D).
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Table 8.1.: Physico-chemical characteristics of DS/PEI nanoparticles either with or
without RA.
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This might reflect differences in the cross-linking of both preparations. RA might act as
a cross-linker agent, where the carboxyl group interacts electrostatically with the amine
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groups of PEI, and the aromatic group interacts hydrophobically with the aromatic group
of another RA molecule. RA+-NPs showed a mass loss of 15.4 ± 5.9%, 42 ± 3.8% and
54.5 ± 6.3%, at pHs 7.4, 5.0 and 6.0, respectively, over 7 days (Fig. 8.1D). Our results
indicate that acidic pH enhanced the degradation of the nanoparticles likely due to the
protonation of PEI amine groups (in excess relatively to the sulphate groups in DS) and
the concomitant repulsion between positive charges [345].
Figure 8.2.: Diameter and release profile of RA+-NPs. Diameter variation (A) and
release profile (B) of RA+-NPs suspended in buffered solutions at pH 5.0, 6.0 and 7.4
over 21 days, at 37 °C.
The release of RA from nanoparticles is dependent on the external pH. Polyelectrolyte
complexes change their three-dimensional conformation according to the pH, affecting
the release of RA. To evaluate this effect, nanoparticles were incubated at pH 7.4, 6.0
or pH 5.0, at 37 °C, under agitation. At determined times the nanoparticle suspensions
were centrifuged and the supernatant evaluated by spectrophotometry at 350 nm. The
nanoparticles diameter was also evaluated at each time point (Fig. 8.2A). At pH 7.4, the
initial diameter (~100 nm) is roughly maintained over 15 days, decreasing afterwards to
approximately 60 nm. At pH 6.0 and 5.0, higher aggregation was observed for all the
time points; however the population with diameters between 100 and 1000 nm (number-
weighting average) accounted for most (> 95%) of the nanoparticles in suspension
(Fig. 8.2A).
Taking into account that RA solubility is approximately 63 ng per mL at physiological
132
8.4 Results and Discussion
pH [264], most of RA released at pH 7.4 is complexed with PEI (Fig. 8.2B). Indeed, the
complexation of RA to PEI is confirmed by a shift in the RA peak at 350 nm, which
is not affected by the subsequent addition of DS (Fig. 8.3). Interestingly, the release of
Figure 8.3.: UV spectral scan of RA, RA conjugated to PEI, RA conjugated to PEI and
after addition of DS, and RA conjugated to PEI and after addition of DS and zinc
sulphate, according to the methodology described in the Materials and Methods sec-
tion, the suspension centrifuged and the pellet resuspended in PBS and characterised
by spectrophotometry. RA was dissolved in DMSO and diluted in PBS.
RA at pH 5.0 or 6.0 is much lower than pH 7.4, over the same period of time. This
can be due to the crystallisation of the RA and the aggregation of the nanoparticles at
acidic pHs which decreases RA diffusion from the nanoparticles [268, 346]. We cannot
eliminate the possibility that RA is released by the nanoparticles at higher percentages
than the values assessed, and the low values observed by us is because RA precipitates
at acidic pHs circumventing its real quantification.
8.4.2. Nanoparticles Internalisation in SVZ Cells
RA+-NPs could potentially be used to induce neurogenesis and influence the brain re-
generative capacities. In adult mammalian brain, neurogenesis persists in restricted
neurogenic niches. These resources play a central role in the generation and integration
of new neurons into pre-existing neural circuitry and are crucial for the maintenance of
brain integrity and plasticity [347, 348, 349]. The SVZ is the main neurogenic niche of
the adult rodent brain [347, 348, 349] and contains a population of neural stem cells that
can give rise to neurons, astrocytes, and oligodendrocytes. Therefore, SVZ cells have a
huge potential for stem cell-based brain repair strategies. Previous studies have shown
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that nanoparticles (typically below 100 nm) formed by PEI (polycation) complexed with
DNA (polyanion) can be internalised by adult mammalian brain cells [350, 351, 352].
However, in spite of the importance of SVZ neural stem cells for brain physiology and
repair, there is no consistent information concerning nanoparticle uptake and intracellular
drug release in SVZ cells.
To evaluate the kinetics of nanoparticle uptake by SVZ cells, they were exposed to
fluorescein isothiocyanate (FITC)-conjugated nanoparticles and their uptake assessed by
confocal live cell imaging and immunocytochemistry. One hour after cell treatment,
nanoparticles accumulate rapidly in cell cytoplasm (data not shown). This accumulation
Figure 8.4.: Cellular nanoparticle uptake. A) Confocal live imaging of SVZ cells after
exposure for 5 h to FITC-labeled RA+-NPs (50 µg/mL). Hoechst-33342 staining (blue)
was used to visualise cell nuclei. Crop images show both transmission and FITC chan-
nel or FITC channel alone. B) Confocal microscopy photomicrographs of untreated
or FITC-labeled RA+-NPs-treated (10 ￿g/mL) SVZ cells for 18 h, imunostained with
anti-FITC antibody and Hoechst-33342. Scale bars are 10 ￿m.
becomes even more expressive at 5 h (Fig. 8.4A). This is in line with other studies,
showing that PEI-based nanoparticles can escape rapidly endosomal fate due to their
buffering capacity leading to osmotic swelling and rupture of endosomes [341]. At 18 h
after cell treatment, the FITC-conjugated nanoparticles are distributed overall the cell
cytoplasm (Fig. 8.4B).
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To determine the cytotoxicity of these nanoparticles, SVZ neurospheres were exposed
to RA+-NPs or RA−-NPs for 2 days and cell death, presumably involving apoptosis or
necrosis, was then evaluated by terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) and propidium iodide (PI) staining, respectively (Fig. 8.5).
No significant effect on cell apoptosis was observed for all the experimental groups tested
with nanoparticle concentrations up to 100 ￿g/mL (Fig. 8.6A).
Figure 8.5.: Scheme of the experimental protocols used for studying the effects of RA+-
NPs on SVZ cell cultures. Dashed line: exposure with RA+-NPs.
In contrast, cell necrosis increases significantly for nanoparticle concentrations of 100
￿g/mL (~4-fold) (77.3 ± 9.1%; n=4 coverslips; 2938 cells counted; P<0.0001), rel-
atively to the control (17.8 ± 1.3%; n=9 coverslips; 8618 cells counted) (Fig. 8.6B).
The toxic effects of 100 ￿g/mL RA+-NPs was not due to RA since the void formulation
RA−-NPs was equally toxic at the same concentration (Fig. 8.6B). Based on these results,
RA+-NPs are not cytotoxic for concentrations equal or below to 10 ￿g/mL. Moreover,
at these concentrations, the internalisation of the nanoparticles did not affect signifi-
cantly the morphology of the cells. Untreated cells or cells treated with RA+-NPs (1
￿g/mL) for 7 days were characterised by immunocytochemistry against neuron-specific
class III beta-tubulin (Tuj1) and glial fibrillary acidic protein (GFAP). RA+-NPs-treated
cells present a healthy morphology undistinguishable from untreated cells (Fig. 8.6C).
To investigate the effect of RA+-NPs on cell proliferation, SVZ neurospheres were ex-
posed to a wide range of nanoparticle concentrations (0.001 to 10 µg/mL) for 2 days
and then exposed to bromodeoxyuridine (BrdU) in the last 4 h of the treatment. BrdU is
a synthetic nucleoside that can be incorporated into newly synthesised DNA substituting
for thymidine during cell replication. SVZ cells either when grown under proliferative (in
serum free medium with growth factors as free floating neurospheres) or differentiation
(after adherence on poly-D-lysine and in absence of growth factors) conditions exposed
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Figure 8.6.: Cell viability after RA+/−-NPs uptake. A) Percentage of TUNEL-positive
cells in control cultures and in cultures exposed to RA+-NPs for 2 days. Data are
expressed as mean ± SEM (n=4-8 coverslips). B) Percentage of PI-positive cells in
control cultures and in cultures exposed to RA+-NPs or RA−-NPs for 2 days. Data are
expressed as mean ± SEM (n=4-9 coverslips). ***P<0.001 using Dunnet’s Multiple
Comparison Test. C) Representative confocal microscopy photomicrographs showing
a typical morphology of Tuj1-positive neurons (red), GFAP-positive glia (green) and
Hoechst-33342 staining (blue nuclei) in SVZ cells maintained for 7 days in the absence
(control) or in the presence of RA+-NPs (1 ￿g/mL). Scale bars are 10 ￿m.
to RA+-NPs had similar proliferation rates as control cells not exposed to nanoparticles
(Fig. 8.7).
Figure 8.7.: Proliferation of SVZ cells cultured in (A) differentiation (after adherence
on poly-D-lysine and in absence of growth factors) or (B) proliferative (in serum free
medium with growth factors as free floating neurospheres) conditions.
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8.4.3. RA+NPs Promote Neuro-Differentiation
SVZ cell cultures are mixed cultures of immature cells, neurons, astrocytes, oligodendro-
cytes, neuronal and glial progenitors in different stages of differentiation [353, 354, 355].
In untreated SVZ cultures we detected about 5 to 15% of new neurons (detected by
SCCI and NeuN immunocytochemistry; Fig. 8.8), which is in accordance with the per-
centage of neurons obtained from standard methods of isolating neural stem cells in
vitro [355, 343]. To evaluate the effect of RA+-NPs on neuronal differentiation of SVZ
cells, the cells were cultured in differentiation conditions for 7 days in media containing
the nanoparticles and then immunolabeled for NeuN, a neuronal-specific nuclear pro-
tein present on mature neurons [356, 357, 358] (Fig. 8.5). In the presence of RA+-NPs
at concentrations of 0.1 ￿g/mL (19.6 ± 2.3%; n=5 coverslips; 3460 cells counted;
P<0.001) and 1 ￿g/mL (19.2 ± 2.2%; n=7 coverslips; 4954 cells counted; P<0.001),
a significant increase in the percentage of NeuN-positive cells was observed relatively to
the untreated cells (11.8 ± 0.6%; n=13 coverslips; 7306 cells counted) (Fig. 8.8A). The
proneurogenic effect mediated by RA+-NPs was absent in cell cultures treated with void
nanoparticles (RA−-NPs), suggesting that this effect was due to the RA and not due
to the nanoparticle formulation per se (Fig. 8.8B). Importantly, the neuronal differentia-
tion effect was absent for high concentrations (> 1 ￿g/mL) of nanoparticles indicating
that an optimal concentration window of RA exists to drive the neuronal commitment
of SVZ cells. Most in vitro studies, using embryonic stem cells and neural stem cell
cultures isolated from the SVZ and hippocampus, suggest that RA exposure stimulates
neurogenesis and neuronal maturation [339, 359, 360, 361, 362, 363]. However, the
range of RA concentrations used in these studies ranged from 0.1 to 1 µM. These con-
centrations are 100 to 1000 fold higher than the payload of RA from nanoparticles that
induces neurogenesis in our studies. Considering the RA payload per mg of NPs, we
found that concentrations of RA payload below 4 nM RA (corresponding to 0.1 µg/mL
nanoparticles) and above 40 nM RA (corresponding to 1 µg/mL nanoparticles) did not
promote neuronal differentiation (Fig. 8.8C). This is consistent with the effect of RA in
animal studies [364, 365]. The acute administration of RA (0.15 mg/kg) helped to re-
verse an age-related deficit in long-term potentiation amplitude and improved the ability
of the mice to perform relational learning tasks [364]. In contrast, the long-term sys-
temic administration (1 mg/kg, for 42 days) of RA in mice leaded to a decrease in both
proliferation and neuronal production in the hippocampus, which were accompanied by
a significant reduction in the ability to perform a learning task [365]. In this case, one
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of the RA effects was to suppress SVZ neurogenesis [365].
Figure 8.8.: RA+-NPs have a proneurogenic effect. A) Representative fluorescence
photomicrographs of NeuN immunostaining (red) in control cultures and cultures ex-
posed to RA+-NPs (0.1 µg/mL) for 7 days. Hoechst 33342 was used for nuclear
staining (blue). B) Percentage of NeuN-immunostained neurons in SVZ cultures af-
ter being exposed for 7 days to RA+-NPs, RA−-NPs, or conditioned medium (CM)
obtained from the resultant supernatant of the centrifugation of nanoparticles sus-
pensions previously left in culture for 7 days. Data are expressed as mean ± SEM
(n=5-15 coverslips). ***P<0.001 using unpaired Student’s t-test for comparison with
SVZ control cultures. C) Percentage of NeuN-immunostained neurons in SVZ cul-
tures after being exposed for 7 days to RA+-NPs or free-RA (solubilised in DMSO
and added to the culture medium at different concentrations). Data are expressed as
mean ± SEM (n=5-15 coverslips).
Because the differentiation process could be either due to RA release in the medium
or within the cell, nanoparticles were left in SFM cell medium devoid of growth factors
for 7 days, at 37 °C, then centrifuged and the resultant supernatant was collected, and
used to treat SVZ neurospheres (7 days treatment protocol). Interestingly, no significant
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proneurogenic effect was observed when the nanoparticle conditioned medium (CM) was
added to SVZ cells (Fig. 8.8B). This shows that the differentiation of SVZ cells was only
mediated by the internalisation of the RA+-NPs and concomitant intracellular release
of RA. We speculate that the spatial gradient of RA within the cell is likely the cause
of this biological response; however future studies are needed to address completely this
issue.
We also found that free RA solubilised in medium applying the same treatment protocol
as for the NP, has only achieved a proneurogenic effect with a concentration of 10 µM
(1000 fold higher concentration than RA released from nanoparticles) (148.6±22.9% per-
centage relative to control; n=6 coverslips from 3 independent cell cultures) (Fig. 8.8C).
As for RA+-NPs, the neuronal differentiation effect was absent for higher concentrations
of free RA (50 µM) (81.3 ± 17.8% percentage relative to control; n=6 coverslips from
3 independent cell cultures). Therefore, RA signaling really depends on an optimal con-
centration window to drive the neuronal commitment. Importantly, results also stress
that neuronal differentiation induced by RA+-NPs requires lower RA concentrations as
compared with free RA. Therefore, our formulation is advantageous as comparing to the
direct incubation with RA.
To assess functional neuronal differentiation, we measured intracellular calcium ([Ca2+]i)
variations in single SVZ cells, following KCl depolarization and histamine stimulation
[343] (Fig. 8.5). KCl depolarization leads to the massive entry of Ca2+ through voltage-
dependent calcium channels in differentiated neurons and is used as a functional marker
of neuronal differentiation [366]. Histamine stimulation increases [Ca2+]i in SVZ im-
mature cells but not in neurons or in glial cells [343]. Therefore, mature neurons have
low Hist/KCl ratios (below 0.8) [343]. To evaluate [Ca2+]i variations, SVZ cells were
loaded with the Fura-2AM calcium probe, perfused continuously for 15 min with Krebs
solution, and subsequently stimulated for 2 min with 50 mM KCl followed by 2 min
stimulation with 100 mM histamine (Fig. 8.9A). In control cultures, most of the cells
showed a predominant immature-like profile, characterised by an increase in [Ca2+]i in
response to histamine but a negligible response to KCl depolarisation. In contrast, SVZ
cells treated with RA+-NPs at concentration of 0.1 µg/mL displayed an increase in the
[Ca2+]i in response to KCl but not to histamine stimulation, indicating their neuronal-like
state (Ctrl: 4.8 ± 1.9%, 9 coverslips, 838 cells; 0.1 µg/mL: 28.2 ± 5.2%, 8 coverslips,
1117 cells; P<0.001) (Fig. 8.9A). Moreover, these cells were characterised for the ex-
pression of NMDA subunit type 1 (NR1) by western blot analysis. Functional NMDA
receptors form the molecular basis of synaptic plasticity and depend on the presence of
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Figure 8.9.: RA+-NPs induce differentiation of SVZ cells into functionally neurons.
A) Representative SCCI response profiles of 20 cells in a control culture and in a
culture treated with RA+-NPs (0.1 µg/mL). Graph shows percentages of neuronal-like
responding cells (Hist/KCl below 0.8) in SVZ control cultures and in cultures exposed
to RA+-NPs (0.01 or 0.1 µg/mL) for 7 days. Data are expressed as mean ± SEM
(n=6-9 coverslips). ***P<0.001 using Dunnet’s Multiple Comparison Test. B) Graph
depicts the percentages relative to control of NR1 protein expression normalized to
GAPDH in cultures exposed to RA+-NPs (0.1 µg/mL) for 7 days. Below the graph, a
representative western blot for 120 kDa NR1 and 37 kDa GAPDH expression is shown.
The data is expressed as percentage of control ± SEM (n=5). *P<0.05 using paired
Student’s t-test for comparison with SVZ control cultures. Scale bars are 10 ￿m.
the channel-forming NR1 subunit [367]. In line with the previous results, SVZ cultures
that presented a neuronal-like profile (treated with 0.1 µg/mL of RA+-NPs) also show
a higher expression of NR1 (~150% comparing with control cultures) (Fig. 8.9B).
8.5. Conclusion
We report a novel method to modulate the differentiation of SVZ cells into neurons
involving the use of RA+-NPs. We show that our NP formulation is very effective in
loading RA (86 ± 28 ￿g of RA per mg of NP), a small molecule with low aqueous
solubility, and to release RA at concentrations higher than its solubility limit (> 63
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ng/mL, at physiological pH 7) due to its complexation with PEI. We further show
that the RA+-NPs have approximately 200 nm in diameter, positive net charge, and
disassemble preferentially at acidic pHs. These RA+-NPs can be taken up rapidly by
SVZ cells (first 5 h) under the tested conditions and localise in the overall cell cytoplasm
after 18 h. The NPs are not cytotoxic and do not interfere with cell morphology and
proliferation for concentrations below 100 ￿g/mL. Importantly, our results show that
the intracellular internalisation of RA+-NPs contribute for neurogenesis and therefore
highlighting the importance of drug spatial positioning and concentration in terms of
stem cell differentiation. We anticipate that these nanoparticles might be delivered into
the brain via the nasal cavity, as recently demonstrated for the delivery of cells [368].
Thus, nanoparticle-mediated delivery of neurogenic-inductive factors (proteins, DNA,
siRNA, mRNA) [369] might provide a new opportunity for the treatment of various
neurodegenerative disorders.
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Final Remarks

9. General Conclusions
Though oxidised dextran has been tested in many research studies, entered clinical tri-
als and is even being comercially used in biomedical applications1, the oxidation degree
characterisation and the arising structural consequences have not been a priority in many
studies. The assumption that all the aldehydes are fully reactive is common throughout
the literature. However, our bidimensional NMR data suggests that only one aldehyde
per residue is responding to N-nucleophiles, under certain pH conditions. Based on pro-
posed oxidised residues structures, available on the literature, our interpretation suggests
that the two main peak populations, observed on the bidimensional spectra, arise from
carbazones on C3, likely, from single oxidised residues. All the other populations might
be disguised under these peaks or they may be arrested as hemiacetals, under the studied
pH conditions. Anyhow, it seems that the totality of the aldehydes are not reacting,
which could impair the correct determination of the OD. However, at more alkaline pH’s,
where the carbazone/hydrazone bonds are more labile, all sorts of aldehyde populations
seem to be reactive.
This issue could pose some problems on the prediction of the dexOx behaviour. The
dextran periodate oxidation is a harsh reaction which promotes chain degradation but
confers high chemical reactivity to a natively neutral molecule, deeply altering its physico-
chemical properties. We have shown how the water solubility is compromised and how the
OD interferes with the resulting viscosity, especially at high concentrations. The solutions
viscosity could impair injectability and miscibility of certain formulations, affecting a
possible clinical application, due to issues on manipulation.
The characterised hydrogels have a dual cross-linking control method, relying on the
dextran OD and the amount of AAD used. The OD allows a given percentage of residues
to serve as reactive points to cross-linkers such as AAD. The amount of AAD used is
crucial in defining the gelation period, mechanical properties and dissolution profile of
the hydrogels. It should be within the same range of the amount of oxidised residues
1www.royerbiomedical.com
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present in dextran, to avoid forming dangling ends and not valid mechanical cross-links.
The inclusion of a bioactive factor within such matrix is usually complete and can be fed
either on the dexOx solution or the AAD solution, allowing the modulation of the burst
release profile.
Oxidised dextran, by itself, is an excellent carrier of aminated entities, from small
molecules to proteins, extending the small drugs bioavailability and confering proteins in-
creased environmental stability. The conjugation of dexOx to vascular endothelial growth
factor yielded a strong conjugate where the OD had a major influence in capturing VEGF
as observed by SDS-PAGE. The entanglement of VEGF by dexOx preserves its quater-
nary structure, impairing it, however, to react in full extension with specific antibodies or
cellular receptors, likely due to a steric constraint. The conjugation to dexOx reduces the
VEGF consumption, but it seems to prolong its activity as observed on the profile of the
Ca2+ uptake assay. The reversibility of this conjugate may be modulated by controlling
the OD, and the reduction of the conjugate, by cyanoborohydride, further inhibits the
bioactivity of VEGF.
Within the hydrogel context, formulating VEGF with dexOx, allows the conjugate to
mature, before the hydrogel preparation, which will reflect strongly in the release profile,
when compared to VEGF formulated together with AAD. The amounts released within
the first 24 hours range from less than 1% to around 45% of the total initial protein,
for VEGF formulated with dexOx and AAD, respectively. Most of the VEGF is released
conjugated to dexOx, taking in account the low amount identified by ELISA. Still this
hydrogel formulation allows for the smooth control of the burst release profile.
DexOx has been described before to have some cytotoxicity, not so evident when it is
cross-linked. Indeed, endothelial corneal cells showed an interesting acceptance upon
being seeded on top of these hydrogels, adhering and proliferating well, likely due to the
arrest of medium proteins. This is a good indication for the use of the hydrogel as a
coating for some biomedical devices. Some work was performed on a wound dressing
context, using VEGF-loaded dexOx hydrogels. The initial indications were that such
application could benefit wound closure rate, however, such study was not concluded.
Instead, we proposed a new approach, composed of a dexOx and fibrin hybrid hydrogel.
The controlled and sustained release of VEGF, from the fibrin-entrapped dexOx hydrogel,
was successful in promoting endothelial cells organisation, that were encapsulated on the
fibrin hydrogels. This hybrid system allows the manipulation of cells and growth factors in
separate environments, though maintaining the communication and consequent interplay
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through close contact of both systems. We envision that these constructs might be
beneficial for the induction of a rapid pro-angiogenic response in ischemic tissues, as
well as matrixes to drive the in situ differentiation of vascular progenitor cells.
The last section of this thesis exploited the use of nanoparticles as intracellular drug
carriers for a small hydrophobic drug. We show that our NP formulation is very effective
in loading retinoic acid, a small molecule with low aqueous solubility, and to release RA at
concentrations higher than its solubility limit due to its complexation with PEI. The RA-
loaded NP have approximately 200 nm in diameter, positive net charge, and disassemble
preferentially at acidic pHs. These RA+-NPs can be taken up rapidly by SVZ cells,
localise in the overall cell cytoplasm, not showing cytotoxicity and not interfering with the
cells morphology and proliferation for concentrations below 100 ￿g/mL. Importantly, our
results show that the intracellular internalisation of RA+-NPs contribute for neurogenesis
better than pre-released RA.
The same formulation has been described as a VEGF carrier [203], though with different
polyelectrolyte mass ratios. The use of nanoparticles allows to reach other cellular fron-
tiers. Some unacomplished projects, involved the integration of such nanoparticles with
the dexOx hydrogels (Fig. 1.4), which could improve the performance of the developed
formulation and open new research opportunities.
Future Work
The studied hydrogel formulation has tremendous potential as a drug carrier in several
biomedical settings. However, the delivery of proteins has to be carefully weighted, as
their bioactivity could be seriously impaired. We believe that some other strategies that
were not fully explored, might yield interesting outcomes. DexOx would be an interesting
platform for a nanoparticle cross-linked matrix.
Several questions related with the VEGF actuation arose, throughout the study. Does the
dexOx binded VEGF promotes similar VEGF-R2 phosphorylation patterns as described
for other systems? We were not able to answer completely how the actuation of VEGF
is performed in the presence of dexOx.
The developed hybrid system is still immature, but has great potential. It could be used
with great advantage in in vitro settings, for the promotion of stem cells differentiation,
through the controlled presentation of specific factors. It could also be studied the
application in vivo for the delivery of therapeutic molecules and cells at the same time.
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Chapter 9 General Conclusions
Further studies are required to assess the real efficacy of such system in vivo. Wound
healing could be a potential unmet medical need suitable for such VEGF delivery system.
This system could also be useful in guiding differentiation of endothelial precursor cells
into mature endothelial cells and have direct application in cardiovascular and other
pro-angiogenic therapies.
Regarding the RA nanoparticulate delivery system, it would be interesting to assess
its potential, after delivery through the nasal cavity, in addressing neurodegenerative
disorders.
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